<SEC-DOCUMENT>0000950123-11-050972.txt : 20110517
<SEC-HEADER>0000950123-11-050972.hdr.sgml : 20110517
<ACCEPTANCE-DATETIME>20110516175340
ACCESSION NUMBER:		0000950123-11-050972
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20110630
FILED AS OF DATE:		20110517
DATE AS OF CHANGE:		20110516
EFFECTIVENESS DATE:		20110517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		11849068

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>f59106dedef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
<TITLE>def14a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>&nbsp;UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>SCHEDULE 14A</B>
</DIV>

 <DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>(RULE 14a-101)</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>INFORMATION REQUIRED IN PROXY STATEMENT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>SCHEDULE 14A INFORMATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Proxy Statement Pursuant to Section 14(a) of the Securities<BR>
Exchange Act of 1934 (Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)</B>

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Filed by the Registrant &nbsp;&nbsp;<FONT face="Wingdings">&#254;</FONT><BR>
Filed by a Party other than the Registrant <FONT face="Wingdings">&#111;</FONT>&nbsp;

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;Preliminary Proxy Statement<BR>

<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;<B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B><BR>


<FONT face="Wingdings">&#254;</FONT>&nbsp;&nbsp;Definitive Proxy Statement<BR>


<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;Definitive Additional Materials<BR>
<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;Soliciting Material Pursuant to &#167;240.14a-12

<DIV align="left"><FONT size="1">

</FONT></DIV>

</DIV>
<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>STEMCELLS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Name of Registrant as Specified In Its Charter)</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Payment of Filing Fee (Check the appropriate box):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 0pt"><FONT face="Wingdings">&#254;</FONT>&nbsp;No fee required.<BR>
<FONT face="Wingdings">&#111;</FONT>&nbsp; Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(4) and 0-11.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Title of each class of securities to which transaction applies:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;Aggregate number of securities to which transaction applies:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule&nbsp;0-11 (set forth the amount on which the filing fee is calculated and state how
it was determined):
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;Proposed maximum aggregate value of transaction:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;Total fee paid:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp; Fee paid previously with preliminary materials.
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>
&nbsp;

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp; Check box if any part of the fee is offset
as provided by Exchange Act Rule&nbsp;0-11(a)(2) and
identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by
registration statement number, or the Form or
Schedule and the date of its filing.
&nbsp; &nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Amount Previously Paid:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;Form, Schedule or Registration Statement No.:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;Filing Party:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;Date Filed:
<DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">SEC 1913 (02-02)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Persons who are to respond to the collection of
information contained in this form are not required to
respond unless the form displays a currently valid OMB
control number.</B></TD>

</TR>
<tr style="font-size: 20pt"><td>&nbsp;</td></tr>
<TR valign="bottom" style="font-sizE: 1px">
    <TD colspan="3" valign="top" style="border-top: 1px solid #000000">&nbsp;
</td>


</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

 </div>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<!-- TOC -->
<A name="F59106toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#F59106000">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To be Held on June 30, 2011</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106001">PROXY STATEMENT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106002">ANNUAL MEETING OF STOCKHOLDERS OF STEMCELLS, INC.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106003">QUORUM, REQUIRED VOTES AND METHOD OF TABULATION</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106004">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106005">INFORMATION CONCERNING DIRECTORS OF THE COMPANY</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106006">EXECUTIVE COMPENSATION</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106007">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106008">PRINCIPAL ACCOUNTING FEES AND SERVICES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106009">REPORT OF THE AUDIT COMMITTEE</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106010">PROPOSAL NUMBER 1 Election of Directors</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106011">NOMINEES FOR ELECTION AS CLASS II DIRECTORS -- TERMS TO EXPIRE 2014</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106012">PROPOSAL NUMBER 2 Ratification of Selection of Independent Public Accountants</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106013">PROPOSAL NUMBER 3 Advisory Vote on Executive Officer Compensation</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106014">PROPOSAL NUMBER 4 Advisory Vote on the Frequency of Future Executive Compensation Advisory Votes</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106015">PROPOSAL NUMBER 5 Approval of Amendment to the Company&#146;s Certificate of Incorporation to Effect a Reverse Stock Split</A></TD></TR>
<TR><TD colspan="9"><A HREF="#F59106016">OTHER MATTERS</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">STEMCELLS,
    INC.<BR>
    <FONT style="font-size: 10pt">3155 Porter Drive<BR>
    Palo Alto, California 94304</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<!-- link1 "NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To be Held on June 30, 2011" -->
<DIV align="left"><A NAME="F59106000"></A></DIV>
<B><FONT style="font-size: 12pt">
    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">To be Held on June&#160;30,
    2011</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To the Stockholders of STEMCELLS, INC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Notice is hereby given that the Annual Meeting of Stockholders
    of StemCells, Inc. (&#147;StemCells&#148; or the
    &#147;company&#148;) will be held on Thursday, June&#160;30,
    2011, at 2&#160;p.m., local time, at 3155 Porter Drive, Palo
    Alto, California 94304 for the following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;to elect the two Class&#160;II directors named in the
    accompanying proxy materials to serve until the 2014 Annual
    Meeting of Stockholders;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;to consider and vote upon a proposal to ratify the
    selection of Grant Thornton LLP as independent public
    accountants for the company for the fiscal year ending
    December&#160;31, 2011;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3.&#160;to conduct an advisory vote on executive compensation;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    4.&#160;to conduct an advisory vote on the frequency of future
    advisory votes on executive compensation;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    5.&#160;to approve an amendment to the company&#146;s
    certificate of incorporation to effect a reverse stock split of
    the company&#146;s issued and outstanding common stock, as
    further described in Proposal&#160;Number 5;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    6.&#160;to transact any and all other business that may properly
    come before the meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors has fixed the close of business on
    May&#160;11, 2011, as the record date for determining those
    stockholders who are entitled to notice of, and to vote at, the
    annual meeting of stockholders and any postponements or
    adjournments thereof. The stock transfer books will not be
    closed between the record date and the date of the meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Representation of at least a majority of all outstanding shares
    of common stock of StemCells is required to constitute a quorum.
    Accordingly, it is important that your shares be represented at
    the meeting. This year, we are again taking advantage of
    Securities and Exchange Commission rules that allow issuers to
    furnish proxy materials to their stockholders on the Internet.
    We believe these rules allow us to provide our stockholders with
    the information they need, while lowering the costs of delivery
    and reducing the environmental impact of our Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Please read the proxy materials carefully. All stockholders are
    invited to attend the Annual Meeting. Your vote is important,
    and we appreciate your cooperation in considering and acting on
    the matters presented.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    By Order of the Board of Directors,
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="f59106def5910601.gif" alt="-s- Kenneth B. Stratton">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Kenneth B. Stratton,&#160;J.D.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Secretary
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    May&#160;16, 2011
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
     Palo Alto, California
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "PROXY STATEMENT" -->
<DIV align="left"><A NAME="F59106001"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROXY
    STATEMENT</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<!-- link1 "ANNUAL MEETING OF STOCKHOLDERS OF STEMCELLS, INC." -->
<DIV align="left"><A NAME="F59106002"></A></DIV>
<B><FONT style="font-size: 12pt">
    ANNUAL MEETING OF STOCKHOLDERS<BR>
    OF<BR>
    STEMCELLS, INC.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The accompanying proxy is solicited on behalf of the Board of
    Directors of StemCells, Inc. (the &#147;company&#148;) for use
    at its annual meeting of stockholders (the &#147;Annual
    Meeting&#148;) to be held on Thursday, June&#160;30, 2011, at
    2&#160;p.m., local time, at the company&#146;s headquarters at
    3155 Porter Drive, Palo Alto, California 94304. The company will
    bear the cost of solicitation of proxies. Directors, officers
    and employees of the company may solicit proxies by telephone,
    facsimile or in person for no additional compensation. The
    company will reimburse banks, brokerage firms, proxy solicitors,
    and other custodians, nominees and fiduciaries for reasonable
    expenses incurred by them in sending proxy materials to the
    beneficial owners of shares.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors has fixed the close of business on
    Wednesday, May&#160;11, 2011, as the record date for determining
    stockholders entitled to notice of, and to vote at, the Annual
    Meeting or at any postponement or adjournment thereof. There
    were 137,840,194&#160;shares of our common stock, $.01&#160;par
    value, outstanding on May&#160;11, 2011, each of which is
    entitled to one vote for each share on the matters to be voted
    upon.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Stockholders are being asked to vote on five proposals at the
    company&#146;s 2011 Annual Meeting. The proposals to be voted on
    and related recommendations from the Board of Directors are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal&#160;Number 1&#160;&#151; To elect the two director
    nominees named in this Proxy Statement to serve as Class&#160;II
    directors on the Board until our 2014 annual meeting of
    stockholders or until that person&#146;s successor is duly
    elected and qualified. The Board of Directors recommends that
    you vote &#147;FOR&#148; each of the nominees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal&#160;Number 2&#160;&#151; To ratify the appointment of
    Grant Thornton LLP as the company&#146;s independent registered
    public accounting firm for the fiscal year ending
    December&#160;31, 2011. The Board of Directors recommends that
    you vote &#147;FOR&#148; this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal&#160;Number 3&#160;&#151; To hold an advisory vote on
    executive compensation as disclosed in this Proxy Statement. The
    Board of Directors recommends that you vote &#147;FOR&#148; this
    proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal&#160;Number 4&#160;&#151; To hold an advisory vote on
    the frequency of holding future advisory votes on executive
    compensation. The Board of Directors recommends that you vote
    for every &#147;3 YEARS&#148; in support of a triennial advisory
    vote on executive compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal&#160;Number 5&#160;&#151; To approve an amendment to
    the company&#146;s certificate of incorporation, as further
    described in Proposal&#160;Number 5, to effect a reverse stock
    split of the company&#146;s issued and outstanding common stock
    and decrease the number of authorized shares of common stock to
    75,000,000 and to authorize the Board of Directors to effect
    this amendment to the certificate of incorporation, within the
    Board&#146;s discretion, at any time within four months after
    the date stockholder approval for the reverse stock split is
    obtained, with the exact exchange ratio and timing of the
    reverse stock split (if at all) to be determined at the
    discretion of the Board of Directors (the &#147;Reverse Stock
    Split&#148;). The Board of Directors recommends that you vote
    &#147;FOR&#148; this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the election of directors, which is Proposal&#160;Number 1,
    you may vote &#147;FOR&#148; both of the nominees or your vote
    may be &#147;WITHHELD&#148; with respect to one or more of the
    nominees. For each of Proposal&#160;Number 2,
    Proposal&#160;Number 3 and Proposal&#160;Number 5, you may vote
    &#147;FOR,&#148; vote &#147;AGAINST&#148; or
    &#147;ABSTAIN.&#148; If you &#147;ABSTAIN&#148; as to
    Proposal&#160;Number 2 or Proposal&#160;Number 3, the abstention
    will have no effect. If you &#147;ABSTAIN&#148; as to
    Proposal&#160;Number 5, the abstention has the same effect as a
    vote &#147;AGAINST&#148; the proposal. For Proposal&#160;Number
    4, you may vote for every &#147;1 YEAR,&#148; &#147;2
    YEARS,&#148; or &#147;3 THREE YEARS,&#148; or
    &#147;ABSTAIN.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Shares of our common stock represented by proxies in the form
    enclosed that are properly executed and returned to us and not
    revoked will be voted as specified in the proxy by the
    stockholder. In the absence of contrary instructions, or in
    instances where no specifications are made, the shares will be
    voted:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;FOR the election as directors of the nominees as
    described herein under &#147;Proposal&#160;Number 1&#160;&#151;
    Election of Directors;&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;FOR ratification of the selection of accountants as
    described herein under &#147;Proposal Number 2&#160;&#151;
    Ratification of Selection of Independent Public
    Accountants;&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iii)&#160;FOR the advisory resolution to approve the
    compensation of the company&#146;s named executive officers as
    described herein under &#147;Proposal&#160;Number 3&#160;&#151;
    Advisory Vote on Executive Officer Compensation;&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (iv)&#160;FOR every &#147;3 YEARS&#148; for the advisory
    resolution to set the frequency with which executive
    compensation will be subject to future advisory stockholder
    votes as described herein under Proposal
    Number&#160;4&#160;&#151; Advisory Vote on the Frequency of
    Future Executive Compensation Advisory Votes;&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (v)&#160;FOR the proposal to approve the Reverse Stock Split, as
    described herein under &#147;Proposal&#160;5&#160;&#151;
    Approval of Amendment to the Company&#146;s Certificate of
    Incorporation to Effect a Reverse Stock Split;&#148;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (vi)&#160;in the discretion of the named proxies as to any other
    matter that may properly come before the Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any stockholder signing and delivering a proxy may revoke it at
    any time before it is voted by delivering to the company&#146;s
    corporate secretary a written revocation or a duly executed
    proxy bearing a date later than the date of the proxy being
    revoked. Any stockholder attending the Annual Meeting in person
    may revoke his, her or its proxy and vote his, her or its shares
    at the Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Our 2011 Proxy Materials are Available on the
    Internet.</I>&#160;&#160;This year we have again elected to
    provide access to our proxy materials over the Internet in
    accordance with rules adopted by the Securities and Exchange
    Commission. Accordingly, we are sending a Notice of Internet
    Availability of Proxy Materials (the &#147;Notice&#148;) to our
    stockholders of record and beneficial owners, which will
    instruct them as to how they may access and review all of the
    proxy materials on the Internet and how they may submit their
    proxy on the Internet. Any stockholder wishing to receive a
    paper copy of our proxy materials can request them from us by
    following the instructions found in the Notice for requesting
    such materials, or by calling 1
    <FONT style="white-space: nowrap">(800)&#160;579-1639.</FONT>
    Requests for a paper copy of our proxy materials should be made
    on or before June&#160;16, 2011 to facilitate timely delivery.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How to
    vote shares at our 2011 Annual Meeting.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    This year company stockholders may cast their vote in any of the
    following ways:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Vote by Internet.</I>&#160;&#160;Any stockholder can vote
    over the Internet at www.proxyvote.com by following the
    instructions on the Notice or proxy card. Internet voting
    facilities for stockholders of record will be available
    24&#160;hours a day and will close at 11:59&#160;p.m. (EDT) on
    June&#160;29, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Vote by Phone.</I>&#160;&#160;Any stockholder can vote by
    phone by following the instructions on the proxy card and
    calling 1
    <FONT style="white-space: nowrap">(800)&#160;690-6903</FONT>
    up until 11:59&#160;p.m. (EDT) on June&#160;29, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Vote by Mail.</I>&#160;&#160;Any stockholder that receives
    proxy materials by mail can vote by mail by signing, dating and
    mailing the enclosed proxy card in the postage-paid envelope
    provided. If the envelope is missing, such a stockholder can
    mail the completed proxy card or voting instruction card to Vote
    Processing,
    <FONT style="white-space: nowrap">c/o&#160;Broadridge,</FONT>
    51 Mercedes Way, Edgewood, NY 11717. The completed card must be
    received no later than June&#160;29, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Voting at the Annual Meeting.</I>&#160;&#160;All company
    stockholders are invited to attend the Annual Meeting in person.
    Any stockholder that attends the meeting in person may deliver a
    completed proxy card in person or vote by completing a ballot,
    which will be available at the meeting. However, each
    stockholder intending to vote in person at the Annual Meeting
    should note that if his, her or its shares are held in the name
    of a bank, broker or other nominee, such stockholder must obtain
    a legal proxy, executed in his, her or its favor, from the
    holder of record to be able to vote at the Annual Meeting.
    Stockholders should allow enough time prior to the Annual
    Meeting to obtain this proxy from the holder of record, if
    needed.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The shares voted electronically or represented by the proxy
    cards received, properly marked, dated, signed and not revoked,
    will be voted at the Annual Meeting.
</DIV>


<!-- link1 "QUORUM, REQUIRED VOTES AND METHOD OF TABULATION" -->
<DIV align="left"><A NAME="F59106003"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">QUORUM,
    REQUIRED VOTES AND METHOD OF TABULATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Consistent with Delaware law and the company&#146;s amended and
    restated by-laws, a majority of the votes entitled to be cast on
    a particular matter, present in person or represented by proxy,
    constitutes a quorum as to such matter. The company will appoint
    one or more election inspectors for the meeting to count votes
    cast by proxy or in person at the Annual Meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">What
    vote is required to approve each item?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Election of directors by stockholders, which is
    Proposal&#160;Number 1, will be determined by a plurality of the
    votes cast by the stockholders entitled to vote at the election
    that are either present in person or represented by proxy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For Proposal&#160;Number 2, the affirmative &#147;FOR&#148; vote
    is required by the holders of a majority of the shares present
    at the Annual Meeting in person or by proxy and voting.
    Abstentions will have no effect on the outcome of this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For Proposal&#160;Number 3, the affirmative &#147;FOR&#148; vote
    of the holders of a majority of the shares present at the Annual
    Meeting in person or by proxy and voting is necessary to
    approve, on an advisory basis, the compensation of our named
    executive officers. Because your vote is advisory, it will not
    be binding on the company, the Board or the Compensation
    Committee of the Board. However, the Board and the Compensation
    Committee will review the voting results and take them into
    consideration when making future decisions about executive
    compensation. Abstentions will have no effect on the outcome of
    this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For Proposal&#160;Number 4, the alternative receiving the
    greatest number of votes will be the frequency that stockholders
    approve. Because your vote is advisory, it will not be binding
    on the company, the Board or the Compensation Committee of the
    Board. However, the Board will review the voting results and
    take them into consideration when determining the frequency of
    future non-binding advisory votes on the compensation of our
    named executive officers. Abstentions will have no effect on the
    outcome of this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Proposal&#160;Number 5 requires the affirmative &#147;FOR&#148;
    vote of the holders of a majority of the company&#146;s shares
    of common stock issued and outstanding. Abstentions have the
    same effect as a vote &#147;AGAINST&#148; the matter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If you hold shares beneficially in street name and do not
    provide your broker or nominee with voting instructions, your
    shares may constitute &#147;broker non-votes.&#148; Generally,
    broker non-votes occur on a matter when a broker is not
    permitted to vote on that matter without instructions from the
    beneficial owner and instructions are not given. If you hold
    shares beneficially in street name and do not vote your shares,
    your broker or nominee can vote your shares at its discretion
    only on Proposal&#160;Number 2. In tabulating the voting result
    for any proposal for which the required vote is based on the
    number of shares present, shares that constitute broker
    non-votes are not considered entitled to vote on that proposal.
    However, for proposals for which the required vote is based on
    the number of shares of common stock issued and outstanding,
    broker non-votes have the same effect as a vote
    &#147;AGAINST&#148; the proposal. Thus, broker non-votes will
    not affect the outcome of Proposal&#160;Number 1 through
    Proposal&#160;Number 4, but will affect the outcome of
    Proposal&#160;Number 5.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Management does not know of any matters to be presented at this
    Annual Meeting other than those set forth in this proxy
    statement and in the notice accompanying this proxy statement.
    If other matters should properly come before the meeting, the
    proxy holders will vote such matters in their discretion. Any
    stockholder has the right to revoke his, her or its proxy at any
    time until it is voted.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS" -->
<DIV align="left"><A NAME="F59106004"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
    RELATED STOCKHOLDER MATTERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table shows the number of shares of our common
    stock beneficially owned, as of April&#160;1, 2011, by
    (i)&#160;each of our directors, (ii)&#160;each of our named
    executive officers, (iii)&#160;all of our directors and
    executive officers as a group, and (iv)&#160;all those known by
    us be to a beneficial owner of more than 5% of the
    company&#146;s common stock. In general, &#147;beneficial
    ownership&#148; refers to shares that an individual or entity
    has the power to vote or dispose of, and any rights to acquire
    common stock that are currently exercisable or will become
    exercisable within 60&#160;days of April&#160;1, 2011. Unless
    otherwise indicated, we believe that each person named below,
    based on information furnished by such owners, holds sole
    investment and voting power with respect to such shares, subject
    to community property laws where applicable. We calculated
    percentage ownership in accordance with the rules of the SEC.
    The percentage of common stock beneficially owned is based on
    137,743,512&#160;shares outstanding as of April&#160;1, 2011. In
    addition shares issuable pursuant to options, restricted stock
    units or other convertible securities that may be acquired
    within 60&#160;days of April&#160;1, 2011 are deemed to be
    issued and outstanding and have been treated as outstanding in
    calculating and determining the beneficial ownership and
    percentage ownership of those persons possessing those
    securities, but not for any other individuals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Amount and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Nature of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>of Beneficial<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Class Beneficially<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Address of Beneficial Owner*</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Ownership</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Owned</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Named Executive Officers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Eric Bjerkholt(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Stewart Craig(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    R. Scott Greer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Ricardo Levy(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,165
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Martin McGlynn(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,924,616
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.36
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Roger Perlmutter(5)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    149,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    John Schwartz(6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Ken Stratton(7)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    230,590
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Ann Tsukamoto(8)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    851,524
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Irving Weissman(9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    729,819
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Rodney Young(10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    881,301
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    **
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    All directors and executive officers as a group
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>5,296,509</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>3.73</B>
</TD>
<TD nowrap align="left" valign="bottom">
    <B>%</B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Stockholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    BlackRock Inc.(11)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,244,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.11
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    The address of all directors and executive officers listed in
    the table is
    <FONT style="white-space: nowrap">c/o&#160;StemCells,</FONT>
    Inc., 3155 Porter Drive, Palo Alto, California 94304.</TD>
</TR>

</TABLE>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    ** </TD>
    <TD></TD>
    <TD valign="bottom">
    Less than one percent.</TD>
</TR>

</TABLE>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 70,000&#160;shares issuable upon exercise of stock
    options exercisable within 60&#160;days.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 83,333&#160;shares issuable upon exercise of stock
    options exercisable within 60&#160;days. Includes
    8,330&#160;shares included in Dr.&#160;Craig&#146;s 401(k) plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 122,165&#160;shares issuable upon exercise of stock
    options exercisable within 60&#160;days.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 1,909,677&#160;shares issuable upon exercise of
    1,851,011 stock options and vesting of 58,666 restricted stock
    units, exercisable or vesting within 60&#160;days. Includes
    41,941&#160;shares included in Mr.&#160;McGlynn&#146;s 401(k)
    plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 143,503&#160;shares issuable upon exercise of stock
    options exercisable within 60&#160;days.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 133,000&#160;shares issuable upon exercise of stock
    options exercisable within 60&#160;days and 15,000 restricted
    stock units.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 153,957&#160;shares issuable upon exercise of 130,624
    stock options and 23,333 restricted stock units, exercisable or
    vesting within 60&#160;days. Includes 10,181&#160;shares
    included in Mr.&#160;Stratton&#146;s 401(k) plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 639,475&#160;shares issuable upon exercise of 616,142
    stock options and 23,333 restricted stock units, exercisable or
    vesting within 60&#160;days. Includes 44,836&#160;shares
    included in Dr.&#160;Tsukamoto&#146;s 401(k) plan. Includes a
    total of 22,834&#160;shares held in trusts for the benefit of
    Dr.&#160;Tsukamoto and her family members, including
    4,000&#160;shares owned by Dr.&#160;Tsukamoto&#146;s parents as
    to which she disclaims beneficial ownership.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 220,292&#160;shares issuable upon exercise of stock
    options exercisable within 60&#160;days. Includes
    14,511&#160;shares held in trust for Dr.&#160;Weissman&#146;s
    children as to which he disclaims beneficial ownership.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (10) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 730,622&#160;shares issuable upon exercise of 673,956
    stock options and vesting of 56,666 restricted stock units,
    exercisable or vesting within 60&#160;days. Includes
    12,911&#160;shares included in Mr.&#160;Young&#146;s 401(k) plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (11) </TD>
    <TD></TD>
    <TD valign="bottom">
    According to a Schedule&#160;13G filed on January&#160;29, 2011
    and subsequently amended on February&#160;8, 2011, by BlackRock,
    Inc., BlackRock may be deemed to beneficially own all shares
    listed in the table, and has sole dispositive and voting power
    with respect to all shares listed in the table. The address of
    the principal place of business of BlackRock is 40 East 52nd
    Street, New York, NY 10022.</TD>
</TR>

</TABLE>


<!-- link1 "INFORMATION CONCERNING DIRECTORS OF THE COMPANY" -->
<DIV align="left"><A NAME="F59106005"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    CONCERNING DIRECTORS OF THE COMPANY</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We currently have seven directors serving on our Board of
    Directors. Since June 2010, our Board has been composed of
    Drs.&#160;Ricardo Levy, Roger Perlmutter, John Schwartz, and
    Irving Weissman and Messrs.&#160;Eric Bjerkholt, Scott Greer and
    Martin McGlynn. The following table shows the names, ages,
    principal occupations, and public company board memberships for
    the last five years of our directors, as of April&#160;1, 2011:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eric Bjerkholt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    51
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Eric Bjerkholt was elected to the Board of Directors in March
    2004. He is Senior Vice President, Corporate Development and
    Finance, and Chief Financial Officer of Sunesis Pharmaceuticals,
    Inc. From 2004 to 2007, he served as Senior Vice President and
    Chief Financial Officer of Sunesis.  Mr. Bjerkholt is a member
    of the board of directors of Round Table Pizza, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    R. Scott Greer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    52
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Scott Greer was appointed to the Board of Directors in June
    2010. He is currently a principal and managing director of
    Numenor Ventures LLC, which he founded in 2002 to provide
    funding and strategic advisory services to early stage
    enterprises. Mr.&#160;Greer currently serves as Chairman of
    Ablexis and Acologix, both development stage biotechnology
    companies, and is also on the board of Nektar Therapeutics and
    BAROnova.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ricardo Levy,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    66
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ricardo Levy,&#160;Ph.D. was elected to the Board of Directors
    in September 2001. He currently serves as a director on the
    boards of a number of private companies as well as the board of
    Accelrys, Inc., a public company focused on molecular modeling
    and simulation software for both life and materials science
    research.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    64
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Martin McGlynn was elected to the Board of Directors in February
    2001. He is President and Chief Executive Officer of the
    company, a position he has held since January 2001.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger Perlmutter,&#160;M.D.,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    58
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Roger Perlmutter,&#160;M.D.,&#160;Ph.D., was elected to the
    Board of Directors in December 2000. He is Executive Vice
    President, Research and Development, of Amgen, Inc., a position
    he has held since January 2001.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John Schwartz,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    76
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    John Schwartz,&#160;Ph.D., was elected to the Board of Directors
    in December 1998 and was elected Chairman of the Board at the
    same time. He is currently President of Quantum Strategies
    Management Company.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Irving Weissman,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    71
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Irving Weissman,&#160;M.D., was elected to the Board of
    Directors in September 1997. He is the Virginia and Daniel K.
    Ludwig Professor of Cancer Research, Professor of Pathology and
    Professor of Developmental Biology at Stanford University.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Because we have a classified board, with each of our directors
    serving a staggered three-year term, only two of our directors
    are standing for reelection at our 2011 Annual Meeting. The
    following table shows the composition of the three classes of
    our Board:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Class&#160;I Directors (terms scheduled to expire in 2013):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Eric Bjerkholt
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    R. Scott Greer
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    John Schwartz,&#160;Ph.D.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Class&#160;II Directors (terms scheduled to expire in 2011, but
    nominated to stand for reelection at our 2011 Annual Meeting):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Ricardo Levy,&#160;Ph.D.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Irving Weissman,&#160;M.D.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Class&#160;III Directors (terms scheduled to expire in 2012):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Martin McGlynn
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Roger Perlmutter,&#160;M.D.,&#160;Ph.D.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The independent members of our Board, as determined by the Board
    of Directors in accordance with the existing Nasdaq Listing
    rules, are Messrs.&#160;Bjerkholt and Greer and Drs.&#160;Levy,
    Perlmutter and Schwartz. The Board of Directors held four
    regular meetings and two special meetings during the fiscal year
    ended December&#160;31, 2010. Each of the directors attended
    more than 75% of the meetings of the Board of Directors and of
    the committees on which he served.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For many years the roles of chairman and chief executive officer
    at the company have been separated. We believe that this is
    appropriate under current circumstances, because it allows
    management to make the operating decisions necessary to manage
    the business, while helping to maintain Board independence so
    that it can provide an effective oversight function. We feel
    that this has provided an appropriate balance of operational
    focus, flexibility and oversight. Our independent directors meet
    at regularly scheduled executive sessions without members of
    management.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Presently, the Board has four standing committees&#160;&#151;
    the Compensation and Stock Option Committee (the
    &#147;Compensation Committee&#148;), the Corporate Governance
    and Nominating Committee (the &#147;Corporate Governance
    Committee&#148;), the Strategic Transactions Committee, and the
    Audit Committee&#160;&#151; as well as a single-member committee
    established under the company&#146;s 2001, 2004 and 2006 equity
    incentive plans. The Board created the Strategic Transactions
    Committee in March 2009 as an <I>ad hoc</I> committee with
    direction to consult with management and advise the full Board
    on various corporate initiatives, such as the acquisition of
    substantially
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    all of the operating assets of Stem Cell Sciences plc, which the
    company completed in April 2009. In June 2010, however, the
    Board reconstituted the Strategic Transactions Committee, which
    Mr.&#160;Greer currently chairs, as a standing committee of the
    Board. All members of the Compensation Committee, the Corporate
    Governance Committee and the Audit Committee are, and are
    required by the charters of the respective committees to be,
    independent as determined under Nasdaq Listing rules.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I><U>Compensation Committee</U>.</I>&#160;&#160;Prior to June
    2010, the Compensation Committee included Dr.&#160;Schwartz and
    Mr.&#160;Bjerkholt. In June 2010, Dr.&#160;Levy joined the
    Compensation Committee as its third member. The Compensation
    Committee held three meetings during the fiscal year ended
    December&#160;31, 2010. The Compensation Committee makes
    recommendations to our Board and management concerning salaries
    in general, determines executive compensation and, except to the
    extent that such decisions have been delegated to, and made by,
    the single-member committee, approves incentive compensation for
    our employees and consultants. The Compensation Committee acts
    pursuant to a written charter which is available through our
    website at www.stemcellsinc.com.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I><U>Corporate Governance Committee</U>.</I>&#160;&#160;The
    Corporate Governance Committee is composed of Drs.&#160;Levy,
    Perlmutter and Schwartz. The Corporate Governance Committee did
    not hold any meetings in 2010; however, it held a meeting in
    March 2011 as well as informal discussions in 2010 to discuss a
    slate of actual and potential nominees to the Board of
    Directors. The committee oversees nominations to the Board and
    considers the experience, ability and character of potential
    nominees to serve as directors, as well as particular skills or
    knowledge that may be desirable in light of the company&#146;s
    position at any time. From time to time, the committee has
    engaged the services of a paid search firm to help the committee
    identify potential nominees to the Board. The Company&#146;s
    Governance Committee and Board seek to nominate and appoint
    candidates to the Board who have significant business
    experience, technical expertise or personal attributes, or a
    combination of these, sufficient to suggest, in the Board&#146;s
    judgment, that the candidate would have the ability to help
    direct the affairs of the company and enhance the Board as a
    whole. The Committee may identify potential candidates through
    any reliable means available, including recommendations of past
    or current members of the Board from their knowledge of the
    industry and of the company. The Committee also considers past
    service on the Board or on the board of directors of other
    publicly traded or technology focused companies. The committee
    has not adopted a formulaic approach to evaluating potential
    nominees to the Board; it does not have a formal policy
    concerning diversity, for example. Rather, the committee weighs
    and considers the experience, expertise, intellect, and judgment
    of potential nominees irrespective of their race, gender, age,
    religion, or other personal characteristics. The committee often
    looks for nominees that can bring new skill sets or diverse
    business perspectives. Potential candidates recommended by
    security holders will be considered as provided in the
    company&#146;s &#147;Policy Regarding Shareholder Candidates for
    Nomination as a Director,&#148; which sets forth the procedures
    and conditions for such recommendations. This policy is
    available through our website at www.stemcellsinc.com. The
    Corporate Governance Committee operates pursuant to a written
    charter, a copy of which is also available through our website
    at www.stemcellsinc.com. The members of the Corporate Governance
    Committee approved the nomination of the Class&#160;II directors
    standing for reelection at the Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I><U>Audit Committee</U>.</I>&#160;&#160;The Audit Committee is
    composed of Mr.&#160;Bjerkholt and Drs.&#160;Schwartz and Levy.
    The Audit Committee held five meetings during the fiscal year
    ended December&#160;31, 2010. The primary function of the Audit
    Committee is to assist our Board in fulfilling its oversight
    responsibilities. The committee does this primarily by reviewing
    our financial reports and other financial information as well as
    the company&#146;s systems of internal controls regarding
    finance, accounting, legal compliance, and ethics that
    management and the Board have established. The committee also
    assesses our auditing, accounting and financial processes more
    generally. The Audit Committee meets quarterly, and at such
    other times as it finds necessary. It recommends to our Board
    the appointment of a firm of independent auditors to audit the
    financial statements of the company and meets with such
    personnel of the company to review the scope and the results of
    the annual audit, the amount of audit fees, the company&#146;s
    internal accounting controls, the company&#146;s financial
    statements contained in this proxy statement and other related
    matters. Each of the members of the Audit Committee is
    independent, and the Board has determined that
    Mr.&#160;Bjerkholt is an &#147;audit committee financial
    expert,&#148; as defined in SEC rules. The Audit Committee acts
    pursuant to a written charter which is available through our
    website at www.stemcellsinc.com.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I><U>Strategic Transactions Committee</U>.</I>&#160;&#160;The
    Strategic Transactions Committee is composed of
    Messrs.&#160;Bjerkholt, Greer and McGlynn and Dr.&#160;Levy. The
    Strategic Transactions Committee held three meetings during the
    fiscal year
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    ended December&#160;31, 2010. The Committee was created at the
    suggestion of our Chief Executive Officer in March 2009 to
    provide advice and direction, on an <I>ad hoc </I>basis, on a
    range of strategic initiatives being considered at the time,
    such as the acquisition of substantially all of the operating
    assets of Stem Cell Sciences plc. The Committee does not have a
    formal charter. However, the Board of Directors has authorized
    the Committee to be available to advise, consult and participate
    with management, as requested by the company&#146;s Chief
    Executive Officer, with respect to the identification,
    implementation, evaluation, and negotiation of potential
    strategic corporate transactions, with the exception of
    financings. Since June 2010, the Strategic Transactions
    Committee has been the Board&#146;s fourth standing committee,
    and as such it routinely provides recommendations both to
    management and to the full Board with regard to such matters as
    the Committee may deem advisable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table shows the members of our four standing Board
    committees:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Corporate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Strategic<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Audit<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Governance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Transactions<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Director</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Independent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Committee</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eric Bjerkholt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Yes
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Chair
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    R. Scott Greer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Yes
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Chair
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ricardo Levy,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Yes
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Chair
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    No
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger Perlmutter,&#160;M.D.,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Yes
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John Schwartz,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Yes
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Chair
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <FONT style="font-family: Wingdings; font-variant: normal">&#252;
    </FONT>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Irving Weissman,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    No
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Oversight and Qualifications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While management is responsible for the
    <FONT style="white-space: nowrap">day-to-day</FONT>
    management of the risks the company faces, the Board, as a whole
    and through its committees, has responsibility for the oversight
    of risk management. An important part of risk management is not
    only understanding the risks facing the company and what steps
    management is taking to manage those risks, but also
    understanding what level of risk is appropriate for the company.
    In support of this oversight function, the Board receives
    regular reports from our Chief Executive Officer and members of
    senior management on operational, financial, legal, and
    regulatory issues and risks. The Audit Committee additionally is
    charged under its charter with oversight of financial risk,
    including the company&#146;s internal controls, and it receives
    regular reports from management, the company&#146;s internal
    auditors and the company&#146;s independent auditors. The
    Chairman of the Board and independent members of the Board work
    together to provide strong, independent oversight of the
    company&#146;s management and affairs through its standing
    committees and, when necessary, special meetings of directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe each of our directors brings valuable skills,
    experience, judgment, and perspectives to our company. The Board
    took the following qualifications into consideration, among
    other things, when nominating or appointing our current
    directors:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="57%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eric Bjerkholt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Mr.&#160;Bjerkholt is a financial expert and currently serves as
    the Senior Vice President and Chief Financial Officer of Sunesis
    Pharmaceuticals, Inc., a biopharmaceutical company. His business
    experience spans approximately 20&#160;years, during which time
    he founded a nutraceutical company and worked as an investment
    banker. Mr.&#160;Bjerkholt currently serves on the board of
    directors of Round Table Pizza. We believe
    Mr.&#160;Bjerkholt&#146;s qualifications to serve on our Board
    of Directors include his considerable financial and business
    experience, especially in the life sciences industry.
    Mr.&#160;Bjerkholt has served on our Board for over seven years.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="57%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    R. Scott Greer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Mr.&#160;Greer was appointed to our Board in June 2010. He is a
    financial expert with over 25&#160;years of experience in the
    life sciences industry. He was founder, CEO and Chairman of
    Abgenix, Inc., a biotechnology company he took public in 1998
    and then sold to Amgen in 2006. Mr.&#160;Greer currently serves
    as Chairman of Ablexis and Acologix, both development stage
    biotechnology companies, and is also on the boards of Nektar
    Therapeutics and BAROnova. We believe Mr.&#160;Greer&#146;s
    qualifications to serve on our Board include his more than
    25&#160;years of experience in the life sciences industry.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ricardo Levy, PhD
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Dr.&#160;Levy has over 30&#160;years of experience leading
    technology companies in both North and South America. In 1974,
    he cofounded Catalytica, Inc., a manufacturing technology and
    energy systems company, and served as CEO from 1991 until the
    company was sold in 2000. Dr.&#160;Levy currently serves as
    director of Accerlys Inc. (formerly Pharmacopeia, Inc.) and
    NovoDynamics, Inc. We believe his qualifications to serve on our
    Board of Directors include his more than 30&#160;years of
    business experience. Dr.&#160;Levy has served on our Board for
    over nine years.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Mr.&#160;McGlynn has been our President and Chief Executive
    Officer since January 2001. He has held management positions of
    increasing responsibility in several countries for more than
    30&#160;years. Prior to joining our company, Mr.&#160;McGlynn
    was President and Chief Executive Officer of Pharmadign, Inc., a
    privately held company in the fields of inflammation and genetic
    immunization. Prior to this, he was President and General
    Manager of Abbott Canada Ltd. and President of Anaquest, Inc., a
    company focused on anesthesia and acute care pharmaceuticals. We
    believe Mr.&#160;McGlynn&#146;s qualifications to serve on our
    Board of Directors include his significant managerial experience
    in our industry and his intimate knowledge of our operations as
    a result of his day to day leadership as our President and Chief
    Executive Officer. Mr.&#160;McGlynn has served on our Board for
    over ten years.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger Perlmutter, MD, PhD
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Dr.&#160;Perlmutter is the Executive Vice President of Research
    and Development of Amgen, Inc., a world leading biotechnology
    company, a position he has held for approximately ten years.
    Prior to joining Amgen, he held scientific leadership positions
    of increasing responsibility at Merck. He also worked as a
    researcher and administrator at the University of Washington. We
    believe Dr.&#160;Perlmutter&#146;s pharmaceutical industry
    experience brings an important industry perspective to the
    Board. We believe his qualifications to serve on our Board of
    Directors include his experience in both business and academic
    research, including his pharmaceutical industry experience.
    Dr.&#160;Perlmutter has served on our Board for over ten years.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="57%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John Schwartz, PhD
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Dr.&#160;Schwartz has over 40&#160;years of business and legal
    experience, including several years spent in the 1990s as
    President and Chief Executive Officer of Systemix, Inc., a
    cell-based therapeutics company which was acquired by Novartis
    in 1997. Before joining Systemix as its Senior Vice President
    and General Counsel in 1993, Dr.&#160;Schwartz served as the
    Vice President and General Counsel of Stanford University. He
    currently runs a registered investment advisor firm called
    Quantum Strategies Management Company. We believe
    Dr.&#160;Schwartz&#146;s qualifications to serve on our Board of
    Directors include his over 40&#160;years of business and legal
    experience in our industry as well as his significant experience
    working at Stanford University. Dr.&#160;Schwartz has served on
    our Board for over 13&#160;years.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Irving Weissman, MD
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Dr.&#160;Weissman has been a leader in the stem cell field for
    over 20&#160;years. He is a professor at Stanford University and
    serves as the director of the Stanford Institute for Stem Cell
    Biology and Regenerative Medicine. He co-founded Systemix in
    1988 and Cellerant Therapeutics, Inc., a hematopoietic stem cell
    development company, in 2001. He is a member of several
    scientific advisory boards and national science institutes,
    including the National Academy of Science, the American Academy
    of Arts and Science, and the Institute of Medicine of the
    National Academy of Sciences. We believe
    Dr.&#160;Weissman&#146;s qualifications to serve on our Board of
    Directors include the fact that he has been a leader in stem
    cell research for over 20&#160;years as well as his substantial
    business experience in our industry. Dr.&#160;Weissman has
    served on our Board for over 13&#160;years and serves as the
    chairman or our Scientific Advisory Board.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Stockholders who wish to communicate with our Board of Directors
    or with a particular director may send a letter to our corporate
    secretary at the following address: StemCells, Inc., 3155 Porter
    Drive, Palo Alto, California 94304
    <FONT style="white-space: nowrap">(c/o&#160;Legal</FONT>
    Department). Any communication should clearly specify that it is
    intended to be made to the entire Board or to one or more
    particular director(s). Our corporate secretary will review all
    such correspondence and forward to our Board a summary of all
    such correspondence and copies of all correspondence that, in
    the opinion of the secretary, deals with the functions of the
    Board or committees thereof or that he otherwise determines
    requires their attention. The secretary maintains a log of all
    correspondence received by us that is addressed to members of
    the Board, and any director may at any time review and request
    copies of any such correspondence.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Concerns relating to accounting, internal controls or auditing
    matters will immediately be brought to the attention of the
    chairman of the Audit Committee and handled in accordance with
    established procedures, which are set out in the Audit
    Committee&#146;s Policy on Receipt, Retention and Treatment of
    Complaints Regarding Accounting, Internal Controls and Auditing
    Matters. A copy of this policy is available through our website
    at www.stemcellsinc.com.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Following are the name, age and other information for our named
    executive officers, as of April&#160;1, 2011. All company
    officers have been elected to serve until their successors are
    elected and qualified or until their earlier resignation or
    removal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn,<BR>
    President and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    64
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Martin McGlynn joined the company in January 2001, when he was
    appointed President and Chief Executive Officer of the company
    and of its wholly-owned subsidiaries. Mr. McGlynn was elected to
    the Board of Directors in February 2001.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto,&#160;Ph.D.<BR>
    Executive Vice President, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    58
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ann Tsukamoto,&#160;Ph.D., joined the company in November 1997
    as Senior Director of Scientific Operations; was appointed Vice
    President, Scientific Operations in June 1998; Vice President,
    Research and Development in February 2002; and Chief Operating
    Officer, with responsibility for the company&#146;s research and
    development efforts, in November 2006. In October 2008,
    Dr.&#160;Tsukamoto was appointed Executive Vice President,
    Research and Development, with responsibility for the
    company&#146;s scientific and clinical development programs.
    Dr.&#160;Tsukamoto is married to one of our outside directors.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young,<BR>
    Chief Financial Officer and Vice President, Finance and
    Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    48
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Rodney Young joined the company in September 2005 as Chief
    Financial Officer and Vice President, Finance. In November 2006
    he became CFO and Vice President, Finance and Administration. He
    is responsible for functions that include Finance, Information
    Technology and Investor Relations. From 2003 to 2005, Mr. Young
    was Chief Financial Officer and a director of Extropy
    Pharmaceuticals, Inc., a private biopharmaceutical company
    focused on developing drugs for pediatric indications.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.<BR>
    Senior Vice President, Development and Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    49
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Stewart Craig,&#160;Ph.D., joined the company in September 2008
    with responsibilities for Development, Manufacturing,
    Regulatory, Quality Systems, and Facilities. From 2005 to 2008,
    Dr.&#160;Craig was Chief Technology Officer and Vice President
    of Progenitor Cell Therapy, a contract services provider for
    research, development, manufacture, and commercialization of
    cell-based therapies, prior to which he has held executive
    positions at Xcyte Therapies, Osiris Therapeutics and SyStemix.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.<BR>
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    42
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ken Stratton,&#160;J.D., joined the company in February 2007 as
    General Counsel, with responsibility for corporate compliance
    and legal affairs. In March 2008, he assumed responsibility for
    the Human Resources function. Prior to joining StemCells,
    Mr.&#160;Stratton served as Deputy General Counsel for Threshold
    Pharmaceuticals and as Senior Legal Counsel for Medtronic,
    Inc.&#146;s Vascular business unit.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Section&#160;16(a)
    Beneficial Ownership Reporting Compliance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Section&#160;16(a) of the Securities Exchange Act of 1934, as
    amended (the &#147;Exchange Act&#148;), requires our executive
    officers, directors, and persons who own more than 10% of a
    registered class of our equity securities, to file with the SEC
    reports of ownership of our securities and changes in reported
    ownership. Executive officers, directors and greater than 10%
    beneficial owners are required by SEC rules to furnish us with
    copies of all Section&#160;16(a) reports they file.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based solely on a review of the copies of such forms furnished
    to us, or written representations from the reporting persons
    that no Form&#160;5 was required, we believe that, during the
    fiscal year ended December&#160;31, 2010, all Section&#160;16(a)
    filing requirements applicable to our officers, directors and
    greater than 10% beneficial owners have been met.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have adopted a Code of Ethics and Conduct that applies to all
    of our directors, officers, employees, and consultants. A copy
    of our code of ethics is posted on our website at
    www.stemcellsinc.com. We intend to disclose any substantive
    amendment or waivers to this code on our website. There were no
    substantive amendments or waivers to this code in 2010.
</DIV>


<!-- link1 "EXECUTIVE COMPENSATION" -->
<DIV align="left"><A NAME="F59106006"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">EXECUTIVE
    COMPENSATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We structure our compensation programs to attract and retain
    talented employees and reward them for helping us achieve our
    short-term and long-term goals. We intend for our compensation
    programs to be equitable and competitive when measured against
    those offered by companies against whom we compete for
    high-level scientific and executive personnel. We also intend
    for them to link pay to both company and individual performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In seeking to accomplish these objectives, we follow a
    compensation strategy designed, ultimately, to reward increasing
    stockholder value. However, because achievement of our principle
    mission&#160;&#151; the research, development and
    commercialization of stem cell therapeutics and related tools
    and technologies for academia and industry&#160;&#151; is a
    long, expensive and challenging process, we often set individual
    compensation by using surrogate endpoints to gauge employee
    contributions towards building sustained stockholder value, such
    as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the achievement of stated corporate goals adopted from time to
    time by the Board;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the leadership an executive officer has shown in inspiring and
    marshalling excellent performances in his or her direct reports;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the anticipation, identification and successful disposition of
    issues and problems that, if not addressed timely and
    effectively, might have a deleterious effect on the
    company;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the speed and effectiveness with which an executive officer
    discovers, assesses and, where appropriate, pursues promising
    opportunities for the company.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Compensation elements.</I>&#160;&#160;We, like most
    biotechnology companies, use a combination of base salary,
    bonuses and equity awards to compensate our employees, including
    our executive officers. As a small company&#160;&#151; we have
    approximately 60&#160;employees in total and only five executive
    officers&#160;&#151; we feel that having so few people in each
    job classification and level makes it inefficient to establish a
    formulaic allocation of total compensation among its various
    elements; we rely, instead, on our experience and judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In exercising this judgment, we periodically collect and review
    information (i)&#160;from third party market reports such as the
    <I>Radford Biotechnology Survey&#160;&#151; Executive
    Report</I>; and (ii)&#160;from the proxy statements of other
    similar biotechnology companies, especially those operating in
    the San&#160;Francisco Bay Area, as well as those pursuing
    cell-based
    therapeutics.<SUP style="font-size: 85%; vertical-align: top">1</SUP>

    In the case of the executive officers who report directly to the
    chief executive officer, we also carefully consider the
    recommendations of the chief executive officer when setting
    compensation. We integrate all of this information with our
    evaluation of the individual performance of each of our
    executive officers.
</DIV>
<!-- XBRL Pagebreak Begin -->
<!-- XBRL Footnotes Begin -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <SUP style="font-size: 85%; vertical-align: top">1</SUP>&#160;In

    2009, for example, we collected executive compensation
    information from the recent SEC filings of Aastrom Biosciences,
    Inc.; Affymax, Inc.; ARYx Therapeutics, Inc.; Athersys, Inc.;
    Cerus Corporation; Cytokinetics, Incorporated; Cytori
    Therapeutics, Inc.; Dynavax Technologies Corporation; Geron
    Corporation; InterMune, Inc.; MAP Pharmaceuticals, Inc.;
    Medivation, Inc.; Neuralstem, Inc.; Osiris Therapeutics, Inc.;
    and Sangamo Biosciences, Inc.
</DIV>
<!-- XBRL Footnotes End -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While we believe our officers and other employees are
    outstanding, we realize that the company is not yet profitable
    and that it is still in a relatively early stage of development.
    We therefore generally prefer to target our compensation
    practices so that our employees&#146; base salaries, bonuses,
    equity compensation, and benefits all fall close to the
    50th&#160;percentile paid by comparable companies for similar
    positions. Actual compensation may fall slightly above or below
    these targets, however, because of any number of factors such as
    general economic conditions, market competition for specific
    jobs, personal performance, and the need for internal equities
    within the company. For example, we have recently paid many of
    our employees, including some of our executive officers, at
    below the 50th&#160;percentile because of the global recession
    and the crisis in the financial markets. At the same time,
    however, we have paid many of our employees, including some of
    our executive officers, at above the 50th&#160;percentile
    because of highly competitive demand for workers with their
    unique skill sets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Interaction of compensation elements.</I>&#160;&#160;The
    basic compensation elements&#160;&#151; base salary, bonuses and
    equity awards&#160;&#151; are, as noted, standard in our
    industry. Though not set independently of one other, we use each
    element as a portion of total compensation because we believe we
    would not otherwise be competitive and because we feel that
    together they are the proper components of a balanced
    compensation package:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    base salary is compensation for current efforts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    bonuses, whether in cash or equity, are typically paid for
    achievements in meeting stated corporate goals;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    equity awards are inducements to remain with the company and to
    build future value.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On occasion, we have considered our employee compensation
    programs, including our executive compensation programs, and the
    effect they may have on company risk. We have concluded that our
    employee compensation programs are simple and straight-forward
    and consistent with those of similarly situated research and
    development companies. In determining that our compensation
    policies and practices do not present risks that are likely to
    have a material adverse effect on our business, our directors
    have, from time to time, discussed with management the various
    pay practices used to compensate our employees at both the
    executive and non-executive levels. These inquiries have
    included discussions about our three primary components of
    compensation, namely base compensation, cash bonuses and equity
    incentive compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors has also periodically considered how
    bonus awards are determined and calculated by the company,
    noting that all bonuses are awarded entirely at the discretion
    of our Board after taking into consideration the progress of our
    company&#146;s programs. Based on its review, our Board has
    concluded that our cash bonus program properly aligns
    compensation with our overall goals, all of which are designed
    to have a positive impact on our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, our Board has periodically examined our equity
    compensation practices, noting that we typically grant customary
    equity awards that vest over many years after the date of grant.
    We believe discretionary equity compensation that vest over
    multiple years does not encourage short-term or high-risk
    opportunistic behavior and instead aligns our employees&#146;
    interests with the long-term interests of our stockholders by
    encouraging activities intended to build long-term value for the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For these reasons, we have concluded that our employee
    compensation programs are designed with the appropriate balance
    of risk and reward in relation to our company&#146;s overall
    business strategy and do not incentivize executives or other
    employees to take unnecessary or excessive risks. As a result,
    we believe that risks arising from our employee compensation
    policies and practices are not reasonably likely to have a
    material adverse effect on the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Other compensation elements and benefits.</I>&#160;&#160;We
    offer all employees various health and welfare benefit plans.
    Our executive officers may participate in these on the same
    terms as other employees. We do not have a pension plan nor do
    we use non-qualified deferred
    compensation.<SUP style="font-size: 85%; vertical-align: top">2</SUP>We

    offer our U.S.&#160;employees (again, including executive
    officers on the same terms as others) a 401(k) defined
    contribution plan, and match employee contributions on a 1:2
    basis (i.e., $1 contribution by the company for every $2
    contribution made by the employee) up to a maximum of 3%
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->
<!-- XBRL Footnotes Begin -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <SUP style="font-size: 85%; vertical-align: top">2</SUP>&#160;Accordingly,

    we omit tables showing pension benefits and non-qualified
    deferred compensation.
</DIV>
<!-- XBRL Footnotes End -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    of the employee&#146;s salary, subject to legal limitations. At
    this time, our 401(k) match is made in the form of shares of
    common stock in the company. We offer our U.K. employees a tax
    preferred pension scheme, and match employee contributions on a
    1:1 basis up to a maximum of 12% of the employee&#146;s salary.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    of Named Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Base salary compensation; target bonuses.</I>&#160;&#160;We
    consider base salary to be a critical component of our executive
    officers&#146; overall compensation packages. We intend the
    salaries of our executive officers to reflect their actual
    responsibilities and job scope. We also endeavor to set base
    compensation levels so that their salaries are competitive with
    salaries paid by comparable companies to employees with similar
    experience, taking into account the cost of living in the
    San&#160;Francisco Bay Area. However, as of late, we have been
    paying heightened attention to continuing weakness in the global
    financial markets as well as the company&#146;s need to
    carefully manage its cash resources. As a result, the last
    company-wide salary increase was in March 2007. Instead, we have
    made occasional adjustments to the salaries of certain employees
    to address perceived below market anomalies, address specific
    retention concerns or reward special contributions made to the
    company. As described below, we changed the base compensation
    paid to certain of our executive officers in both 2009 and 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to base salary, each full-time employee of the
    company, including each of our named executive officers, is
    given a personal target bonus (calculated as a percentage of
    base salary), based upon factors such as seniority, job title
    and the existing targets of co-workers with comparable job
    responsibilities within the company. Bonuses at the company are
    discretionary and awarded by the Board in its sole discretion.
    But when bonuses are awarded, we use the personal target of each
    employee to calculate his or her bonus amount.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    With these various principles in mind, we recently took the
    following actions with respect to the base compensation and
    bonus targets of our executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    From March 2007 through 2008, we maintained the annual base
    salary of Mr.&#160;McGlynn at $385,000, plus a housing and
    transportation allowance. Effective January 2009, however, we
    eliminated Mr.&#160;McGlynn&#146;s housing and transportation
    allowance of approximately $200,000 per year and increased
    Mr.&#160;McGlynn&#146;s annual base salary by $140,000, from
    $385,000 to $525,000, and began providing him a car allowance in
    the amount of $10,000 per year. The net effect of these changes
    was a decrease in Mr.&#160;McGlynn&#146;s base compensation of
    approximately 11% for 2009. There have been no changes to
    Mr.&#160;McGlynn&#146;s base compensation since this time.
    Concurrent with these changes, we increased
    Mr.&#160;McGlynn&#146;s target bonus from 40&#160;percent to
    55&#160;percent of his base salary, beginning with the 2009
    fiscal year, to reflect the Board&#146;s view that
    Mr.&#160;McGlynn&#146;s leadership is a major factor in the
    achievement of the company&#146;s corporate goals and to further
    align his compensation to corporate success.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    From March 2007 through 2009, we maintained the annual base
    salary of Mr.&#160;Young at $275,000. In January 2010, however,
    we increased Mr.&#160;Young&#146;s annual base salary to
    $325,000 in recognition of contributions made on behalf of the
    company and job scope. In January 2010, we also increased
    Mr.&#160;Young&#146;s target bonus rate from 25% to 30% of his
    base salary, beginning with the 2010 fiscal year, to further
    align his compensation to corporate success. In February 2011,
    we increased Mr.&#160;Young&#146;s target bonus rate from 30% to
    40% of his base salary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Since March 2007, we have maintained the annual base salary of
    Dr.&#160;Tsukamoto at $300,000. In January 2010, however, we
    increased Dr.&#160;Tsukamoto&#146;s target bonus from 25% to 30%
    of her base salary, beginning with the 2010 fiscal year, to
    further align her compensation to corporate success. In February
    2011, we increased Dr.&#160;Tsukamoto&#146;s target bonus rate
    from 30% to 40% of her base salary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dr.&#160;Craig joined the company in September 2008, with an
    annual base salary of $275,000 and a target bonus rate of 25% of
    his base salary. In January 2010, however, we increased
    Dr.&#160;Craig&#146;s target bonus from 25% to 30% of his base
    salary, beginning with the 2010 fiscal year, to further align
    his compensation to corporate success. In February 2011, we
    increased Dr.&#160;Craig&#146;s target bonus rate from 30% to
    40% of his base salary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mr.&#160;Stratton joined the company in February 2007, with an
    annual base salary of $220,000 and a target bonus rate of 20% of
    his base salary. In February 2008, however, we increased
    Mr.&#160;Stratton&#146;s annual base salary to $250,000 in
    recognition of contributions made on behalf of the company and
    because he had assumed additional responsibilities in early
    2008. In January 2010, we increased Mr.&#160;Stratton&#146;s
    annual base salary to $275,000 in recognition of contributions
    made on behalf of the company and job scope. In January 2010, we
    also increased
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mr.&#160;Stratton&#146;s target bonus rate from 20% to 30% of
    his base salary, beginning with the 2010 fiscal year, to further
    align his compensation to corporate success. In February 2011,
    we increased Mr.&#160;Stratton&#146;s target bonus rate from 30%
    to 40% of his base salary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The base compensation and target bonus information presented
    above can be summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="8%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="8%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="8%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended 12/31/08<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended 12/31/09<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended 12/31/10<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>As of 04/01/11<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Base Compensation/<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Base Compensation/<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Base Compensation/<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Base Compensation/<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Target Bonus</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Target Bonus</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Target Bonus</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Target Bonus</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    585,000/40
</TD>
<TD nowrap align="left" valign="bottom">
    %(1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525,000/55
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525,000/55
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525,000/55
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CFO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    325,000/30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    325,000/40
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    EVP, R&#038;D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    300,000/25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    300,000/25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    300,000/30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    300,000/40
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    SVP, D&#038;O
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/40
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    GC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    250,000/20
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    250,000/20
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000/40
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consisting of $385,000 base salary and approximately $200,000 in
    housing, transportation and insurance benefits, which were
    eliminated in January 2009 and which were not used to calculate
    Mr.&#160;McGlynn&#146;s bonus for fiscal year 2008.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Bonus compensation.</I>&#160;&#160;We view periodic bonuses,
    whether paid in cash or equity, as an important element of
    compensation for several reasons. Bonuses help align individual
    employee efforts with overall corporate strategies and
    objectives. Bonuses also help us manage salary expense, while
    still allowing us to reward successes. By using discretionary
    bonuses as part of the compensation mix, we have greater
    flexibility in managing the timing and amounts of compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Over the past few years, we have awarded bonuses on an annual
    basis after considering, among other things, the company&#146;s
    accomplishments against stated corporate goals adopted by the
    Board, the company&#146;s financial position, the status of its
    development programs, clinical progress and corporate
    development activities, and general economic factors. This has
    necessarily involved a subjective assessment by the Compensation
    Committee of corporate performance and market conditions each
    year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The process of establishing our corporate goals over the past
    few years has been a lengthy one. For each fiscal year, our
    executive officers have presented the Compensation Committee of
    the Board with approximately five to ten proposed corporate
    goals, each often consisting of multiple
    <FONT style="white-space: nowrap">sub-parts.</FONT>
    Management has usually presented its recommended corporate goals
    to the Compensation Committee concurrent with our proposed
    corporate budgets for the following fiscal year. Goals have been
    designed to be challenging, so that one would not expect
    consistent achievement of all of them. Typically these goals
    have included some preclinical and clinical goals for our
    <FONT style="white-space: nowrap">HuCNS-SC</FONT>
    cell product candidate, financing and corporate development
    goals, goals related to advancement in cell manufacturing
    practices, and goals related to advancement of our Liver
    Program. While all these goals have been considered important,
    and we have used a cross-functional and balanced approach to
    setting them, we have typically prioritized our goals by
    assigning relative weightings to each of them, with all of them
    together adding up to 100%. However, by design, no one goal has
    ever accounted for a majority of the relative weightings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After receiving management&#146;s recommended goals, members of
    the Compensation Committee typically review them with our
    executive officers and oftentimes provide suggestions for
    additional goals or changes to the recommended goals. After our
    executive officers and directors have completed this iterative
    process, which has often taken several weeks, the Compensation
    Committee adopts revised corporate goals consistent with the
    foregoing principles and recommends the updated corporate goals
    to the full Board for consideration and approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Thereafter, during each fiscal year, our executive officers have
    used the Board-approved corporate goals as a management tool,
    for example to coordinate activities, motivate personnel and
    help prioritize the use of company resources. The executive
    officers have sometimes referred back to the corporate goals
    when providing business updates to the Board, similar to
    management&#146;s reference back to an approved annual budget.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Recently, at the end of each fiscal year, our Chief Executive
    Officer has presented the Compensation Committee with his
    assessments of corporate performance against the Board-approved
    corporate goals, together with a summary of any important
    factors that weighed in his assessments, which he has provided
    as context.
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Because our corporate goals have not been formulaic or
    quantitative in nature (we have not had a corporate goal tied to
    specific stock price, revenues or expenses, for example), our
    CEO&#146;s assessments have been largely qualitative in nature.
    Along with these assessments, our CEO has provided a percentage
    score for each goal reflecting the degree to which each goal was
    or was not, in his judgment, achieved during the year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Compensation Committee has usually considered these
    percentage scores as well as our Chief Executive Officer&#146;s
    commentary about corporate performance and more general
    assessments of the state of our business when determining
    whether to award employees a company-wide corporate bonus in any
    given year, and if so how much of the available bonus pool to
    award. However, the Compensation Committee members have used
    their own judgment to determine the size of any bonus award, if
    any. Therefore, there has been no direct correlation between the
    aggregate percentage score given to any year&#146;s corporate
    goals by our CEO and the ultimate bonus payout. In any given
    year, the Board may grant more than 100% of the bonus pool for
    the year. The Board may also grant less than 100% of the bonus
    pool even if all of the corporate goals have been achieved.
    While the Compensation Committee and the Board as a whole use
    the corporate goals as a measure of success, the amount of any
    bonus grant, as well as how and when it will be paid, is
    completely within the Board&#146;s sole discretion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    With these various principles in mind, we recently took the
    following actions with respect to corporate bonuses for 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In January 2011, as part of its annual year-end review of
    performance, the Compensation Committee (with input from the
    Chief Executive Officer and other Board members) considered,
    among other things, significant company performance
    accomplishments in 2010, the company&#146;s successes measured
    against its 2010 corporate goals, the degree of difficulty in
    achieving these goals, as well as other events and circumstances
    that affected performance. The 2010 goals, as approved by our
    Board, consisted generally of the following: (i)&#160;progress
    in our CNS Program, including activities aimed at initiating
    clinical trials of our HuCNS-SC proprietary cell-based product
    in multiple therapeutic indications; (ii)&#160;progress in our
    Liver Program; (iii)&#160;successful fundraising efforts;
    (iv)&#160;successful corporate development activities; and
    (v)&#160;advancement of our scientific development programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Highlights of the 2010 accomplishments taken into account by the
    Compensation Committee in determining the overall company
    performance included:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><U><FONT style="font-family: 'Times New Roman', Times">Therapeutic
    Product Development</FONT></U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In February 2010, the first patient in a Phase I trial of our
    HuCNS-SC human neural stem cells in Pelizaeus-Merzbacher Disease
    (PMD) was enrolled and dosed at UCSF Benioff Children&#146;s
    Hospital, marking the first time that neural stem cells have
    been transplanted as a potential treatment for a myelination
    disorder. In February 2011, the fourth and final patient in this
    trial was enrolled and transplanted with our HuCNS-SC cells. We
    expect to report results of this trial in early 2012.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In August 2010, we published new preclinical data demonstrating
    that our proprietary human neural stem cells restore lost motor
    function in mice with chronic spinal cord injury. This is the
    first published study to show that human neural stem cells can
    restore mobility even when administered at time points beyond
    the acute phase of trauma, suggesting the prospect of treating a
    much broader population of injured patients than previously
    demonstrated. The paper was published in the international
    peer-reviewed journal <I>PLoS ONE.</I>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In October 2010, we initiated a Phase Ib clinical trial of our
    HuCNS-SC cells in neuronal ceroid lipofuscinosis (NCL, also
    often referred to as Batten disease). The goal of the Phase Ib
    trial was to enroll six patients with less advanced stages of
    the disease than those who participated in our Phase I NCL
    trial. This Phase Ib trial was discontinued by the company in
    April 2011 for lack of enrollment.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In December 2010, we received authorization from Swissmedic, the
    Swiss regulatory agency, to initiate a Phase I/II clinical trial
    in Switzerland of our HuCNS-SC cells in chronic spinal cord
    injury. The trial is designed to assess both safety and
    preliminary efficacy in patients with varying degrees of
    paralysis who are three to 12&#160;months post-injury, and will
    enroll patients in different cohorts based upon the severity of
    injury.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><U><FONT style="font-family: 'Times New Roman', Times">Tools
    and Technologies Programs</FONT></U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In January 2010, we launched
    GS1-R<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    the first commercially available cell culture medium to enable
    the derivation, maintenance and growth of true (germline
    competent) rat embryonic stem cells. GS1-R is expected to have
    significant utility in the creation of genetically engineered
    rat models of human disease for use in academic, medical and
    pharmaceutical research.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In February 2010, we launched
    GS2-M<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    a new cell culture medium that enables the derivation and
    long-term maintenance of true mouse induced pluripotent stem
    (iPS) cells. GS2-M has been shown to increase the efficiency of
    reprogramming &#145;pre-iPS&#146; cells to derive fully
    pluripotent stem cells, and to maintain mouse iPS cells in a
    pluripotent state in long-term culture.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2010, published independent research demonstrated that
    our GS2-M cell culture media formulation enhances the
    pluripotency of human embryonic stem and induced pluripotent
    stem (iPS) cells. Our GS2-M medium has already been shown to
    enable the derivation and long-term maintenance of mouse iPS
    cells. With this new application of GS2-M, researchers may now
    be able to significantly advance human pluripotent stem cell
    research.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In October 2010, we launched
    NDiff<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    N2, a defined serum-free cell culture supplement that has
    demonstrated utility for the <I>in&#160;vitro </I>neural
    differentiation of mouse embryonic stem cells, and a range of
    other applications, including the derivation, maintenance and
    expansion of neural stem cells and the differentiation of human
    and mouse neural stem cells into functional neurons.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In December 2010, we launched
    STEM101<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    STEM121<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and
    STEM123<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    three new antibody reagents that significantly improve the
    visualization of human cells, including human stem cells and
    their progeny. These high potency antibody reagents, which
    expand the range of our SC Proven portfolio of research
    products, provide tools for the detection, tracking and
    characterization of human cells both <I>in&#160;vitro </I>and
    <I>in vivo </I>when transplanted into animal models of human
    diseases.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In January 2011, we launched
    STEM24<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and
    STEM133<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    two new antibody reagents that have utility for the detection of
    a range of different human cell types.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><U><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property and Licensing Activities</FONT></U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In March 2010, the United Kingdom (UK) Intellectual Property
    Office granted us patent number GB2451523 with broad claims
    covering true (germline competent) rat stem cells and
    genetically engineered rats derived from these cells. The
    patented technology is expected to have significant utility to
    academic and pharmaceutical industry researchers by enabling
    them to create novel rat models for the study of human diseases.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In August 2010, independent researchers used our technology to
    achieve the first genetically engineered rat derived from rat
    embryonic stem cells. This breakthrough work, published in the
    international peer-reviewed journal <I>Nature</I>, makes
    possible the types of genetic manipulations previously only
    possible in mice. Both mice and rats are used as animal models
    of human disease; however certain aspects of the rat&#146;s
    physiology, behavior, and metabolism are closer to the human,
    making rats the preferred species for drug development and
    studying human disease.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><U><FONT style="font-family: 'Times New Roman', Times">Financing
    and Other Business-related Activities</FONT></U></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2010, we raised gross proceeds of $6,055,000 through the
    sale of 7,000,000&#160;shares of common stock to an
    institutional investor at a price of $0.865 per share. No
    warrants were issued in this transaction.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In October 2010, we were awarded cash grants totaling $978,000
    for projects related to our CNS and Liver programs. These grants
    were certified under the federal government&#146;s Qualifying
    Therapeutic Discovery Project (QTDP) program, which was created
    as part of the Patient Protection and Affordable Care Act of
    2010. All four project applications submitted by us were
    approved, and we received the entire grant amounts in December
    2010.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In January 2011, we raised gross proceeds of $10,000,000 through
    the sale of 10,000,000&#160;shares of common stock to selected
    institutional investors at a price of $1.00 per share.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Following this review, the Compensation Committee awarded a
    discretionary bonus equal to 90% of the available bonus pool,
    based upon the committee members&#146; assessments of market
    conditions, corporate risks, company successes in 2010,
    including the successful regulatory authorization for a spinal
    cord study of HuCNS-SC cells in Switzerland, historic employee
    compensation practices more generally, and our market
    comparables, among other things, including the committee
    member&#146;s qualitative assessments of the Company&#146;s
    performance in 2010 measured against its 2010 corporate goals.
    The bonuses were calculated using each employee&#146;s annual
    base salary as of January&#160;1, 2010, and paid in February
    2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Accordingly, in February 2011, the company paid Mr.&#160;McGlynn
    a 2010 bonus in the amount of $259,875, because on
    January&#160;1, 2010 his base salary and target bonus were,
    respectively, $525,000 and 55%. The company paid Mr.&#160;Young
    a 2010 bonus in the amount of $87,750, because on
    January&#160;1, 2010 his base salary and target bonus were,
    respectively, $325,000 and 30%, and the company paid
    Dr.&#160;Tsukamoto a 2010 bonus in the amount of $81,000,
    because on January&#160;1, 2010 her base salary and target bonus
    were, respectively, $300,000 and 30%. The company also paid
    Dr.&#160;Craig and Mr.&#160;Stratton each a 2010 bonus in the
    amount of $74,250, because on January&#160;1, 2010 their base
    salary and target bonus were, respectively, $275,000 and 30%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Equity Compensation&#160;&#151; general
    practices.</I>&#160;&#160;We believe that equity compensation
    awards are an important component of our overall compensation
    policy because equity compensation can provide strong inducement
    to remain with the company and to build future stockholder
    value. In order to achieve these objectives, we believe that
    equity compensation awards need to be structured to provide both
    meaningful value and a meaningful opportunity to realize that
    value. Accordingly, from time to time, we have considered
    several forms of equity compensation awards, including stock
    options, stock appreciation rights, restricted stock, and
    restricted stock units, because each of these have certain
    advantages and disadvantages relative to the others with respect
    to how they might reward effort and success and how they might
    help us retain high contributors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Generally speaking, over the years, we have used stock options
    as the most common equity compensation instrument. However,
    since 2006 we have granted our named executive officers a
    mixture of options, restricted stock units and stock
    appreciation rights, as described below, because we feel each of
    these forms of equity has unique and important features for
    employee retention and for incentivizing the executive officers
    to build a profitable and sustainable business. We have
    typically granted company-wide equity awards to full-time
    employees once every year or two. In addition, we have typically
    granted stock option awards to newly hired employees, effective
    as of their date of hire, and occasionally to existing employees
    upon their promotion. Both on-hire awards to non-executive
    officers and awards upon the promotion of current employees are
    usually made by either Mr.&#160;McGlynn, acting as the
    Board&#146;s single-member committee, or by the Compensation
    Committee. Awards to executive officers are made by either the
    Compensation Committee or by the full Board. Company-wide awards
    have usually been made at either a regularly scheduled Board or
    Compensation Committee meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Unless otherwise specifically noted in the tables herein, all
    option awards:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to our employees, including our executive officers, are intended
    to be qualified incentive stock options (ISOs) to the fullest
    extent permitted by law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have an exercise price set at the closing market price of our
    common stock on the grant date, or on an adjacent market trading
    date if the market on which we are listed (currently the Nasdaq
    Global Market) is not open on the grant date;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    vest over four years, with one-fourth of the shares included in
    any grant vesting on the first anniversary of the grant and the
    remainder vesting 1/48th&#160;per month thereafter, always
    provided that the grantee remains in the company&#146;s employ
    on the vesting dates. These awards are time-vesting and do not
    depend on performance factors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    With these various principles in mind, we recently took the
    following actions with respect to equity compensation.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In early 2009, consistent with our practice of reviewing equity
    incentives on a periodic basis, we evaluated the equity awards
    held by the company&#146;s employees in order to evaluate the
    retention value these past awards likely provided. We noted that
    a number of key employees continued to hold predominantly
    unexercisable options with a strike price more than 200% the
    company&#146;s recent trading price. Furthermore, our review of
    market trends indicated that biotechnology companies with
    volatile trading prices were using restricted stock units with
    increasing regularity. We also continued to believe the
    retention benefit of equity compensation would be enhanced by
    awarding a mixture of both options and restricted stock units.
    The Compensation Committee therefore determined to award equity
    grants to the company&#146;s employees, including those working
    for its U.K. subsidiaries and the company&#146;s named executive
    officers. Specifically, in May 2009, after a review of the
    market and company-specific information described above, the
    Compensation Committee approved a company-wide award to
    employees of 1,046,400 restricted stock units and options to
    purchase up to 1,055,800&#160;shares of common stock, in the
    aggregate. All of the restricted stock units awarded at this
    time have four-year vesting, with one-fourth vesting on each of
    the first four anniversaries following the grant date. All of
    the options awarded at this time will vest one-fourth on the
    first anniversary following the grant and then 1/48th&#160;each
    month thereafter, in keeping with the company&#146;s standard
    practices. In this award, our named executive officers received,
    in the aggregate, 741,333 restricted stock units and options to
    purchase up to 278,000&#160;shares of common stock. The
    Compensation Committee decided to defer the equity grant award
    to Dr.&#160;Craig, consisting of 93,333 restricted stock units
    and 35,000 options, until his one-year anniversary of hire in
    September 2009. The Compensation Committee also approved the
    grant of up to 750,000 stock options to employees working for
    our Stem Cell Sciences (UK) Ltd. and Stem Cell Sciences Holdings
    Limited subsidiaries, which we awarded in 2010 because of
    foreign tax considerations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In June 2010, after a review of the market and company-specific
    information described above, the Compensation Committee approved
    a company-wide award to employees of 1,900,000 restricted stock
    units and options to purchase up to 1,845,000&#160;shares of
    common stock, in the aggregate. Of particular importance, the
    Compensation Committee noted that a majority of the stock
    options issued to employees had strike prices significantly
    below the current market price of the company&#146;s stock and
    were therefore of limited retention value. All of the restricted
    stock units awarded at this time have four-year vesting, with
    one-fourth vesting on each of the first four anniversaries
    following the grant date, except for the restricted stock units
    granted to Mr.&#160;McGlynn and Dr.&#160;Tsukamoto, each of
    which has three-year vesting, with one-third vesting on each of
    the first three anniversaries following the grant date. All of
    the options awarded at this time will vest one-fourth on the
    first anniversary following the grant and then 1/48th&#160;each
    month thereafter, in keeping with the company&#146;s standard
    practices. In this June 2010 grant, our named executive officers
    received, in the aggregate, 2,500,000 restricted stock units and
    options to purchase up to 2,650,000&#160;shares of common stock.
    In September 2010, Mr.&#160;McGlynn voluntarily surrendered his
    rights and interests in 200,000 restricted stock units from this
    June 2010 grant in order to bring his grant into accordance with
    the provisions of the company&#146;s equity incentive plan under
    which the grant was made.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In January 2011, we awarded Mr.&#160;McGlynn 200,000 additional
    restricted stock units in recognition of his service and
    importance to the company&#146;s long-term goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table summarizes the restricted stock units
    awarded to our named executive officers in March 2008, May 2009,
    June 2010, and January 2011:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number of Restricted Stock Units Granted</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name &#038; Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>May 2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June 2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>January 2011</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn&#160;&#151; President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    412,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto,&#160;Ph.D.&#160;&#151; Executive VP,
    Research&#160;&#038; Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    700,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young&#160;&#151; CFO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.&#160;&#151; SVP,
    Development&#160;&#038; Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    99,333
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.&#160;&#151; General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;McGlynn was granted 1,200,000 restricted stock units in
    June 2010, however, he voluntarily surrendered 200,000 of these
    in September 2010 in order to bring his grant into accordance
    with the provisions of the company&#146;s equity incentive plan
    under which the grant was made.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Craig joined the company after the relevant grant date.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Granted on Dr.&#160;Craig&#146;s one-year anniversary of
    employment, September&#160;15, 2009.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may grant additional options, restricted stock units or other
    equity compensation to current employees, including our
    executive officers, in 2011.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment,
    Severance and
    <FONT style="white-space: nowrap">Change-in-Control</FONT>
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Employment agreements.</I>&#160;&#160;Mr.&#160;McGlynn joined
    the company as our president and chief executive officer on
    January&#160;15, 2001. Under the terms of an employment
    agreement between Mr.&#160;McGlynn and the company, dated
    January&#160;2, 2001, as amended, Mr.&#160;McGlynn received an
    initial annual base salary of $275,000 per year, reviewable
    annually by the Board of Directors, and a bonus, in the
    Board&#146;s sole discretion, of up to 25% of his base salary.
    Over time, however, we have increased Mr.&#160;McGlynn&#146;s
    base salary and target bonus so that they are, respectively,
    $525,000 and 55% of his base salary. Pursuant to his January
    2001 employment agreement, we granted Mr.&#160;McGlynn an option
    to purchase 400,000&#160;shares of our common stock with an
    exercise price equal to the fair market value of the common
    stock on the initial date of his employment, one-fourth to vest
    on the first anniversary of his employment and the remaining
    three-fourths to vest in equal monthly installments during his
    second through fourth years of employment. These options
    remained unexercised and expired in 2011. The employment
    agreement also provided that the Board could, in its sole
    discretion, grant Mr.&#160;McGlynn a bonus option to purchase up
    to an additional 25,000&#160;shares, which it did. These options
    also remained unexercised and expired in 2011. We also agreed to
    pay Mr.&#160;McGlynn a $50,000 relocation bonus and to reimburse
    him for relocation expenses, and have done so. Since January
    2009, we have been paying Mr.&#160;McGlynn an annual car
    allowance of $10,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dr.&#160;Tsukamoto joined the company in November 1997 and has
    served as our executive vice president of research and
    development since September 2008. Under the terms of an
    employment agreement between Dr.&#160;Tsukamoto and the company,
    dated February&#160;2, 1998, Dr.&#160;Tsukamoto received an
    annual base salary of $130,000 per year and a discretionary
    target bonus of up to 10% of her base salary. Over time,
    however, we have increased her base salary and target bonus so
    that they are, respectively, $300,000 and 40% of her base
    salary. Also pursuant to her employment agreement, we provide
    Dr.&#160;Tsukamoto with $750,000 of term life insurance on an
    annual basis during her employment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mr.&#160;Young joined the company in September 2005 as our chief
    financial officer and vice president of finance. Under the terms
    of his agreement with the company, dated August&#160;16, 2005,
    Mr.&#160;Young received an initial annual base salary of
    $250,000 per year, with a target bonus of up to 25% of his base
    salary. Over time, however, we have increased
    Mr.&#160;Young&#146;s base salary and target bonus so that they
    are, respectively, $325,000 and 40% of his base salary. Pursuant
    to his August 2005 employment agreement, we granted
    Mr.&#160;Young an option to purchase 450,000&#160;shares of our
    common stock. This option will vest over 48&#160;months; with
    one-fourth of the shares vesting on the first anniversary of the
    date on which Mr.&#160;Young&#146;s employment began and with
    the remaining shares vesting, subject to his continued
    employment by the company, at the rate of 1/48th&#160;per month
    on the last day of each month during the ensuing 36&#160;months.
    In addition, the employment agreement provided for an option
    grant on the first anniversary of his employment to acquire an
    additional 25,000&#160;shares of our common stock. The grant of
    25,000&#160;shares was duly made, and will vest in the same
    manner as his earlier option grant over 48&#160;months, subject
    to Mr.&#160;Young&#146;s continued employment by the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dr.&#160;Craig joined the company in September 2008 as our
    senior vice president of development and operations. Under the
    terms of his agreement with the company, dated July&#160;24,
    2008, Dr.&#160;Craig has received an annual base salary of
    $275,000 per year, with a target bonus of up to 25% of his base
    salary. Over time, however, we have increased
    Dr.&#160;Craig&#146;s target bonus so that it is 40% of his base
    salary. Pursuant to Dr.&#160;Craig&#146;s July 2008 employment
    agreement, we granted him an option to purchase
    200,000&#160;shares of our common stock. This option will vest
    over 48&#160;months, with one-fourth of the shares vesting on
    the first anniversary of the date on which Dr.&#160;Craig&#146;s
    employment began and with the remaining shares vesting, subject
    to his continued employment by the company, at the rate of
    1/48th&#160;per month on the last day of each month during the
    ensuing 36&#160;months.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mr.&#160;Stratton joined the company in February 2007 as our
    general counsel. Under the terms of his agreement with the
    company, dated February&#160;2, 2007, Mr.&#160;Stratton
    initially received an annual base salary of $220,000 per year,
    with a target bonus of up to 20% of his base salary. Over time,
    however, we have increased Mr.&#160;Stratton&#146;s base
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    salary and target bonus so that they are, respectively, $275,000
    and 40% of his base salary. Pursuant to Mr.&#160;Stratton&#146;s
    February 2007 employment agreement, we granted him an option to
    purchase 150,000&#160;shares of our common stock. This option
    will vest over 48&#160;months, with one-fourth of the shares
    vesting on the first anniversary of the date on which
    Mr.&#160;Stratton&#146;s employment began and with the remaining
    shares vesting, subject to his continued employment by the
    company, at the rate of 1/48th&#160;per month on the last day of
    each month during the ensuing 36&#160;months.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Severance arrangements.</I>&#160;&#160;Each of our executive
    officers has entered into a severance agreement with the company
    under which he or she would receive payments upon termination of
    his or her employment by us without
    cause<SUP style="font-size: 85%; vertical-align: top">3</SUP> or

    consequent to a change of control or, in the case of
    Mr.&#160;McGlynn, by virtue of disability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the case of Mr.&#160;McGlynn, upon termination without cause,
    we would continue to pay his salary and provide benefits for one
    year, at the base wage rate then in effect. If the termination
    of Mr.&#160;McGlynn&#146;s employment were associated with a
    change of control, the company would pay (in a lump sum)
    (i)&#160;two years of his salary and the reasonably projected
    cost of healthcare benefits, (ii)&#160;a bonus with respect to
    the termination year at 25% of the base salary, pro-rated for
    the portion of the year served, and (iii)&#160;a tax gross up
    for his continued healthcare benefits. In addition, all unvested
    stock options would vest and all stock options would be
    exercisable for two years after termination. If
    Mr.&#160;McGlynn&#146;s employment were terminated on account of
    disability, we would continue to pay his salary for up to six
    months (or until he obtained other employment or became eligible
    for disability income under a company plan, if sooner).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the case of Dr.&#160;Tsukamoto, upon involuntary termination
    without cause whether or not associated with a change of
    control, we would continue to pay Dr.&#160;Tsukamoto&#146;s
    salary and provide benefits for twelve months, at the rate then
    in effect. Dr.&#160;Tsukamoto&#146;s agreement provides that if
    the termination were associated with a change of control, any
    unvested options granted pursuant to the company&#146;s 1992
    Equity Incentive Plan would vest upon termination; however, none
    of these options are still outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the case of Mr.&#160;Young, upon involuntary termination
    without cause, we would continue to pay his salary and provide
    benefits for six months, at the rate then in effect. If the
    termination were associated with a change of control, we would
    continue to pay Mr.&#160;Young&#146;s salary and provide
    benefits (including his share of COBRA, grossing up for the tax
    effects, if any) for twelve months; in this event, any unvested
    options and any other stock awards held by him would vest upon
    termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the case of Dr.&#160;Craig, upon involuntary termination
    without cause, whether or not associated with a change of
    control, we would continue to pay his salary and provide
    benefits for six months, at the rate then in effect.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the case of Mr.&#160;Stratton, upon involuntary termination
    without cause, we would continue to pay his salary and provide
    benefits for six months, at the rate then in effect. If the
    termination were associated with a change of control, we would
    continue to pay Mr.&#160;Stratton&#146;s salary and provide
    benefits for twelve months; in this event, any unvested options
    and any other stock awards held by him would vest upon
    termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If we terminate the employment of any executive officer for
    cause, or if the officer resigns without good cause, he or she
    would not be entitled to any severance or other benefits.
</DIV>
<!-- XBRL Pagebreak Begin -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <SUP style="font-size: 85%; vertical-align: top">3</SUP>&#160;Or

    termination by the executive officer for good reason, as defined
    in their respective agreements.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Payments Upon Termination or
    <FONT style="white-space: nowrap">Change-in-Control</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table displays the value of what the executive
    officers would have received from us had their employment been
    terminated on December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="8%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Accelerated Vesting of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options and Restricted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Salary</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Bonus</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Health</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Units*</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated without cause
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    24,835
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    549,835
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated, change of control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,050,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    131,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    91,556
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,272,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Disability(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    262,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    262,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto,&#160;Ph.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated without cause
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,301
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    314,301
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated, change of control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,301
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,119,750
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,434,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated without cause
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    170,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated, change of control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    325,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    688,750
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,009,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated without cause
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    137,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    146,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated, change of control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    137,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    322,800
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    469,306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated without cause
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    137,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    145,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Terminated, change of control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    275,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    408,900
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    700,348
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    Value shown represents the difference between the closing market
    price of our stock on December&#160;31, 2010 of $1.08 per share
    and the applicable exercise price of each grant.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes tax
    <FONT style="white-space: nowrap">gross-up</FONT> on
    2&#160;years of healthcare costs.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Payments stop before 6&#160;months if individual obtains other
    full-time employment or qualifies for payments under any
    disability income plan provided by the company.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    All unvested options and restricted stock units issued under the
    applicable equity incentive plans vest upon a change of control
    under the terms of those plans.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee and Stock Option Report</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Compensation and Stock Option Committee has reviewed and
    discussed the Compensation Discussion and Analysis required by
    Item&#160;402(b) of SEC
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    with management. Based on this review and these discussions, the
    Compensation Committee has recommended to the Board of Directors
    that the Compensation Discussion and Analysis be included in the
    company&#146;s proxy statement for 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    COMPENSATION AND STOCK OPTION COMMITTEE<BR>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    John Schwartz,&#160;Ph.D., Chairman<BR>
    Eric Bjerkholt<BR>
    Ricardo Levy,&#160;Ph.D.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Notwithstanding anything to the contrary set forth in any of
    our previous filings under the Securities Act of 1933, as
    amended, or the Exchange Act that incorporate future filings, in
    whole or in part, the foregoing Compensation and Stock Option
    Committee Report shall not be incorporated by reference into any
    such filings.</I>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officer Compensation Tables</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following tables set forth information with respect to the
    compensation of our executive officers for the fiscal years
    ended December&#160;31, 2010, 2009 and 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Because the &#147;Stock awards&#148; and &#147;Option
    awards&#148; column reflects the dollar amounts recognized as
    compensation expense for financial statement reporting purposes
    in accordance with U.S.&#160;GAAP, these imputed values include
    amounts from awards granted from 2003 through 2010.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Bonus<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(2)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(3)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(3)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(4)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    525,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,050,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    260,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,139,312
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    540,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    202,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    410,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    132,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,324,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    385,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    519,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    229,221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,210,971
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Ann Tsukamoto,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    714,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    169,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,288,647
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    EVP, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    311,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,532
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    602,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
     and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    618,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Rodney Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    325,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    683,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    CFO and VP,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    396,667
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    127,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    882,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    Finance and Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    275,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Stewart Craig,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    275,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    664,496
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    Senior VP, Development and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    159,599
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,712
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    567,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    186,460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,187
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    275,762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Ken Stratton,&#160;J.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    275,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,713
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    621,314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 9pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,532
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    535,646
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    244,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    418,706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    We pay salaries on a bi-weekly basis. There were 27 pay periods
    in 2010.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Each employee&#146;s target bonus is based on his or her salary
    as of January 1 of the year to which it applies. For 2010, the
    Board awarded 90% of the target bonus for all company employees.
    For further description of the non-equity incentive plan see the
    discussion in our &#147;Compensation Discussion and
    Analysis&#148; and &#147;Compensation of Named Executive
    Officers,&#148; above.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Amounts shown represent the full grant date value of the option
    awards granted in each year as computed in accordance with FASB
    ASC Topic 718. Assumptions used in the calculation of these
    amounts are included in Note&#160;10, &#147;Stock-Based
    Compensation&#148; in our
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the period ended December&#160;31, 2010, filed with the SEC
    on March&#160;11, 2011.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    The amounts shown in the &#147;All Other Compensation&#148;
    column for 2010 include the following:</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Employer<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Match on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Employee<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Defined<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Health and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Contribution<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Welfare<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plans<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Transportation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Benefit<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(a)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Allowance ($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Plans ($)(b)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Compensation</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,117
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto, Ph.D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,277
</TD>
<TD nowrap align="left" valign="bottom">
    (c)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    EVP, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,973
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    CFO and VP, Finance and Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,386
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Senior VP, Development and Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,713
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -16pt; margin-left: 16pt">
    (a)&#160;Under a 401(k) plan, which is open to substantially all
    of our employees, we make matching contributions in the form of
    company common stock based on each participant&#146;s voluntary
    salary deferrals, subject to plan and legal limits. We match
    participant contributions on a 1:2 basis up to a maximum of 3%
    of the employee&#146;s salary. Registered stock is valued and
    transferred to the employee&#146;s 401(k) account at the end of
    calendar each quarter.</DIV>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -17pt; margin-left: 17pt">
    (b)&#160;We offer all employees various health and welfare
    benefit plans. Our executive officers may participate in these
    on the same terms as other employees.</DIV>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -16pt; margin-left: 16pt">
    (c)&#160;Includes life insurance benefit of $1,180.</DIV>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants of
    Plan-Based Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table shows grants of plan-based equity awards
    made to our named executive officers during the fiscal year
    ended December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>or Base<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Grant Date<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Fair Value<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>of Option<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name &#038; Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Units #(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options #(2)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/share)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards&#160;($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/25/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1,000,000
</TD>
<TD nowrap align="left" valign="top">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1,050,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/25/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    300,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1.05
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    260,970
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto,&#160;Ph.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    700,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    714,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    EVP, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1.02
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    169,020
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    204,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    CFO and VP, Finance and Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    50,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1.02
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    42,255
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    204,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Senior VP, Development and Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1.02
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    84,510
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    200,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    204,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    6/1/10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    50,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1.02
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    42,255
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Restricted stock units granted in 2010 to our named executive
    officers were made pursuant to our 2006 equity incentive plan.
    The restricted stock units granted to Mr.&#160;McGlynn and
    Dr.&#160;Tsukamoto vest over a three-year period from the date
    of grant: one-third of the award will vest on each grant date
    anniversary over the following </TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    three years. The restricted stock units granted to the other
    named executive officers vest over a four-year period from the
    date of grant: one-fourth of the award will vest on each grant
    date anniversary over the following four years.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    The options granted in 2010 to our named executive officers were
    made pursuant to our 2006 equity incentive plan. Generally,
    stock options granted to employees have a maximum term of
    10&#160;years, and vest over a four year period from the date of
    grant: 25% vest at the end of the first year, and 75% vest
    monthly in equal increments over the remaining three years. We
    may grant options with different vesting terms from time to
    time. However, the options granted in 2010 to our named
    executive officer have our standard vesting terms. Unless an
    employee&#146;s termination of service is due to retirement,
    disability or death, upon termination of service, any
    unexercised vested options will be forfeited at the end of three
    months or the expiration of the option, whichever is earlier.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;McGlynn received a grant of 1,200,000 restricted stock
    units on June&#160;25, 2010; however, in accordance with the
    company&#146;s equity compensation policies, Mr.&#160;McGlynn
    voluntarily rescinded 200,000 of these restricted stock units on
    September&#160;21, 2010.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal 2010&#160;Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following tables show equity awards held by our named
    executive officers as of December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/sh)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1/15/2001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.88
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1/15/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10/2/2001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.09
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10/2/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/12/2002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/12/2012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/2/2002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.01
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/2/2012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/2/2004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    350,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/2/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7/21/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    672,665
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7/21/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/23/2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    375,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/23/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/25/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/25/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/26/2001
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/26/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    EVP, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10/22/2001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10/22/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10/7/2002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60.000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.61
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10/7/2012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/3/2004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    225,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/3/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7/21/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,976
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7/21/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/23/2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    125,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/23/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/6/2005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    450,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.43
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/6/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    CFO and VP, Finance and Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7/21/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7/21/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/6/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/6/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/23/2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    125,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/23/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,645
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,355
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    09/15/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/15/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Senior VP, Development and Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.71
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/15/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    02/28/2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    02/28/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Market Value of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Restricted <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Restricted<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock Units<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock Units<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>That Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>That Have Not<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Vested (3)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Vested (4)<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date of Award</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>#</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>$</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3/10/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    81,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    190,081
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/25/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,080,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3/10/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    74,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    EVP, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    75,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    700,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    756,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3/10/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    74,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    CFO and VP, Finance and Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    170,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    183,601
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    216,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    75,600&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Senior VP, Development and Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    216,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3/10/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/15/2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    75,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/1/2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    216,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Unless otherwise noted, options are granted at the close of
    market price on the grant date (or on an adjacent market trading
    day if the Nasdaq Global Market is closed on the grant date).
    They vest over a period of four years as follows: one-fourth of
    the option vests on the first anniversary of the grant date and
    1/48th of the original grant vests each additional month of
    service.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    This was one of eight non-qualified, performance-based options
    granted by the Compensation Committee on June&#160;26, 2001 to
    employees who had been given year-long goals in January 2001.
    The exercise price was set at $3.10, which the committee
    determined to be approximately equal to the average market price
    during January 2001. The grants vested on December&#160;31, 2001
    to the extent that the individual goals had been achieved by the
    respective employees. It was determined that 12,000 of the
    12,500&#160;shares originally covered by the option issued to
    Dr.&#160;Tsukamoto had been earned, and the remaining
    500&#160;shares were cancelled. In accordance with APB 25, the
    company recorded $19,375 of compensation expense in 2001 in
    respect of this award.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Restricted stock units granted under our 2006 Equity Incentive
    Plan. These restricted stock units vest ratably over a three to
    four-year period on each grant date anniversary.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based on the per share closing market price of $1.08 for our
    common stock on December&#160;31, 2010.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="67%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Acquired on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Value Realized<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Vesting&#160;(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>on Vesting ($)(1)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Martin McGlynn<BR>
    President and CEO
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    196,166
</TD>
<TD nowrap align="left" valign="top">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    231,696
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ann Tsukamoto, Ph.D<BR>
    EVP, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    92,083
</TD>
<TD nowrap align="left" valign="top">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    109,308
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rodney Young<BR>
    CFO and VP, Finance and Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    125,416
</TD>
<TD nowrap align="left" valign="top">
    (4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    145,641
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stewart Craig,&#160;Ph.D.<BR>
    Senior VP, Development and Operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23,333
</TD>
<TD nowrap align="left" valign="top">
    (5)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    18,666
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ken Stratton,&#160;J.D.<BR>
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    50,833
</TD>
<TD nowrap align="left" valign="top">
    (6)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    58,983
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Calculated as the aggregate market value on the date of vesting
    of the shares with respect to which restrictions lapsed during
    2010 (calculated before payment of any applicable withholding or
    other income taxes).</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;McGlynn was granted: (i)&#160;412,500 restricted stock
    units on March&#160;10, 2008, 137,500 of which vested on
    March&#160;10, 2010, when the market price of our common stock
    per share was $1.22; and (ii)&#160;234,667 restricted stock
    units on May&#160;15, 2009, 58,666 of which vested on
    May&#160;15, 2010, when the market price per share of our common
    stock was $1.09.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Tsukamoto was granted: (i)&#160;206,250 restricted
    stock units on March&#160;10, 2008, 68,750 of which vested on
    March&#160;10, 2010, when the market price per share of our
    common stock was $1.22; and (ii)&#160;93,333 restricted stock
    units on May&#160;15, 2009, 23,333 of which vested on
    May&#160;15, 2010, when the market price per share of our common
    stock was $1.09.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Young was granted: (i)&#160;206,250 restricted stock
    units on March&#160;10, 2008, 68,750 of which vested on
    March&#160;10, 2010, when the market price per share of our
    common stock was $1.22; and (ii)&#160;226,667 restricted stock
    units on May&#160;15, 2009, 56,666 of which vested on
    May&#160;15, 2010, when the market price per share of our common
    stock was $1.09.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Craig was granted 93,333 restricted stock units on
    September&#160;15, 2009, 23,333 of which vested on
    September&#160;15, 2010, when the market price per share of our
    common stock was $0.80.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Stratton was granted: (i)&#160;82,500 restricted stock
    units on March&#160;10, 2008, 27,500 of which vested on
    March&#160;10, 2010, when the market price per share of our
    common stock was $1.22; and (ii)&#160;93,333 restricted stock
    units on May&#160;15, 2009, 23,333 of which vested on
    May&#160;15, 2010, when the market price per share of our common
    stock was $1.09.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Cash Compensation.</I>&#160;&#160;Prior to December 2009,
    non-employee directors received quarterly retainers for Board
    service in the amount of $4,500 ($8,750 for the Chairman of the
    Board). Each of the chairs of the standing committees also
    received quarterly stipends of either $1,000 (Audit Committee)
    or $500 (Compensation and Corporate Governance Committees).
    Non-employee directors also received $1,500 for each board
    meeting attended in person or by videoconference and $1,000 for
    each standing committee meeting attended in person or by
    videoconference, plus $500 for each board or committee meeting
    attended by phone. The non-employee directors serving on the
    Strategic Transactions Committee received $1,200 per meeting
    attended in person or by videoconference, plus $500 for each
    meeting attended by phone, but the chair of the Strategic
    Transactions Committee did not receive a quarterly stipend. All
    dollar amounts were paid in cash.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In early 2009, however, management began a review of our
    director compensation practices. We wanted to assess whether we
    were being responsive to market dynamics, as we had not adjusted
    director compensation for almost five years. We obtained and
    reviewed, among other things, the <I>2009 Radford Board of
    Directors Compensation Analysis&#160;&#151; Level&#160;2, Life
    Sciences Edition</I>, which provided us with a broad survey of
    director compensation paid by publicly traded life science
    companies in the United States. We also benchmarked our
    compensation practices against compensation information from
    other publicly traded companies in the stem cell
    field.<SUP style="font-size: 85%; vertical-align: top">4</SUP>

    From this information, we determined that the median (i.e.,
    50th&#160;percentile) cash compensation paid by comparable
    companies tended to be approximately 40% higher than that paid
    by the company and that the average initial equity grants
    awarded by comparable companies tended to be approximately 25%
    higher.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Therefore, in both June and December 2009, management presented
    to the Board a series of recommendations to change both the cash
    and equity compensation paid to our non-employee directors. The
    Board considered in particular the market comparables collected
    by management. In recognition of the fact that the
    company&#146;s director compensation fell significantly below
    the average compensation paid by market comparables, the Board
    approved the recommended changes to the cash-based and equity
    compensation paid to the company&#146;s non-employee directors.
</DIV>
<!-- XBRL Pagebreak Begin -->
<!-- XBRL Footnotes Begin -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV><DIV style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <SUP style="font-size: 85%; vertical-align: top">4</SUP>&#160;In

    2009 we collected director compensation information from the
    recent SEC filings of Aastrom Biosciences, Inc.; Athersys, Inc.;
    Cytori Therapeutics, Inc.; Geron Corporation; Neuralstem, Inc.;
    and Osiris Therapeutics, Inc.
</DIV>
<!-- XBRL Footnotes End -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Since December 2009, non-employee directors have received
    quarterly retainers for Board service in the amount of $6,250
    ($12,500 for the Chairman of the Board). The chairs of the
    standing committees have received quarterly stipends of either
    $2,500 (Audit Committee) or $1,250 (Compensation Committee,
    Corporate Governance Committee and, since it became a standing
    committee in June 2010, the Strategic Transactions Committee).
    Non-employee directors have also received $2,000 for each board
    meeting attended in person or by videoconference and $1,000 for
    each board meeting attended by phone, as well as $1,000 for each
    standing committee meeting attended in person or by
    videoconference and $500 for each committee meeting attended by
    phone. All these dollar amounts have been paid in cash, and we
    expect that this will remain the case for the foreseeable
    future. However, in March 2011, the Board unanimously approved a
    <FONT style="white-space: nowrap">sub-plan</FONT>
    under our 2006 Amended and Restated Equity Incentive Plan,
    permitting directors to elect to receive all or a portion of
    their board fees in the form of company common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Directors are reimbursed for their expenses in attending
    meetings of the Board and meetings of committees of the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Equity Compensation.</I>&#160;&#160;Prior to June 2009,
    non-employee directors received an initial option to purchase
    20,000&#160;shares upon appointment to the Board, with one-third
    of these option shares vesting on each of the first three
    anniversaries following the grant. Following appointment, each
    non-employee director received an option to purchase
    10,000&#160;shares upon each anniversary of his or her
    appointment, vesting one year after issuance, with each
    exercisable at the fair market value of the stock on the date of
    the respective grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In June 2009, however, the Board adopted management&#146;s
    recommendation to award non-employee directors with annual
    equity grants paid in restricted stock units rather than common
    stock options. The Board&#146;s decision to change the annual
    grants followed several months of deliberation by the
    company&#146;s management and Compensation Committee, which
    considered among other things equity compensation practices at
    various comparable companies, as described above, outside
    reports, the company&#146;s trading history, and market trends,
    such as the growing use of restricted stock units as director
    compensation by comparable companies. Each of the annual grants
    from June 2009 until June 2010 was for 10,000 restricted stock
    units, vesting on the first anniversary of the grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Then, in December 2009 and June 2010, the Board approved further
    changes proposed by management to the equity compensation
    practices for non-employee directors. Among other changes, the
    Board approved management&#146;s recommendation to award newly
    appointed directors an initial grant of restricted stock units
    rather than options. Presently, newly appointed non-employee
    directors will receive an initial grant upon their first
    appointment to the Board of 150,000 restricted stock units, with
    one third of this grant vesting on each of the three
    anniversaries following the grant. Thereafter, each non-employee
    director, other than the Chairman of the Board, is to receive an
    annual grant on each anniversary of his or her appointment to
    the Board in the form of 10,000 restricted stock units, vesting
    on the first anniversary of the grant. In addition, the Board
    determined that the Chairman of the Board is to receive an
    annual grant of 15,000 restricted stock units, vesting on the
    first anniversary of the grant. Each of the annual grants since
    June 2010 has been for 10,000 restricted stock units (15,000 for
    the Chairman), vesting on the first anniversary of the grant.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table summarizes cash-based and equity
    compensation information for our non-employee directors,
    including annual Board and committee retainer fees and meeting
    attendance fees, for the year ended December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>or Paid<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>in Cash<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eric Bjerkholt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,500
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,800
</TD>
<TD nowrap align="left" valign="bottom">
    (3)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    R. Scott Greer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,000
</TD>
<TD nowrap align="left" valign="bottom">
    (4)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    151,500
</TD>
<TD nowrap align="left" valign="bottom">
    (5)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ricardo Levy,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,000
</TD>
<TD nowrap align="left" valign="bottom">
    (6)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,700
</TD>
<TD nowrap align="left" valign="bottom">
    (7)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger Perlmutter,&#160;M.D.,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
    (8)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,700
</TD>
<TD nowrap align="left" valign="bottom">
    (9)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John Schwartz,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,000
</TD>
<TD nowrap align="left" valign="bottom">
    (10)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,550
</TD>
<TD nowrap align="left" valign="bottom">
    (11)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Irving Weissman,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,000
</TD>
<TD nowrap align="left" valign="bottom">
    (12)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,100
</TD>
<TD nowrap align="left" valign="bottom">
    (13)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
    (14)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    The amounts shown in this column represent the full grant date
    fair value of restricted stock unit grants in 2010 as computed
    in accordance with FASB ASC Topic 718. Assumptions used in the
    calculation of these amounts are included in Note&#160;10,
    &#147;Stock-Based Compensation&#148; in our
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the period ended December&#160;31, 2010, filed with the SEC
    on March&#160;11, 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an annual retainer of $25,000, a fee for
    Mr.&#160;Bjerkholt&#146;s role on the Audit Committee of
    $10,000, and additional fees of $16,500 for Board and committee
    meetings attended. Also includes $13,750 earned in 2010 but paid
    in 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Bjerkholt was granted 10,000 restricted stock units on
    March&#160;1, 2010, vesting on the one year anniversary of the
    grant. As of December&#160;31, 2010, he had stock options and
    restricted stock units outstanding for the purchase of
    80,000&#160;shares of common stock, in the aggregate.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an annual retainer of $25,000, a fee for
    Mr.&#160;Greer&#146;s role on the Strategic Transactions
    Committee of $5,000, and additional fees of $9,500 for Board and
    committee meetings attended. Also includes $11,000 earned in
    2010 but paid in 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Greer was granted 150,000 restricted stock units on
    June&#160;3, 2010, with one third vesting on each of the three
    anniversaries after the grant. As of December&#160;31, 2010, he
    did not have any options outstanding for the purchase of common
    stock.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an annual retainer of $25,000, a fee for
    Dr.&#160;Levy&#146;s role on the Corporate Governance Committee
    of $5,000, and additional fees of $18,000 for Board and
    committee meetings attended. Also includes $12,500 earned in
    2010 but paid in 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Levy was granted 10,000 restricted stock units on
    September&#160;26, 2010, vesting on the one year anniversary of
    the grant. As of December&#160;31, 2010, Dr.&#160;Levy had stock
    options and restricted stock units outstanding for the purchase
    of 142,165&#160;shares of common stock, in the aggregate.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an annual retainer of $25,000, and additional fees of
    $8,000 for Board and committee meetings attended. Also includes
    $9,250 earned in 2010 but paid in 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Perlmutter was granted an 10,000 restricted stock units
    on December&#160;14, 2010, vesting on the one year anniversary
    of the grant. As of December&#160;31, 2010, Dr.&#160;Perlmutter
    had stock options and restricted stock units outstanding for the
    purchase of 163,503&#160;shares of common stock, in the
    aggregate.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (10) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an annual retainer of $50,000, a fee for
    Dr.&#160;Schwartz&#146;s role on the Compensation Committee of
    $5,000, and additional fees of $18,000 for Board and committee
    meetings attended. Also includes $17,750 earned in 2010 but paid
    in 2011.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (11) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Schwartz was granted 15,000 restricted stock units on
    April&#160;18, 2010, vesting on the one year anniversary of the
    grant. As of December&#160;31, 2010, Dr.&#160;Schwartz had stock
    options and restricted stock units outstanding for the purchase
    of 148,000&#160;shares of common stock, in the aggregate.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (12) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes an annual retainer of $25,000 and additional fees of
    $10,000 for Board and committee meetings attended. Also includes
    $9,250 earned in 2010 but paid in 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (13) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Weissman was granted 10,000 restricted stock units on
    October&#160;1, 2010, vesting on the one year anniversary of the
    grant. As of December&#160;31, 2010, Dr.&#160;Weissman had stock
    options and restricted stock units outstanding for the purchase
    of 216,827&#160;shares of common stock, in the aggregate.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (14) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Weissman receives $50,000 per year for his services as
    a consultant and as the chairman of our Scientific Advisory
    Board.</TD>
</TR>

</TABLE>


<!-- link1 "CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS" -->
<DIV align="left"><A NAME="F59106007"></A></DIV>


<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Related parties can include any of our directors or executive
    officers, certain of our stockholders and their immediate family
    members. Each year, we prepare and require our directors and
    executive officers to complete Director and Officer
    Questionnaires identifying any transactions with us in which the
    officer or director or their family members have an interest.
    This helps us identify potential conflicts of interest. A
    conflict of interest occurs when an individual&#146;s private
    interest interferes, or appears to interfere, in any way with
    the interests of the company as a whole. Our code of ethics
    requires all directors, officers and employees who may have a
    potential or apparent conflict of interest to immediately notify
    our general counsel, who serves as our compliance officer. In
    addition, the Corporate Governance Committee of the Board of
    Directors is responsible for considering and reporting to the
    Board any questions of possible conflicts of interest of Board
    members. Our code of ethics further requires pre-clearance
    before any employee, officer or director engages in any personal
    or business activity that may raise concerns about conflict,
    potential conflict or apparent conflict of interest. Copies of
    our code of ethics and the Corporate Governance Committee
    charter are posted on the corporate governance section of our
    website at www.stemcellsinc.com.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In evaluating related party transactions and potential conflicts
    of interest, our compliance officer and independent directors
    apply the same standards of good faith and fiduciary duty they
    apply to their general responsibilities. They will approve a
    related party transaction only when, in their good faith
    judgment, the transaction is in the best interest of the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Dr.&#160;Weissman, a member of the Board of Directors, was
    retained in September 1997 to serve as a consultant to us.
    Pursuant to his consulting agreement, Dr.&#160;Weissman provides
    consulting services to us and serves on our Scientific Advisory
    Board. In return, we pay Dr.&#160;Weissman $50,000 per year for
    his services. We also agreed to nominate Dr.&#160;Weissman for a
    position on the Board of Directors, and he agreed to serve if
    elected. Since October&#160;1, 2000, he has been compensated for
    this service in the same manner and amount as other non-employee
    members of the Board. The consulting agreement with
    Dr.&#160;Weissman contains confidentiality, non-competition, and
    assignment of invention provisions and is for a term of fifteen
    years, subject to earlier termination by either party.
</DIV>


<!-- link1 "PRINCIPAL ACCOUNTING FEES AND SERVICES" -->
<DIV align="left"><A NAME="F59106008"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    ACCOUNTING FEES AND SERVICES</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Audit and
    Tax Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors, upon the recommendation of the Audit
    Committee, has selected the independent accounting firm of Grant
    Thornton LLP to audit the accounts of the company for the year
    ending December&#160;31, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Audit Committee considered the tax compliance services
    provided by Grant Thornton LLP, concluded that provision of such
    services is compatible with maintaining the independence of the
    independent accountants, and approved the provision by Grant
    Thornton LLP of tax compliance services with respect to the year
    ending December&#160;31, 2010.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Audit Committee received the following information
    concerning the fees of the independent accountants for the years
    ended December&#160;31, 2009 and 2010, has considered whether
    the provision of these services is compatible with independence
    of the independent accountants, and concluded that it is:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="81%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>12/31/10</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>12/31/09</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Audit fees(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    422,867
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    446,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    61,097
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,820
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Audit fees represents fees for the integrated audit of our
    annual consolidated financial statements and reviews of the
    interim consolidated financial statements, and review of
    audit-related SEC filings; also includes fees related to issuing
    comfort letter(s) in 2009 and 2010.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Audit and tax fees include administrative overhead charges and
    reimbursement for
    <FONT style="white-space: nowrap">out-of-pocket</FONT>
    expenses.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Pre-Approval
    Policies and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Audit Committee has adopted policies and procedures for
    pre-approving all services (audit and non-audit) performed by
    our independent auditors. In accordance with such policies and
    procedures, the Audit Committee is required to pre-approve all
    audit and non-audit services to be performed by the independent
    auditors in order to assure that the provision of such services
    is in accordance with the rules and regulations of the SEC and
    does not impair the auditors&#146; independence. Under the
    policy, pre-approval is generally provided up to one year and
    any pre-approval is detailed as to the particular service or
    category of services and is subject to a specific budget. In
    addition, the Audit Committee may pre-approve additional
    services on a
    <FONT style="white-space: nowrap">case-by-case</FONT>
    basis. During 2010 and 2009, all services performed by our
    independent auditors were pre-approved.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "REPORT OF THE AUDIT COMMITTEE" -->
<DIV align="left"><A NAME="F59106009"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    THE AUDIT COMMITTEE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Audit Committee oversees our accounting and financial
    reporting processes and the audits of our financial statements
    on behalf of the Board, and selects an independent public
    accounting firm to perform these audits. Management has the
    primary responsibility for establishing and maintaining adequate
    internal control over financial reporting, preparing the
    financial statements, and establishing and maintaining adequate
    controls over public reporting. Our independent registered
    public accounting firm for fiscal 2010, Grant Thornton LLP, had
    responsibility for conducting an audit of our annual financial
    statements in accordance with the standards of the Public
    Company Accounting Oversight Board (United States) and
    expressing an opinion on the conformity of those audited
    financial statements with generally accepted accounting
    principles.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Audit Committee oversaw the independent public accounting
    firm&#146;s qualifications and independence, as well as its
    performance. The Audit Committee assisted the Board in
    overseeing the preparation of the company&#146;s financial
    statements, the company&#146;s compliance with legal and
    regulatory requirements, and the performance of the
    company&#146;s internal audit function. The Audit Committee met
    with personnel of the company and Grant Thornton LLP to review
    the scope and the results of the annual audit, the amount of
    audit fees, the company&#146;s internal accounting controls, the
    company&#146;s financial statements contained in the
    company&#146;s Annual Report to Stockholders and other related
    matters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Audit Committee has reviewed and discussed with management
    the financial statements for fiscal year 2010 audited by Grant
    Thornton LLP, as well as management&#146;s report on internal
    control over financial reporting, using the criteria set forth
    by the Committee of Sponsoring Organizations of the Treadway
    Commission (COSO) in Internal Control&#160;&#151; Integrated
    Framework. The Audit Committee has discussed with Grant Thornton
    LLP various matters related to the financial statements,
    including those matters required to be discussed by SAS 114 (The
    Auditor&#146;s Communication with Those Charged with
    Governance). The Audit Committee has also discussed with Grant
    Thornton LLP its report on internal control over financial
    reporting, has received the written disclosures and the letter
    from Grant Thornton LLP required by Public Company Accounting
    Oversight Board (PCAOB) Ethics and Independence Rule&#160;3526,
    <I>Communication with Audit Committees Concerning Independence
    </I>(Rule&#160;3526), and has discussed with Grant Thornton LLP
    its independence.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based upon such review and discussions, the Audit Committee
    recommended to the Board of Directors, and the Board approved
    the recommendation, that the audited financial statements be
    included in the company&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ending December&#160;31, 2010 for filing
    with the SEC.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    AUDIT COMMITTEE
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Eric Bjerkholt, Chairman
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Ricardo Levy,&#160;Ph.D.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    John Schwartz,&#160;Ph.D.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "PROPOSAL NUMBER 1 Election of Directors" -->
<DIV align="left"><A NAME="F59106010"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;NUMBER
    1<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Election
    of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The number of directors is currently fixed at seven. Both our
    restated certificate of incorporation, as amended to date, and
    our amended and restated by-laws provide for the classification
    of the Board of Directors into three classes (Class&#160;I,
    Class&#160;II and Class&#160;III), as nearly equal in number as
    possible, with the term of office of one class expiring each
    year. Unless otherwise instructed, the enclosed proxy will be
    voted to elect the nominees named below, who are now
    Class&#160;II directors, as Class&#160;II directors for a term
    of three years expiring at the 2014 Annual Meeting of
    Stockholders and until their successors are duly elected and
    qualified. Both Class&#160;II director nominees have been
    recommended by the company because of their past experience
    serving on the company&#146;s Board of Directors, the breadth of
    their business expertise, sound judgment, and demonstrated
    leadership, among other things. In prior years, the Class&#160;I
    and Class&#160;III directors were nominated for appointment to
    the Board for similar reasons. Proxies cannot be voted for a
    greater number of persons than the number of nominees named
    below. It is expected that the nominees will be able to serve,
    but if any are unable to serve, the proxy will be voted for a
    substitute nominee or nominees designated by the Board of
    Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The nominees for election as Class&#160;II directors are as
    follows:
</DIV>


<!-- link1 "NOMINEES FOR ELECTION AS CLASS II DIRECTORS -- TERMS TO EXPIRE 2014" -->
<DIV align="left"><A NAME="F59106011"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOMINEES
    FOR ELECTION AS CLASS&#160;II DIRECTORS&#160;&#151; TERMS TO
    EXPIRE 2014</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="42%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="17%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Principal Occupation</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Age*</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ricardo Levy,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Lead Director, Renegy Holdings, Inc.
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    66
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Irving Weissman,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Professor, Stanford University
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    71
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Ages are as of April&#160;1, 2011.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Ricardo Levy,&#160;Ph.D.</I>&#160;&#160;was elected to the
    company&#146;s Board of Directors in September 2001. He most
    recently served as Lead Director of Renegy Holdings, the
    successor of Catalytica Energy Systems, Inc., an environmental
    emissions solutions provider. Prior to his role with Renegy
    Holdings, Dr.&#160;Levy served as Chairman of the Board of
    Catalytica Energy Systems from 1995, when the company was formed
    as a subsidiary of Catalytica, Inc., until October 2007 when the
    company merged to form&#160;Renegy. Dr.&#160;Levy was a founder
    of Catalytica, Inc. in 1974, serving as Chief Operating Officer
    from 1974 until 1991, and President and Chief Executive Officer
    until December 2000, when Catalytica, Inc. and its subsidiary
    Catalytica Pharmaceuticals, Inc. were sold to DSM N.V. Before
    founding Catalytica, Inc., Dr.&#160;Levy was a founding member
    of Exxon&#146;s chemical physics research team, and prior to
    that served as Chief Executive Officer of Sudamericana C.A. in
    Quito, Ecuador. He continues to serve as Special Advisor to the
    Board of Directors of Renegy Holdings, and also as a member of
    the Board of Directors of Accelrys Inc. (formerly Pharmacopeia,
    Inc.) and NovoDynamics, Inc., a private company focused on
    advanced image discovery. Dr.&#160;Levy holds Bachelor of
    Science and PhD degrees in Chemical Engineering from Stanford
    University, and a Master of Science Degree from Princeton
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Irving Weissman,&#160;M.D.</I>&#160;&#160;was elected to the
    Board of Directors of the company in September 1997 and has
    served as the chairman of the company&#146;s Scientific Advisory
    Board since that time. Irving L. Weissman is Professor of
    Pathology and Developmental Biology at Stanford University,
    Director of the Stanford Institute for Stem Cell Biology and
    Regenerative Medicine and Director of the Stanford Ludwig Center
    for Cancer Stem Cell Research. Among his many scientific
    achievements, Dr.&#160;Weissman&#146;s laboratory was the first
    to discover the mammalian stem cell and the hematopoietic
    (blood-forming) stem cell. Dr.&#160;Weissman was also
    responsible for the formation of three stem cell companies:
    SyStemix, Inc., StemCells, Inc., and Cellerant, Inc. He is a
    member of the Board of Directors and the Scientific Advisory
    Board of StemCells. Professor Weissman received his B.S. from
    Montana State College in 1961 and an M.D. from Stanford
    University in 1965. During medical school he conducted research
    on thymus cell migration for nine months with Sir James Gowans
    at Oxford University, England. He was a postdoctoral fellow in
    Dr.&#160;H. S. Kaplan&#146;s laboratory at Stanford University
    from
    <FONT style="white-space: nowrap">1965-1967,</FONT>
    and was appointed as a Research Associate in the Department of
    Radiology upon completion of the fellowship. He was appointed
    Assistant Professor of Pathology, Stanford School of Medicine in
    1969, Associate Professor in 1974, and Professor in 1981. He was
    an Investigator of the Howard Hughes Medical Institute from
    <FONT style="white-space: nowrap">1990-1992.</FONT>
    He was the Karel Beekhuis Professor of Cancer Biology from 1987
    until 2005 and the Chair of the Immunology Program, a
    degree-granting program from
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="white-space: nowrap">1986-2001.</FONT>
    In 2002 he became Director of the Stanford Cancer/Stem Cell
    Institute, which was split into the Stanford Institute of Stem
    Cell Biology and Regenerative Medicine, and the Stanford Cancer
    Center in 2003; Weissman was Director of both, and was principal
    investigator on the successful NCI Cancer Center grant. He
    stepped down as Cancer Center Director in 2008, but remains
    director of the Stem Cell Institute. In May 2005, he was named
    the Virginia and D. K. Ludwig Professor for Clinical
    Investigation in Cancer Research. Professor Weissman is an
    elected member of the National Academy of Sciences
    (1989-present), the Institute of Medicine at the National
    Academy (2002-present), the American Academy of Arts and
    Sciences (1990-present), The American Association for the
    Advancement of Science (1990), the American Academy of
    Microbiology (1997-present), and the American Philosophical
    Society (2008-Present), and also served as President of the
    International Society of Stem Cell Research (ISSCR) from 2009 to
    2010. Professor Weissman has received numerous awards for his
    many achievements throughout his career.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE
    <U>FOR</U> THE ELECTION OF THE NOMINEES DESCRIBED ABOVE.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "PROPOSAL NUMBER 2 Ratification of Selection of Independent Public Accountants" -->
<DIV align="left"><A NAME="F59106012"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;NUMBER
    2<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Ratification
    of Selection of Independent Public Accountants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The company is asking the stockholders to ratify the selection
    of Grant Thornton LLP as the company&#146;s independent public
    accountants for the fiscal year ending December&#160;31, 2011.
    The affirmative vote of the holders of a majority of the shares
    represented and voting at the Annual Meeting will be required to
    ratify the selection of Grant Thornton LLP.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the event the stockholders fail to ratify the appointment,
    the Audit Committee of the Board of Directors will consider it
    as a direction to select other auditors for the subsequent year.
    Even if the selection is ratified, the Audit Committee of the
    Board at its discretion could decide to terminate the engagement
    of Grant Thornton LLP and engage another firm at any time if the
    Audit Committee determines that such a change would be necessary
    or desirable in the best interests of the company and its
    stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A representative of Grant Thornton LLP is expected to attend the
    Annual Meeting and is not expected to make a statement, but will
    be available to respond to appropriate questions and may make a
    statement if such representative desires to do so.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE
    <U>FOR</U> THE PROPOSAL&#160;TO RATIFY THE SELECTION OF GRANT
    THORNTON LLP AS THE COMPANY&#146;S INDEPENDENT PUBLIC
    ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2011.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "PROPOSAL NUMBER 3 Advisory Vote on Executive Officer Compensation" -->
<DIV align="left"><A NAME="F59106013"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;NUMBER
    3</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Advisory Vote on Executive Officer Compensation</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">&#147;Say
    on Pay&#148; Vote</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Dodd-Frank Wall Street Reform and Consumer Protection Act of
    2010 enables our stockholders to cast an advisory vote at the
    Annual Meeting to approve the compensation of our named
    executive officers as disclosed in the &#147;Executive
    Compensation&#148; section of this proxy statement, including
    the Compensation Discussion and Analysis (the
    &#147;CD&#038;A&#148;), and the related tables and narrative.
    The vote on this resolution is not intended to address any
    specific element of compensation; rather the vote relates to the
    compensation of our named executive officers generally, as
    described in this proxy statement. Stockholders are urged to
    read carefully the CD&#038;A and other information in the
    &#147;Executive Compensation&#148; section of this proxy
    statement before casting their vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At this year&#146;s Annual Meeting, the company is also giving
    stockholders the opportunity to express a preference as to how
    often such &#147;say on pay&#148; advisory votes should be
    conducted in the future. The Board believes that these advisory
    votes are an important means of obtaining feedback from our
    stockholders about executive compensation, which is set by the
    Compensation Committee and the independent directors and is
    designed to link pay with performance. Although these votes are
    non-binding, our Board of Directors and Compensation Committee
    value the opinions of our stockholders and will consider the
    outcome of these votes when making future compensation decisions
    affecting our executive officers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Compensation Philosophy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The key elements of our compensation programs, which are
    described at length in the CD&#038;A, can be summarized as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>We seek to link pay to performance in a manner that promotes
    the company&#146;s long-term success.</I>&#160;&#160;We
    structure our compensation programs to attract and retain
    talented employees and reward them for helping us achieve our
    short-term and long-term goals. We intend for our compensation
    programs to be equitable and competitive when measured against
    those offered by companies against whom we compete for
    high-level scientific and executive personnel. We also intend
    for them to link pay to both company and individual performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In seeking to accomplish our objectives and commitment to good
    corporate governance, we follow a compensation strategy
    designed, ultimately, to reward increasing stockholder value.
    However, because achievement of our principle
    mission&#160;&#151; the research, development and
    commercialization of stem cell therapeutics and related tools
    and technologies for academia and industry&#160;&#151; is a
    long, expensive and challenging process, we often set individual
    compensation by using surrogate endpoints to gauge employee
    contributions towards building sustained stockholder value, such
    as the achievement of stated corporate goals adopted from time
    to time by the Board and the speed and effectiveness with which
    an executive officer discovers, assesses and, where appropriate,
    pursues promising opportunities for the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>We use customary compensation components.</I>&#160;&#160;We,
    like most biotechnology companies, use a combination of base
    salary, bonuses and equity awards to compensate our employees,
    including our executive officers:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    base salary is compensation for current efforts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    bonuses, whether in cash or equity, are typically paid for
    achievements in meeting stated corporate goals;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    equity awards are inducements to remain with the company and to
    build future value.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a small company and principally focused on advancing our
    HuCNS-SC therapeutic candidate through clinical development. We
    therefore do not employ compensation practices that we feel are
    better managed by larger companies or earnings driven companies,
    such as employee stock purchase plans, annual compensation
    benchmarking, and defined benefit pension plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>We target the 50% percentile.</I>&#160;&#160;While we believe
    our officers and other employees are outstanding, we realize
    that the company is not yet profitable and that it is still in a
    relatively early stage of development. We therefore
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    generally prefer to target our compensation practices so that
    our employees&#146; base salaries, bonuses, equity compensation,
    and benefits all fall close to the 50th&#160;percentile paid by
    comparable companies for similar positions. We also endeavor to
    set base compensation levels so that their salaries are
    competitive with salaries paid by comparable companies to
    employees with similar experience, taking into account the cost
    of living in the San&#160;Francisco Bay Area. However, as of
    late, we have been paying heightened attention to the global
    recession and the company&#146;s need to carefully manage its
    cash resources.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>We try to minimize risk and opportunistic
    behavior.</I>&#160;&#160;On occasion, we have considered our
    employee compensation programs, including our executive
    compensation programs, and the effect they may have on company
    risk. We believe our compensation practices are simple and
    straight-forward and consistent with those of similarly situated
    research and development companies. We believe further that our
    bonus and equity grant practices are well designed to reduce the
    likelihood of short-term profiting at the expense of the
    company&#146;s long-term interests. All bonuses are awarded
    entirely at the discretion of our Board, for example, after
    taking into consideration the progress of our company&#146;s
    programs and long-term prospects. We do not make formulaic bonus
    payments, such as bonuses driven by our financial reports, which
    we feel helps guard the company against opportunistic financial
    reporting. Instead, we believe our cash bonus program properly
    aligns compensation with the achievement of our overall
    operational goals, all of which are designed to have a positive
    impact on our business. With regard to equity compensation,
    which is customary in our industry, we typically grant equity
    awards that vest over many years after the date of grant. We
    believe discretionary equity compensation that vests over
    multiple years does not encourage short-term or high-risk
    opportunistic behavior and instead aligns our employees&#146;
    interests with the long-term interests of our stockholders by
    encouraging activities intended to build company long-term
    value. We also believe that equity compensation awards are an
    important component of our overall compensation policy because
    equity compensation can provide strong inducement to remain with
    the company and to build future stockholder value. For all these
    reasons, we have concluded that our employee compensation
    programs are designed with the appropriate balance of risk and
    reward in relation to our company&#146;s overall business
    strategy and do not incentivize executives or other employees to
    take unnecessary or excessive risks.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Further details concerning how we implement our philosophy and
    goals, and how we apply the above principles to our compensation
    program, are provided in the CD&#038;A.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Directors&#146;
    Recommendation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Compensation Committee and the Board of Directors believe
    that the information provided in our CD&#038;A demonstrates that
    our executive compensation programs align our executives&#146;
    compensation with the company&#146;s short-term and long-term
    performance and provides the compensation and incentives needed
    to attract, motivate and retain key executives who are crucial
    to the company&#146;s long-term success. Accordingly, the
    following resolution will be submitted for a stockholder
    advisory vote at the 2011 Annual Meeting:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    &#147;RESOLVED, that the stockholders of StemCells, Inc. (the
    &#147;company&#148;) approve, on an advisory basis, the
    compensation of the company&#146;s named executive officers, as
    disclosed pursuant to Item&#160;402 of Securities and Exchange
    Commission
    <FONT style="white-space: nowrap">Regulation&#160;S-K,</FONT>
    including the Compensation Discussion and Analysis, the
    compensation tables and narrative disclosures.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE
    <U>FOR</U> THE ADVISORY RESOLUTION TO APPROVE THE COMPENSATION
    OF THE COMPANY&#146;S NAMED EXECUTIVE OFFICERS AS PRESENTED IN
    ITS PROXY STATEMENT.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "PROPOSAL NUMBER 4 Advisory Vote on the Frequency of Future Executive Compensation Advisory Votes" -->
<DIV align="left"><A NAME="F59106014"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;NUMBER
    4</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Advisory Vote on the Frequency of Future Executive
    Compensation Advisory Votes</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to seeking our stockholders&#146; advisory vote on
    the compensation of our named executive officers, we are asking
    our stockholders to express a preference as to how frequently
    future advisory votes on executive compensation should take
    place. Although the frequency vote is non-binding, the
    Compensation Committee and the Board appreciate receiving
    stockholder input and will review the results of the vote. The
    stockholder vote under this proposal is not to approve the
    Board&#146;s recommendation but is instead a direct advisory
    vote on the particular frequency at which each stockholder would
    like future advisory votes on executive officer compensation to
    be conducted. You may cast your vote on your preferred voting
    frequency by choosing the option of every &#147;1 YEAR,&#148;
    &#147;2 YEARS,&#148; or &#147;3 YEARS,&#148; or you may abstain
    from voting on this Proposal&#160;Number 4.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After careful consideration of this proposal, our Board of
    Directors has determined that an advisory vote on executive
    compensation that occurs triennially, meaning every &#147;3
    YEARS,&#148; would be the most appropriate alternative for the
    company, and therefore our Board recommends that you vote for a
    three-year interval for the advisory vote on executive
    compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board believes that triennial votes provide assurance that
    the Board and the Compensation Committee remain accountable for
    executive compensation decisions on a frequent basis, but permit
    a more long-term approach to evaluating our executive
    compensation programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe our compensation decisions must reflect long-term
    strategic goals and avoid excessive focus on short-term
    financial results or short-term stock price fluctuations. Given
    the company&#146;s lengthy product development cycles, our focus
    on long-term performance and the three- or four-year vesting
    periods for our long-term incentive compensation, we believe
    that a triennial vote on executive compensation will enable
    stockholders to provide the most constructive feedback on our
    executive compensation policies and program. Conversely, the
    Board believes that a more frequent vote could encourage
    stockholders and the company to take a short-term view of both
    executive compensation and company performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A three-year cycle for voting on executive compensation would
    also enable us to implement any appropriate changes to our
    executive compensation program and understand the effects of
    those changes prior to the next advisory vote. The Board
    believes that advisory votes more frequent than three years
    would make it more difficult to analyze the results of prior
    votes in a comprehensive and timely manner, thereby limiting the
    depth and completeness with which we can react and respond to
    any stockholder concerns.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Directors&#146;
    Recommendation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While our Board believes a triennial advisory vote on executive
    compensation is consistent with our corporate governance and
    executive compensation philosophy, policies and practices, we
    understand that our stockholders may have different views as to
    what is the best approach for the company, and we look forward
    to hearing from our stockholders on this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS SELECT
    EVERY &#147;3 YEARS&#148; ON THE PROPOSAL&#160;CONCERNING THE
    FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<!-- link1 "PROPOSAL NUMBER 5 Approval of Amendment to the Company&#146;s Certificate of Incorporation to Effect a Reverse Stock Split" -->
<DIV align="left"><A NAME="F59106015"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;NUMBER
    5</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Approval of Amendment to the Company&#146;s</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Certificate of Incorporation to Effect a Reverse Stock
    Split</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">General</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors has unanimously adopted a resolution
    approving, declaring advisable and recommending to the
    stockholders for their approval a proposal to amend the
    company&#146;s restated certificate of incorporation to
    (1)&#160;effect a reverse stock split of the company&#146;s
    issued and outstanding common stock at any whole number ratio
    between, and inclusive of, one for seven and one for eleven (the
    &#147;Reverse Stock Split&#148;) and (2)&#160;decrease the
    number of authorized shares of common stock to 75,000,000
    (collectively with the Reverse Stock Split, the
    &#147;Amendment&#148;). Approval of this Proposal&#160;Number 5
    will grant the Board of Directors the authority, without further
    action by the stockholders, to carry out the Amendment to the
    company&#146;s certificate of incorporation at any time within
    four months after the date stockholder approval for the
    Amendment is obtained, with the exact exchange ratio and timing
    of the Amendment (if at all) to be determined at the discretion
    of the Board of Directors. Our Board&#146;s decision whether or
    not (and when) to effect the Amendment (and at what whole number
    ratio to effect the Reverse Stock Split) will be based on a
    number of factors, including market conditions, existing and
    anticipated trading prices for our common stock and the
    continued listing requirements of the NASDAQ Global Market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A sample form of the certificate of amendment relating to this
    Proposal&#160;Number 5, which we would file with the Secretary
    of State of the State of Delaware to carry out the Amendment to
    our certificate of incorporation, is attached to this proxy
    statement as Schedule&#160;1.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Rationale
    for a Reverse Stock Split</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock trades on the NASDAQ Global Market, which we
    believe helps support and maintain stock liquidity and company
    recognition for our stockholders. Companies listed on the NASAQ
    Global Market, however, are subject to various rules and
    requirements imposed by the NASDAQ Stock Market which must be
    satisfied in order to continue having their stock listed on the
    exchange (these are called the NASDAQ&#146;s continued listing
    standards). One of these standards is the &#147;minimum bid
    price&#148; requirement, which requires that the bid price of
    the stock of listed companies be at least $1.00 per share. A
    listed company risks being delisted and removed from the NASDAQ
    Global Market if the closing bid price of its stock remains
    below $1.00 per share for an extended period of time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The closing bid price of our common stock has been below $1.00
    per share since January&#160;19, 2011. On March&#160;3, 2011, we
    received a delisting determination letter from the NASDAQ Stock
    Market indicating that we were at risk of delisting because we
    have not been in compliance with the minimum bid price standard
    set forth in NASDAQ Marketplace Rule&#160;5550(a)(2). We believe
    we meet the NASDAQ&#146;s other continued listing standards. We
    therefore believe we can regain compliance with the minimum bid
    price requirement and remain listed on the NASDAQ Global Market
    if the closing bid price of our common stock were to reach $1.00
    or higher for a minimum of ten consecutive trading days at any
    time prior to August&#160;30, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Companies facing the risk of delisting for failing to satisfy
    the minimum bid price requirement have several alternatives
    available to them in order to regain compliance. The most common
    solution is to effect a reverse stock split in order to increase
    the trading price to above $1.00 per share for at least ten
    consecutive trading days.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All other things being equal, a reverse stock split by a
    publicly traded company reduces the number of shares outstanding
    but leaves the market capitalization of the company the same,
    which increases the price per share of the company&#146;s stock.
    Put another way, after a reverse stock split, the enterprise
    value of the company is spread over fewer shares and so the per
    share price of the stock will be higher. As an example, a
    hypothetical company with a market value of $50&#160;million and
    100&#160;million shares outstanding would have a trading price
    of $0.50 per share ($50&#160;million divided by
    100&#160;million), while the same company with only
    25&#160;million shares outstanding would have a trading price of
    $2.00 per share ($50&#160;million divided by 25&#160;million).
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are asking stockholders to approve this Proposal&#160;Number
    5 because we believe a reverse stock split will result in a
    higher price per share for outstanding shares of our common
    stock. This, we believe, could provide a number of potential
    advantages. We describe each of these below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Advantages from a Reverse Stock Split</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Potential Advantage&#160;#1&#160;&#151; Maintain NASDAQ
    Global Market Listing.</I>&#160;&#160;We believe that having our
    common stock delisted from the NASDAQ Global Market would be
    undesirable for our stockholders and potentially bad for our
    business. Among other things, being delisted could reduce the
    liquidity of our common stock. We also deem valuable our ticker
    symbol, which is easily recognized as &#147;STEM&#148; and which
    we could lose if we were delisted by the NASDAQ Global Market.
    Also, being listed on the NASDAQ Global Market carries with it
    certain prestige and we feel it improves the recognition of our
    company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While no assurances can be given, our Board believes that a
    reverse stock split, at a whole number exchange ratio ranging
    from one for seven (every seven shares outstanding would be
    combined into one share) to one for eleven (every eleven shares
    outstanding would be combined into one share), would result in
    an increase in the company&#146;s price per share, and thereby
    help the company meet the $1.00 per share minimum bid price
    requirement. While the company&#146;s stock price could trade
    above $1.00 on its own accord over the next few months, our
    Board believes that it is in the company&#146;s best interests
    and in the interests of our stockholders to seek approval of the
    proposed Amendment to effect the Reverse Stock Split, so that we
    can regain compliance even if the company&#146;s stock trading
    price does not increase above $1.00 per share by August&#160;30,
    2011, the end of our compliance period. Even if our common
    stock&#146;s closing bid price were to satisfy the minimum
    closing bid price requirements prior to approval of this
    Proposal&#160;Number 5, we may still effect the Amendment if our
    stockholders approve this Proposal and our Board of Directors
    determines that effecting the Reverse Stock Split would be in
    the best interests of the company and its stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Potential Advantage&#160;#2&#160;&#151; Facilitate Potential
    Future Financings.</I>&#160;&#160;By preserving our NASDAQ
    Global Market listing, we can continue to consider and pursue a
    wide range of future financing options to support our ongoing
    clinical development programs. To move our products through the
    clinical, regulatory and reimbursement processes, we will need
    to raise additional money. We believe being listed on a national
    securities exchange, such as the NASDAQ Global Market, is valued
    highly by many long-term investors such as large institutions. A
    listing on a national securities exchange also has the potential
    to create better liquidity and reduce volatility for buying and
    selling shares of our stock, which benefits our current and
    future stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Potential Advantage&#160;#3&#160;&#151; Increase Our Common
    Stock Price to a Level&#160;More Appealing for
    Investors.</I>&#160;&#160;We believe that the Reverse Stock
    Split could enhance the appeal of our common stock to the
    financial community, including institutional investors, and the
    general investing public. We believe that a number of
    institutional investors and investment funds are reluctant to
    invest in lower priced securities and that brokerage firms may
    be reluctant to recommend lower priced stock to their clients,
    which may be due in part to a perception that lower-priced
    securities are less promising as investments, are less liquid in
    the event that an investor wishes to sell his, her or its
    shares, or are less likely to be followed by institutional
    securities research firms. We believe that the reduction in the
    number of issued and outstanding shares of our common stock
    caused by the Reverse Stock Split, together with the anticipated
    increased stock price immediately following and resulting from
    the Reverse Stock Split, may encourage further interest and
    trading in our common stock and thus possibly promote greater
    liquidity for our stockholders, thereby resulting in a broader
    market for our common stock than that which currently exists.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Certain
    Risks Associated with the Reverse Stock Split</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The proposed Reverse Stock Split carries with it several
    significant risks.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We cannot assure you, for example, that the market price per
    share of our common stock after the Reverse Stock Split will
    rise or remain constant in proportion to the reduction in the
    number of shares of common stock outstanding before the Reverse
    Stock Split. For example, using the closing price of our common
    stock on April&#160;1, 2011 of $0.92 per share as an example, if
    our Board of Directors were to implement the Reverse Stock Split
    at a one for seven ratio, we cannot assure you that the
    post-split market price of our common stock would be or would
    remain
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    at a price of seven times greater than $0.92, or $6.44 ($0.92 x
    7). In many cases, the market price of a company&#146;s shares
    declines after a reverse stock split. Thus, while our stock
    price might meet the continued listing requirements for the
    NASDAQ Global Market initially, we cannot assure you that it
    would continue to do so.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The market price of our common stock will also be based on our
    performance and other factors, some of which are unrelated to
    the number of shares outstanding. If the Reverse Stock Split is
    effected and the market price of our common stock declines, the
    percentage decline as an absolute number and as a percentage of
    our overall market capitalization may be greater than would
    occur in the absence of a Reverse Stock Split. Furthermore, the
    liquidity of our common stock could be adversely affected by the
    reduced number of shares that would be outstanding after the
    Reverse Stock Split.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We also cannot assure you that the Reverse Stock Split will
    result in per share stock prices that will attract additional
    investors or increase analyst coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Failure to carry out the Reverse Stock Split also carries
    several significant risks, however. For example, if our
    stockholders do not approve the Reserve Stock Split, the company
    could be delisted from the NASDAQ Global Market, thereby
    potentially decreasing the liquidity of our stock and hurting or
    stock&#146;s market price.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Principal
    Effects of the Amendment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Text of the Amendment to our certificate of
    incorporation.</I>&#160;&#160;If the stockholders approve this
    Proposal&#160;Number 5 to authorize our Board of Directors to
    implement the Amendment and our Board of Directors decides to
    implement the Amendment, we will amend Section&#160;THREE of our
    restated certificate of incorporation to add substantially the
    following paragraph at the end thereof:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    &#147;Effective at 5:00&#160;p.m. Pacific Time the date of
    filing of the Certificate of Amendment with the State of
    Delaware (the &#147;Effective Time&#148;), each [seven] ...
    [eleven]&#160;shares of Common Stock issued and outstanding
    immediately prior to the Effective Time, without further action,
    will be combined into and automatically become one share of
    issued and outstanding Common Stock of the Corporation. The
    Corporation will not issue fractional shares on account of the
    foregoing Reverse Stock Split; all shares that are held by a
    stockholder as of the Reverse Split Effective Time shall be
    aggregated and each fractional share resulting from the Reverse
    Stock Split after giving effect to such aggregation shall be
    rounded up to the nearest whole number.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Immediately following the Effective Time, the total number of
    shares of capital stock which the Corporation shall have the
    authority to issue shall be 76,000,000&#160;shares, consisting
    of (i)&#160;75,000,000&#160;shares of Common Stock and
    (ii)&#160;1,000,000&#160;shares of Undesignated Preferred
    Stock.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Specifically, to carry out the Amendment, we would file with the
    Secretary of State for the State of Delaware a certificate of
    amendment in substantially the form attached as Schedule&#160;1.
    Stockholders are encourage to review this carefully as it would
    modify the capitalization of the company upon filing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Effective increase in the number of shares authorized for
    issuance.</I>&#160;&#160;Because the ratio at which the
    authorized capital stock would be decreased is less than the
    ratio at which the issued and outstanding shares would be
    decreased, there will be a greater proportion of shares
    available for issuance following the Amendment. We believe this
    effective increase in the number of shares authorized but
    unissued is important to the future growth of the company
    because we will need to raise significant additional funds in
    order to advance the company&#146;s various development
    programs, including the continued clinical testing of its
    HuCNS-SC<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    product candidate (purified human neural stem cells). These
    additional shares available for issuance may be used to raise
    money to fund the company&#146;s working capital and other
    corporate needs, for future acquisitions of assets, programs or
    businesses, and for other corporate purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Adoption of the Amendment, which would effectively increase the
    number of authorized shares, would not have any immediate effect
    on the proportionate voting power or other rights of the
    existing stockholders. However, upon issuance, any additional
    shares of authorized common stock issued after the amendment to
    the restated certificate of incorporation is effected would have
    rights identical to the currently outstanding shares of common
    stock.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To the extent that the additional authorized shares of capital
    stock are issued in the future, they may decrease the voting
    rights of existing stockholders and, depending on the price at
    which they are issued, could be economically dilutive to
    existing stockholders and have a negative effect on the market
    price of the common stock. Current stockholders have no
    preemptive or similar rights, which means that current
    stockholders do not have a prior right to purchase any new issue
    of capital stock in order to maintain their proportionate
    ownership of the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The company could also use the additional shares of capital
    stock for potential strategic transactions including, among
    other things, acquisitions, spin-offs, strategic partnerships,
    joint ventures, restructurings, divestitures, business
    combinations, and investments, although the company has no
    present plans to do so. The company cannot provide assurances
    that any such transactions will be consummated on favorable
    terms or at all, that they will enhance stockholder value or
    that they will not adversely affect the company&#146;s business
    or the trading price of our stock. However, we believe the
    effective increase in the company&#146;s authorized capital will
    be important to preserving the company&#146;s ability to
    opportunistically acquire assets and technologies to grow our
    business; a vote against this proposal could therefore hurt our
    ability to grow our business and complete our existing product
    development efforts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Management is unaware of any specific effort to obtain control
    of the company, and has no present intention of using the
    proposed effective increase in the number of authorized shares
    of common stock as an anti-takeover device. However, the
    company&#146;s authorized, but unissued, capital stock could be
    used to make an attempt to effect a change in control more
    difficult.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Neither Delaware law, the company&#146;s restated certificate of
    incorporation, nor the Company&#146;s amended and restated
    by-laws provides for appraisal or other similar rights for
    dissenting stockholders in connection with this proposal.
    Accordingly, the company&#146;s stockholders will have no right
    to dissent and obtain payment for their shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Reverse Stock Split ratio and resulting share
    numbers.</I>&#160;&#160;The Reverse Stock Split will be effected
    simultaneously for all of our then-existing common stock (the
    &#147;Old Shares&#148;) and the exchange ratio will be the same
    for all of our shares of issued and outstanding common stock.
    The Reverse Stock Split will affect all of our stockholders
    uniformly and will not affect any stockholder&#146;s percentage
    ownership interests in us, except to the extent that the Reverse
    Stock Split results in any of our stockholders owning a
    fractional share. Shares of common stock issued pursuant to the
    Reverse Stock Split (the &#147;New Shares&#148;) will remain
    fully paid and nonassessable. The Reverse Stock Split will not
    affect our continuing to be subject to the periodic reporting
    requirements of the Securities Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The information in the following table, which summarizes the
    possible effect of the Reverse Stock Split, is based on the
    following issued and outstanding equity, as of April&#160;1,
    2011: (i)&#160;137,743,512&#160;shares of common stock issued
    and outstanding; (ii)&#160;options outstanding to acquire up to
    13,840,851&#160;shares of common stock, and (iii)&#160;warrants
    outstanding to acquire up to 14,382,828&#160;shares of common
    stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Post-Split Common<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock Authorized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Common Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Warrant and Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Common Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>but Unissued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding after<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares Reserved<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Authorized after<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unreserved after<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>the Reverse Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>after the Reverse<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>the Reverse Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>the Reverse Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Split Ratio for Issued and Outstanding Shares</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Split(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Split</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Split</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Split(1)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1 for 7
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,677,645
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,031,954
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,290,401
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1 for 8
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,217,939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,527,960
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,254,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1 for 9
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,304,835
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,135,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,559,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1 for 10
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,774,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,822,368
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,403,281
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1 for 11
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,522,137
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,565,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,912,074
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    The actual number of shares of common stock outstanding after
    the Reverse Stock Split may be higher depending on the number of
    fractional shares that are rounded up. As of April&#160;1, 2011,
    the company had approximately 85&#160;million authorized but
    unissued and available shares of common stock.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Procedure
    for Effecting Reverse Stock Split and Exchange of Stock
    Certificates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If this Proposal&#160;Number 5 is approved by our stockholders
    and if our Board of Directors concludes that the Amendment is in
    the best interests of the company and its stockholders on a date
    within four months after stockholder approval is obtained, our
    Board of Directors will cause the Reverse Stock Split to be
    implemented at the whole number ratio between one for seven and
    one for eleven as selected by our Board of Directors in its sole
    discretion. We will file the Certificate of Amendment with the
    Delaware Secretary of State at such time as our Board of
    Directors has determined the appropriate effective time for the
    Amendment, including the Reverse Stock Split. Our Board of
    Directors may delay effecting the Amendment without resoliciting
    stockholder approval to any time within four months after the
    date stockholder approval is obtained (if at all). The Amendment
    will become effective on the date the Certificate of Amendment
    is filed with the Delaware Secretary of State (the
    &#147;Effective Date&#148;). Beginning on the Effective Date,
    each certificate representing Old Shares will be deemed for all
    corporate purposes to evidence ownership of New Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As soon as practicable after the Effective Date, stockholders
    will be notified that the Reverse Stock Split has been effected.
    We will retain an exchange agent (the &#147;Exchange
    Agent&#148;) for purposes of implementing the exchange of stock
    certificates. Holders of Old Shares will be asked to surrender
    to the Exchange Agent certificates representing Old Shares in
    exchange for certificates representing New Shares in accordance
    with the procedures to be set forth in a letter of transmittal
    to be sent by us. No new certificates will be issued to a
    stockholder until such stockholder has surrendered such
    stockholder&#146;s outstanding certificate(s) together with the
    properly completed and executed letter of transmittal to the
    Exchange Agent. Any Old Shares submitted for transfer, whether
    pursuant to a sale or other disposition, or otherwise, will
    automatically be exchanged for New Shares. <B>STOCKHOLDERS
    SHOULD NOT DESTROY ANY STOCK CERTIFICATES AND SHOULD NOT SUBMIT
    ANY CERTIFICATES UNTIL REQUESTED TO DO SO.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Fractional
    Shares</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No fractional shares will be issued in connection with the
    Reverse Stock Split. Stockholders of record who otherwise would
    be entitled to receive fractional shares, will be entitled to
    rounding up of their fractional share to the nearest whole share.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Effect on
    Options, Warrants and Other Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All outstanding options, warrants and other securities entitling
    their holders to purchase shares of our common stock would be
    adjusted as a result of the Reverse Stock Split, as required by
    the terms of each security. In particular, the conversion ratio
    for each security would be reduced, and the exercise price, if
    applicable, would be increased, in accordance with the terms of
    each security and based on the exchange ratio implemented in the
    Reverse Stock Split.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Accounting
    Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Amendment will not affect the common stock capital account
    on our balance sheet. As of the Split Effective Time, the stated
    capital on our balance sheet attributable to our common stock
    will be reduced proportionately based on the selected exchange
    ratio, and the additional paid-in capital account will be
    credited with the amount by which the stated capital is reduced.
    In future financial statements, we will restate net income or
    loss per share and other per share amounts for periods ending
    before the Reverse Stock Split to give retroactive effect to the
    Reverse Stock Split. The per share net income or loss and net
    book value of our common stock will be increased because there
    will be fewer shares of our common stock outstanding.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Discretionary
    Authority of the Board of Directors to Abandon Reverse Stock
    Split</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors reserves the right to abandon the
    Amendment without further action by our stockholders at any time
    before the effectiveness of the filing with the Delaware
    Secretary of State of the Certificate of Amendment to the
    company&#146;s certificate of incorporation, even if the Reverse
    Stock Split has been authorized by our stockholders at the
    Annual Meeting. By voting in favor of the Reverse Stock Split,
    you are expressly also authorizing our Board of Directors to
    determine not to proceed with, and abandon, the Reverse Stock
    Split if it should so decide.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">No
    Dissenter&#146;s Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under applicable Delaware law, our stockholders are not entitled
    to dissenter&#146;s rights with respect to the Reverse Stock
    Split, and we will not independently provide stockholders with
    any such right.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Directors&#146;
    Recommendation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The affirmative vote of a majority of all issued and outstanding
    shares of common stock is required to approve the Reverse Stock
    Split at the Annual Meeting. If you abstain from voting on this
    proposal to approve the Reverse Stock Split, it will have the
    same effect as a vote &#147;AGAINST&#148; the proposal. Your
    vote is therefore extremely important.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE <U>FOR</U> THE
    PROPOSAL&#160;TO AMEND THE COMPANY&#146;S CERTIFICATE OF
    INCORPORATION TO EFFECT THE REVERSE STOCK SPLIT OF THE
    COMPANY&#146;S ISSUED AND OUTSTANDING COMMON STOCK AND TO
    DECREASE THE NUMBER OF SHARES&#160;OF COMMON STOCK AUTHORIZED
    FOR ISSUANCE TO 75,000,000 AND TO AUTHORIZE THE COMPANY&#146;S
    BOARD OF DIRECTORS TO EFFECT THE AMENDMENT.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <U>Please Note:</U> This proxy statement contains forward
    looking statements within the meaning of Section&#160;27A of the
    Securities Act and Section&#160;21E of the Securities Exchange
    Act that involve substantial risks and uncertainties. Such
    statements include, without limitation, all statements as to
    expectation or belief and statements as to the future trading
    price and liquidity of our common stock, whether traded on the
    NASDAQ Global Market or otherwise; our future results of
    operations; our ability to satisfy all the listing requirements
    of NASDAQ; the prospect for analyst coverage; and the need for,
    and timing of, additional capital and capital expenditures. Our
    actual results may vary materially from those contained in such
    forward-looking statements because of risks to which we are
    subject, including the fact that uncertainties in our ability to
    obtain the capital resources needed to continue our current
    research and development operations and to conduct the research,
    preclinical development and clinical trials necessary for
    regulatory approvals; the uncertainty regarding our ability to
    obtain a corporate partner or partners, if needed, to support
    the development and commercialization of our potential
    cell-based therapeutics products; the uncertainty regarding the
    outcome of our clinical trials or studies we may conduct in the
    future; the uncertainty regarding the validity and
    enforceability of our issued patents; the uncertainty regarding
    whether any products that may be generated in our cell-based
    therapeutics programs will prove clinically safe and effective;
    the uncertainty regarding whether we will achieve significant
    revenue from product sales or become profitable; competition
    from third parties; intellectual property rights of third
    parties; litigation risks; and other risks to which we are
    subject. All forward-looking statements attributable to us or to
    persons acting on our behalf are expressly qualified in their
    entirety by the cautionary statements and risk factors set forth
    in &#147;Risk Factors&#148; in Part&#160;I, Item&#160;1A of our
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2010.
</DIV>


<!-- link1 "OTHER MATTERS" -->
<DIV align="left"><A NAME="F59106016"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    MATTERS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Proposals</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Stockholders who wish to present proposals for inclusion in the
    company&#146;s proxy materials for the 2012 Annual Meeting of
    Stockholders may do so by following the procedures prescribed in
    <FONT style="white-space: nowrap">Rule&#160;14a-8</FONT>
    under the Exchange Act. To be eligible, the stockholder
    proposals must be received by our corporate secretary on or
    before December&#160;&#160;&#160;, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Stockholders who wish to make a proposal at the 2012 Annual
    Meeting of Stockholders, other than one that will be included in
    our proxy materials, must notify us no later than
    March&#160;&#160;&#160;, 2012 (see
    <FONT style="white-space: nowrap">Rule&#160;14a-4</FONT>
    under the Exchange Act). If a stockholder who wishes to present
    a proposal fails to notify us by March&#160;&#160;&#160;, 2012,
    the proxies that management solicits for the meeting will confer
    discretionary authority to vote on the stockholder&#146;s
    proposal if it is properly brought before the meeting.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Nominations of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Stockholders or groups of stockholders that, individually or as
    a group, have beneficially owned at least 5% of the
    company&#146;s common stock for at least one year prior to the
    date of such submission (the &#147;Nominating Stockholder&#148;)
    may submit a candidate for nomination for election as a director
    at any annual meeting of stockholders in accordance with Board
    policy. The submission must be in writing and delivered to
    StemCells, Inc., Attn: Secretary, Board of Directors, 3155
    Porter Drive, Palo Alto, California 94304, no later than on or
    about April&#160;4, 2012 for nominees to be considered for
    nomination at the 2012 annual meeting. Submissions must include
    the name, address and number of shares of common stock
    beneficially owned by each participant in the Nominating
    Stockholder group, a representation that the Nominating
    Stockholder meets the requirements described in the Board policy
    and will continue to meet them through the date of the annual
    meeting, a description of all arrangements or understandings
    between or among the Nominating Stockholder group (or any
    participant in the Nominating Stockholder group) and the
    candidate or any other person or entity regarding the candidate,
    all information regarding the candidate that the company would
    be required to disclose in a proxy statement under SEC rules,
    including whether the candidate is independent or, if not, a
    description of the reasons why not, the consent of the candidate
    to serve as a director, and representations by the candidate
    regarding his or her performance of the duties of a director.
    Full details may be obtained from the secretary of the Board of
    Directors at the address above or on our website at
    www.stemcellsinc.com. The Corporate Governance Committee will
    consider and evaluate up to two candidates recommended in
    accordance with this policy in connection with any annual
    meeting. The Corporate Governance Committee will consider and
    evaluate candidates recommended by stockholders on the same
    basis as candidates recommended by other sources.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, the company&#146;s by-laws provide that a
    stockholder entitled to vote for the election of directors at a
    meeting may nominate persons for election as directors by giving
    timely notice thereof in proper written form to the Secretary
    accompanied by a petition signed by at least 100 record holders
    of capital stock of the company representing in the aggregate 1%
    or more of the outstanding shares entitled to vote in the
    election of directors, which petition must show the class and
    number of shares held by each person. To be timely, such notice
    and petition must be received at the principal executive offices
    of the company not less than 60&#160;days nor more than
    90&#160;days prior to the meeting, except if less than
    70&#160;days notice of the date of the meeting is given to
    stockholders, in which case the notice and petition must be
    received not later than the close of business on the tenth day
    following the day on which notice of the date of the meeting was
    mailed or public disclosure of such date was made. The
    requesting stockholder is required to provide information with
    respect to the nominee(s) for director similar to that described
    above, as more fully set forth in the company&#146;s by-laws.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;10-K</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The company&#146;s Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2010, as filed with
    the SEC, is available without charge upon request by writing to
    StemCells, Inc. at 3155 Porter Drive, Palo Alto, California
    94304, Attention: Investor Relations. A copy of this report is
    also available through our website at www.stemcellsinc.com or,
    alternatively, at www.sec.gov.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">&#147;Householding&#148;
    of Proxy Materials</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The SEC has adopted rules that permit companies and
    intermediaries such as brokers to satisfy delivery requirements
    for proxy statements with respect to two or more stockholders
    sharing the same address by delivering a single proxy statement
    addressed to those stockholders. This process, which is commonly
    referred to as &#147;householding,&#148; potentially provides
    extra convenience for stockholders and cost savings for
    companies. The company and some brokers household proxy
    materials, delivering a single proxy statement to multiple
    stockholders sharing an address unless contrary instructions
    have been received from the affected stockholders. Once you have
    received notice from your broker or us that they or we will be
    householding materials to your address, householding will
    continue until you are notified otherwise or until you revoke
    your consent. If, at any time, you no longer wish to participate
    in householding and would prefer to receive a separate proxy
    statement, or if you are receiving multiple copies of the proxy
    statement and wish to receive only one, please notify your
    broker if your shares are held in a brokerage account or us if
    you hold registered shares. You can notify us by sending a
    written request to StemCells, Inc., 3155 Porter Drive, Palo
    Alto, California 94304, Attention: Investor Relations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Board of Directors knows of no business that will come
    before the meeting for action except as described in the
    accompanying Notice of Meeting. However, as to any such
    business, the persons designated as proxies will have authority
    to act in their discretion.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    By Order of the Board of Directors
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="f59106def5910601.gif" alt="-s- Kenneth B. Stratton">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Kenneth B. Stratton,&#160;J.D.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Secretary
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    May&#160;16, 2011
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Schedule&#160;1</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTIFICATE
    OF AMENDMENT TO THE<BR>
    RESTATED CERTIFICATE OF INCORPORATION OF<BR>
    STEMCELLS, INC.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    StemCells, Inc. (the &#147;Corporation&#148;), a corporation
    duly organized and existing under the General Corporation Law of
    the State of Delaware (the &#147;DGCL&#148;), hereby certifies
    that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;Upon the filing and effectiveness (the &#147;Effective
    Time&#148;) pursuant to the DGCL of this Certificate of
    Amendment of the Amended and Restated Certificate of
    Incorporation of the Corporation (the &#147;Charter&#148;), each
    [seven to eleven]&#160;shares of the Corporation&#146;s common
    stock, par value $.001 per share, issued and outstanding
    immediately prior to the Effective Time (the &#147;Old
    Shares&#148;) shall automatically be combined into one validly
    issued, fully paid and non-assessable share of common stock
    without any further action by the Corporation or the holder
    thereof, subject to the treatment of fractional share interests
    as described below (the &#147;Reverse Stock Split&#148;). The
    Corporation shall not issue fractional shares in connection with
    the Reverse Stock Split. Holders of Old Shares who would
    otherwise be entitled to receive a fraction of a share on
    account of the Reverse Stock Split shall have their fractional
    share rounded up to the nearest whole number as of the Effective
    Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;Upon the Effective Time, the first paragraph of
    section&#160;THREE of the Charter is hereby amended to read in
    its entirety as set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The total number of shares of stock that this Corporation shall
    have authority to issue is 76,000,000, consisting of
    75,000,000&#160;shares of Common Stock, with a par value of
    $0.01 per share (the &#147;Common Stock&#148;), and
    1,000,000&#160;shares of Undesignated Preferred Stock with a par
    value of $0.01 per share (the &#147;Undesignated Preferred
    Stock&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3.&#160;This Certificate of Amendment shall become effective on
    [&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;],
    2011 at 12:01&#160;a.m. Eastern Time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    4.&#160;This Certificate of Amendment was duly adopted in
    accordance with Section&#160;242 of the DGCL. The Board of
    Directors duly adopted resolutions setting forth and declaring
    advisable this Certificate of Amendment and directed that the
    proposed amendment be considered by the stockholders of the
    Corporation. A meeting of stockholders was duly called upon
    notice in accordance with Section&#160;222 of the DGCL and held
    on June&#160;30, 2011, at which meeting the necessary number of
    shares were voted in favor of the proposed amendment. The
    stockholders of the Corporation duly adopted this Certificate of
    Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    5.&#160;The remaining provisions of the Restated Certificate of
    Incorporation, including without limitation the remaining
    provisions of section&#160;THREE, are not affected by the
    aforementioned amendment and remain in full force and are not
    affected by this Certificate of Amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    IN WITNESS WHEREOF, StemCells, Inc. has caused this Certificate
    of Amendment to be signed by its President and Chief Executive
    Officer, Martin M. McGlynn, and its corporate Secretary, Kenneth
    B. Stratton, on this [&#160;&#160; day
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;],
    2011.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    STEMCELLS, INC.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 2pt; margin-left: 49%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Martin M. McGlynn
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    President and Chief Executive Officer
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 2pt; margin-left: 49%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Kenneth B. Stratton
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Secretary
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>


<DIV style="FONT-FAMILY: Helvetica,Arial,sans-serif">
<P><DIV style="position: relative; float: left; width: 2%">

<dIV align="left" style="font-size: 10pt; margin-top: 540pt">&nbsp;
</DIV>

<TABLE style="FONT-SIZE: 7pt" cellSpacing=0 cellPadding=0 width="100%" border="0">
<tr><td nowrap> <BR>
<BR>
<BR>
<BR>
<BR>

<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>

<div style="margin-right: -170pt"><IMG src="f59106def5910622.gif" alt="(NUMBER)">
</div>
</td>
</tr>
</table>
</DIV>

<DIV style="position: relative; float: RIGHT; width: 1%">

<dIV align="left" style="font-size: 10pt; margin-top: 450pt">&nbsp;

</DIV>

<div align="left">
<TABLE style="FONT-SIZE: 7pt" cellSpacing=0 cellPadding=0 width="100%" border="0">
<tr><td nowrap>
<div style="margin-right: -40pt"><IMG src="f59106def5910620.gif" alt="(NUMBER)">

</div>
</td>
</tr>
</table>
</div>
</DIV>





<DIV style="position: relative; float: middle; width: 97%">

<DIV align=center>

<TABLE style="FONT-SIZE: 7pt" cellSpacing=0 cellPadding=0 width="100%" border="0">

  <TR vAlign=bottom>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="52%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD noWrap width="5%"></TD></TR>
  <TR vAlign=bottom><!-- Blank Space -->
    <TD>
      <DIV style="MARGIN-LEFT: 15px; TEXT-INDENT: -15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD><IMG src="f59106def5910616.gif" alt="(BARCODE)">
</TD>
    <TD>&nbsp;</TD>
<TD rowspan="2"><IMG src="f59106def5910617.gif" alt="(BARCODE)">&nbsp;</TD>
</TR>

  <TR style="FONT-SIZE: 6pt" vAlign=bottom>
    <TD vAlign=top>
<DIV align="center" style="font-size: 6pt; margin-left: 2%; margin-top: 0pt">
<IMG src="f59106def5910615.gif" alt="(STEMCELLS LOGO)">&nbsp;




</DIV><BR><BR>


</TD>
  <TD>&nbsp;</TD>

    <TD vAlign=top align=left>
      <DIV align=left style="font-size: 6pt">
<B>VOTE BY INTERNET - www.proxyvote.com</B><br>
Use the Internet to transmit your voting instructions and for electronic delivery of
information up until 11:59 P.M. Eastern Time the day before the meeting date.
Have your proxy card in hand when you access the web site and follow the
instructions to obtain your records and to create an electronic voting instruction
form.
</div>



<div style="font-size: 6.5pt; margin-top: 7pt"><B>Electronic Delivery of Future PROXY MATERIALS</B><br>
If you would like to reduce the costs incurred by our company in mailing proxy
materials, you can consent to receiving all future proxy statements, proxy cards
and annual reports electronically via e-mail or the Internet. To sign up for
electronic delivery, please follow the instructions above to vote using the Internet
and, when prompted, indicate that you agree to receive or access proxy materials
electronically in future years.
</DIV>



<div style="font-size: 6.5p; margin-top: 6pt"><B>VOTE BY PHONE - 1-800-690-6903</B><br>
Use any touch-tone telephone to transmit your voting instructions up until 11:59
P.M. Eastern Time the day before the meeting date. Have your proxy card in hand
when you call and then follow the instructions.
</DIV>

<div style="font-size: 6.5p; margin-top: 6pt"><B>VOTE BY MAIL</B><br>
Mark, sign and date your proxy card and return it in the postage-paid envelope we
have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
Edgewood, NY 11717.
</DIV>


</td>
  <TD>&nbsp;</TD>

</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="margin-top: 0pt">
<TABLE style="font-size: 8pt; background: #EEEEEE" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR style="font-size: 0px">
    <TD width="1%"></TD>
    <TD width="50%"></TD>
    <TD width="1%"></TD><!-- VRule -->
    <TD width="1%"></TD>
    <TD width="7%"></TD>
    <TD width="7%"></TD>
    <TD width="30%"></TD>
    <TD width="1%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 5px">
    <TD width="1%" style="border-top: 1px solid #000000; border-left: 1px solid #000000">&nbsp;</TD>
    <TD colspan="1" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="left" style="border-top: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
    <TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" valign="top" align="left"><DIV style="margin-left:5px; text-indent:-0px"><b>CONTROL # <FONT face="Wingdings">&#224;</FONT> <font style="width: 10%; border: 1px solid black; padding: 1px;">000000000000</font></b></div></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>NAME</b></DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size:4pt">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE COMPANY NAME INC. - COMMON</b></DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:5px; text-indent:-0px"><b>SHARES</b></div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE COMPANY NAME INC. - CLASS A</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE COMPANY NAME INC. - CLASS B</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE
COMPANY NAME INC. - CLASS C</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE
COMPANY NAME INC. - CLASS D</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE
COMPANY NAME INC. - CLASS E</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE
COMPANY NAME INC. - CLASS F</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:15px; text-indent:-0px"><b>THE
COMPANY NAME INC. - 401 K</b>
</DIV></TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><b>123,456,789,012.12345</b></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size:3pt">
    <TD width="1%" style="border-left: 1px solid #000000; border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD valign="top" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">&nbsp;</TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-left: 0px solid #000000; background: #ffffff">&nbsp;</TD>
    <TD valign="top" style="background: #ffffff">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; background: #ffffff">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><DIV style="margin-left:15px; text-indent:-0px">PAGE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 1&nbsp;&nbsp; OF&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</div></TD>
    <TD width="1%" style="border-right: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size:3pt">
    <TD width="1%" style="border-left: 0px solid #000000; border-bottom: 0px solid #000000; background: #ffffff">&nbsp;</TD>
    <TD valign="top" style="border-bottom: 0px solid #000000; background: #ffffff">&nbsp;</TD>
    <TD style="border-right: 1px solid #000000; border-bottom: 0px solid #000000; background: #ffffff">&nbsp;</TD>
    <TD valign="top" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-right: 1px solid #000000; border-bottom: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size:7pt; background: #ffffff">
    <TD NOWRAP width="1%" style="border-left: 0px solid #000000; background: #ffffff" colspan="2"><DIV style="margin-left:0px; text-indent:-0px">
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;<FONT face="Wingdings" style="font-size:12pt">&#120;</FONT>

</DIV></TD>

    <TD style="border-right: 0px solid #000000; background: #ffffff">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD width="1%" style="border-right: 0px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<DIV align=center>
<TABLE style="FONT-SIZE: 6pt" cellSpacing=0 cellPadding=0 width="100%" border="0"><!-- Begin Table Head -->

  <TR style="FONT-SIZE: 1pt" vAlign=bottom>
    <TD width="58%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD></TR><!-- End Table Head --><!-- Begin Table Body -->


  <TR vAlign=bottom>
    <TD vAlign=top> &nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=top align=center style="font-size:7pt" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=top align=right nowrap style="font-size:7pt">KEEP THIS PORTION FOR YOUR RECORDS</TD></TR>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1px dashed">
      &nbsp;</TD>
    <TD style="BORDER-TOP: #000000 1px dashed">&nbsp;</TD>
    <TD style="BORDER-TOP: #000000 1px dashed" vAlign=top align=left>&nbsp;
    </TD>
    <TD style="BORDER-TOP: #000000 1px dashed">&nbsp;</TD>
    <TD vAlign=top align=right nowrap style="BORDER-TOP: #000000 1px dashed; Font-size:7pt">DETACH
      AND RETURN THIS PORTION
ONLY</TD></TR>

<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center" style="FONT-SIZE: 8pt; margin-bottom: 2pt"><B>THIS &nbsp;PROXY&nbsp; CARD&nbsp; IS&nbsp; VALID&nbsp; ONLY&nbsp; WHEN&nbsp; SIGNED&nbsp; AND&nbsp; DATED.</B></DIV>




<DIV style="width: 100%; border: 3px solid #eeeeee ; padding: 1px;">




<DIV align=center>
<TABLE border="0" cellpadding="0" cellSpacing="0" style="FONT-SIZE: 7pt" width="100%">
<!-- Begin Table Head -->
  <TR style="FONT-SIZE: 1pt" valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
  <TR valign="bottom">

    <TD align="left" colspan="4" valign="top" style="font-size: 7pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 7pt"><b>For<BR> All</b></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 7pt"><b>Withhold<BR> All</b></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 7pt"><b>For All<br> Except</b></TD>
    <TD>&nbsp;</TD>
    <TD rowspan="2" valign="Top" style="font-size: 6pt"><DIV align="justify" style="margin-right: 3px">To withhold authority to vote for any individual nominee(s),
mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below.<BR>

<BR>
<font style="border-bottom: 1px solid #000000; width: 100%">&nbsp;</font>
</DIV></TD>
    <TD colspan="2" rowspan="2" style="border: 1px solid #000000; background: #EEEEEE">
<div style="margin-top: 2pt; margin-bottom: 2pt">
&nbsp;&nbsp;&nbsp;<font style="font-size: 30pt; border: 1px solid #000000; width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
&nbsp;&nbsp;&nbsp;<font style="font-size: 25pt; border-top: 2px solid #000000; border-right: 2px solid #000000; width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;</font>

</div>
<div style="font-size: 2pt">&nbsp;</div>
</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>

<TD align="left" colspan="3" valign="top" style="font-size: 7pt"><b>The
Board of Directors recommends you vote<BR> FOR the following:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 8pt"><br><FONT face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 8pt"><br><FONT face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 8pt"><br><FONT face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
  <TR style="FONT-SIZE: 7pt" valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="1" NOWRAP><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD NOWRAP>Election of Directors<br>
<b>Nominees</b></TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD ALIGN=RIGHT STYLE="BORDER-RIGHT: BLACK 0PT SOLID; BORDER-TOP: BLACK 0PT SOLID" VALIGN="TOP">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
  <TR style="FONT-SIZE: 5pt" valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="1">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


  <TR style="FONT-SIZE: 1pt" valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="1">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>



  <TR style="FONT-SIZE: 7pt" valign="bottom"><!-- Blank Space -->
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">01</TD>
    <TD align="left" valign="top" colspan="10">Ricardo Levy, Ph. D.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
02&nbsp;&nbsp;&nbsp;&nbsp;Irving Weissman, M.D.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" colspan="1" valign="bottom">
<DIV style="BORDER-BOTTOM: #000000 0px solid; FONT-SIZE: 1pt">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV style="position: relative; float: left; width: 47%">


<DIV align="justify" style="font-size: 7pt; margin-left:4%; margin-right:2%; margin-top: 0pt">&nbsp;</DIV>

<DIV align="center">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 1pt">
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD></TD>
    <TD colspan="5" valign="top" align="left"><B>The Board of Directors recommends you vote FOR proposals 2 and 3.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>For</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>Against</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>Abstain</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD></TD>
    <TD nowrap align="left" valign="top"><B>2</B></TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="left" valign="top" colspan="0">
To ratify the selection of Grant Thornton LLP
as independent public accountants of the
Company for the fiscal year ending December 31,
2011.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD></TD>
    <TD nowrap align="left" valign="top"><B>3</B></TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>    <TD nowrap valign="top">&nbsp;</TD>

    <TD align="left" valign="top" colspan="0">
Approval of a non-binding advisory vote of the
compensation paid to Stemcells&#146; named executive
officers.

</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"></TD>
    <TD></TD>
    <TD colspan="5" valign="top" align="left"><B>The Board  of
Directors recommends you vote 3 YEARS on the following proposal:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>1&nbsp;year</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>2&nbsp;years</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>3&nbsp;years</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>Abstain</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD></TD>
    <TD nowrap align="left" valign="top"><B>4</B></TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="left" valign="top" colspan="0">
Recommend, by non-binding vote, the
frequency of future advisory votes on
executive compensation.
</TD>
    <TD>&nbsp;</TD>


    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD></TD>
    <TD colspan="5" valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD valign="top"></TD>
    <TD></TD>
    <TD colspan="5" nowrap valign="top" align="left">For address change/comments, mark here. </TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>

</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"></DIV></TD>
    <TD></TD>
    <TD align="left" valign="top" colspan="5">(see reverse for instructions)</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"></TD>
    <TD></TD>
    <TD colspan="5" nowrap valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>



<!-- End Table Body -->
</TABLE>
</DIV>
</DIV>


<DIV style="position: relative; float: right; width: 47%">

<DIV align="center">

<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left"><B>
The Board of Directors recommends you vote FOR
the following proposal:
</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>For</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>Against</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>Abstain&nbsp;&nbsp;</B></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top"><B>5</B></TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD align="left" valign="top" colspan="2">
To approve an amendment to the company&#146;s
certificate of incorporation, as described in
the accompanying proxy statement, to effect a
reverse stock split of the company&#146;s issued and
outstanding common stock and decrease the
number of authorized shares of common stock to
75,000,000 and to authorize the Board of
Directors to effect this amendment to the
certificate of incorporation, within the
Board&#146;s discretion, at any time within four
months after the date stockholder approval for
the reverse stock split is obtained.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom" style="font-size: 10pt">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD colspan="5" valign="top" align="left"><B>NOTE:</B> In their
discretion, upon such other matters that may properly come before the
meeting or any postponements or adjournments thereof.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD colspan="5" nowrap valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>



<TR valign="bottom">
    <TD colspan="5" nowrap valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 22pt">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



</DIV>
<BR clear="all"><BR>



<DIV align="left">
<TABLE style="font-size: 7pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR valign="bottom">

    <TD colspan="7" valign="top" align="justify"><div style="margin-left: 2px">
Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary,
please give full
title as such. Joint owners should each sign personally. All holders must sign. If a corporation or
partnership, please sign in full
corporate or partnership name, by authorized officer.</div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 18pt; margin-left:4%; margin-right:2%; margin-top: 0pt">&nbsp;</DIV>

<DIV align=center style="margin-top: -20pt; background color: #eeeeee">
<TABLE border="0" cellpadding="0" cellSpacing="0" style="FONT-SIZE: 7pt" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size:1pt">
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD></TR>
<!-- End Table Head --><!-- Begin Table Body -->

  <TR style="FONT-SIZE: 10pt" valign="bottom">

    <TD>&nbsp;</TD>
    <TD align="left" colSpan=2 style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid"      valign="top">&nbsp; </TD>
    <TD align="left" style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 0px solid; BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid" valign="top">&nbsp; </TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="middle" rowspan="2"><B>JOB #</B> </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp; </TD>
    <TD>&nbsp;</TD>
    <TD align="left" colSpan=2 style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 1px solid; BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid" valign="top">&nbsp; </TD>
    <TD align="left" style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 0px solid; BORDER-RIGHT: #000000 1px solid; BORDER-TOP: #000000 1px solid" valign="top">&nbsp; </TD>
    <TD align="left" valign="top">&nbsp; </TD>

<TD align="right" valign="middle" style="font-size: 9pt" rowspan="2"><B>SHARES</B><BR><B>CUSIP #</B><br><B>SEQUENCE #</B></TD></TR>
  <TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" colSpan=2 style="BORDER-BOTTOM: #000000 0px solid; BORDER-LEFT: #000000 0px solid; BORDER-RIGHT: #000000 0px solid; BORDER-TOP: #000000 0px solid" valign="top">Signature [PLEASE SIGN WITHIN BOX] </TD>

<TD align="left" style="BORDER-BOTTOM: #000000 0px solid; BORDER-LEFT: #000000 0px solid; BORDER-RIGHT: #000000 0px solid; BORDER-TOP: #000000 0px solid" valign="top">Date </TD>
     <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" colSpan=2 style="BORDER-BOTTOM: #000000 0px solid; BORDER-LEFT: #000000 0px solid; BORDER-RIGHT: #000000 0px solid; BORDER-TOP: #000000 0px solid" valign="top">Signature (Joint Owners) </TD>
    <TD align="left" style="BORDER-BOTTOM: #000000 0px solid; BORDER-LEFT: #000000 0px solid; BORDER-RIGHT: #000000 0px solid; BORDER-TOP: #000000 0px solid" valign="top">Date</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
</DIV>




</DIV>


<BR clear="all"><BR>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#F59106toc">Table of Contents</A></H5><P>

<DIV style="FONT-FAMILY: Helvetica,Arial,sans-serif">

<DIV style="position: relative; float: left; width: 2%">
<dIV align="left" style="font-size: 10pt; margin-top: 400pt">&nbsp;

</DIV>

<TABLE style="FONT-SIZE: 7pt" cellSpacing=0 cellPadding=0 width="100%" border="0">
<tr><td nowrap align="right"> <div style="margin-top: 130pt"><IMG src="f59106def5910621.gif" alt="NUMBER"></div>
</td>
</tr>
</table>
</DIV>

<DIV style="position: relative; float: right; width: 97%">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="30%"></TD>
    <TD width="5%"></TD>
    <TD width="60%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

    <TD align="left" valign="top">&nbsp;
</TD>

    <TD>&nbsp;</TD>
    <TD rowspan="2" align="center" valign="top"><DIV style="border: 1px solid #000000; background color=eeeeee"><BR><BR><BR></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD rowspan="2" align="left" valign="top"><DIV style="border: 1px solid #000000; background color=eeeeee"><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">

    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 9pt; margin-top: 80pt"><B>
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
</B>
The Notice  &#038; Proxy Statement, Form 10-K is/are
available at
The
<u>www.proxyvote.com</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 1px dashed #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<P>
<DIV style="width: 100%; border: 3px solid black; padding: 0px;">


<DIV align="center" style="margin-top: 2pt">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="17%"></TD>
    <TD width="3%"></TD>
    <TD width="60%"></TD>
    <TD width="3%"></TD>
    <TD width="17%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="border: 1px solid #000000; background color=eeeeee"><br><br><br><br><br></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="font-size: 8pt" nowrap><B>
STEMCELLS, INC.<br>
ANNUAL MEETING OF STOCKHOLDERS, JUNE 30, 2010<br>
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
</B></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 6pt; margin-left: 4%; margin-right:4%; line-height: 12pt">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned stockholder, by completing this card, hereby appoints Martin McGlynn and Kenneth Stratton, or either of them with
power of substitution to each, proxies of the undersigned to vote at the Annual Meeting of Stockholders of StemCells, Inc. to be held on
June 30, 2010 at 3155 Porter Drive, Palo Alto, California at 2:00 p.m., local time, or at any postponements or adjournments thereof, all of the
shares of Common Stock, par value $.01 per share, of StemCells, Inc. that the undersigned would be entitled to vote if personally present.
The undersigned instructs such proxies or their substitutes to act on the following matter as specified by the undersigned, and to vote in such
manner as they may determine on any other matter that may properly
come before the meeting.
</DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 12pt; margin-left: 4%; margin-right:4%; line-height: 12pt">
<b>WHEN PROPERLY EXECUTED, THIS PROXY WILL BE VOTED AS DESIGNATED BY THE UNDERSIGNED. IF NO CHOICE IS
SPECIFIED, THE PROXY WILL BE VOTED FOR EACH OF THE NOMINEES FOR DIRECTOR LISTED BELOW, IN FAVOR OF
PROPOSALS 2, 3 and 5, AND FOR EVERY &#147;3 YEARS&#148; WITH RESPECT TO PROPOSAL 4. IN THIER DISCRETION, THE PROXIES ARE
ALSO AUTHORIZED TO VOTE UPON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING AND
ADJOURNMENT THEREOF.</b>
</DIV>




<DIV align="left" style="font-size: 9pt; margin-top: 30pt; margin-left: 24pt"><B>Address
change/comments:</B></DIV>

<DIV style="margin-left: 4%; margin-right: 4%; width: 100%; border: 1px solid black; padding: 3px; margin-top: 3pt">


<DIV align="left" style="font-size: 8pt; margin-top: 6pt; border-bottom: 1px solid black">&nbsp;</DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 6pt; border-bottom: 1px solid black">&nbsp;</DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 6pt; border-bottom: 1px solid black">&nbsp;</DIV>

<DIV align="left" style="font-size: 6pt">&nbsp;</DIV>
</DIV>


<DIV align="center" style="font-size: 7pt; margin-top: 3pt">(If you noted any Address Changes and/or Comments above, please mark corresponding box on the reverse side.)</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(Continued and to be signed on reverse side)</B><br><br></DIV>

</DIV>
</DIV>
<BR clear="all"><BR>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>







</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>f59106def5910601.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910601.gif
M1TE&.#EA:@`J`.8``%965EE967IZ>FEI:>3DY)>7EPD)">?GYYR<G-O;VR4E
M)=34U#`P,&9F9HZ.CJ^OKQ45%3<W-V)B8L3$Q"TM+>[N[AH:&J6EI;V]O>+B
MXK*RL@T-#;"PL!$1$6!@8,K*RLC(R!T='2$A(4Q,3("`@+6UM7Y^?HR,C'9V
M=G1T=**BHH2$A%%143DY.:"@H(*"@DI*2IJ:FCX^/IB8F$)"0BDI*9&1D<W-
MS8B(B+>WMWQ\?*NKJP0$!*>GIUY>7D9&1FUM;9.3DP<'!UQ<7`("`E-34S0T
M-$!`0$A(2-/3T_[^_OCX^/'Q\?W]_?O[^_3T].CHZ-C8V+BXN+Z^OCL[.]#0
MT/?W]_+R\OS\_+JZNHJ*BG%Q<?#P\-G9V>SL[-S<W-_?W\#`P,_/S^OKZV]O
M;SP\/,[.SL/#P_/S\^'AX<?'QZBHJ-?7U\;&QO7U]>WM[<+"POGY^=W=W=[>
MWL'!P>KJZKFYN?;V]IZ>GI24E.GIZ;^_OW-S<P$!`0```/___R'Y!```````
M+`````!J`"H```?_@']_2PY=@H>"31-?B(V.CY"-2I&4E9:7@@)^?(X91GTH
MF**CI*66:'U]`HU,-40\5*:RL[24!3Q^)(TF?GX&!8,O+&ZUQ<:B,K@?B$E"
M?GT#3R4AO1%.Q]C9B%&X$$R($KU^`Q:]?;Y/VNK'641]`8W4O43/N'XLZ_FU
M`+T<C5NI_-#S8P^8OH.E:/1*X@C(LW//_-3`@K"B*`5^0DQR5$6*AX<;Q%#B
M$J8")AP&8EB4Q8-'A$A3!OJQ$0E*@`Y^(GRCE`0`+@,)1C5)X&5=$AP^!I#H
MTFL$I#$,<!%AT>01@0'.Z/'80^D"!'$\7&":TN#G`VP83(B8UTM&+QJ/_[`<
M(>BG3!U'9DQLH&M.`R0K?.:=([*J$H81//J\XE&D&!8$-#80<988EXH-/&0\
MBF&.QX)&4!02Y"&D3TL_9ZS^$$>O3X2JD;P`$&*`'HP(0D+-JI`"@N+$SX2$
M\''!"@,AFALE.'?.`2(V$HAH;6D`HNY&:R`D3J48@B%(3[3P,&"`QX8+#\@'
M-?6!C`',+7D0B1`D`Z(6?1@T<E*F%P\`AWPQ@`&CU2..'R.@T<@=*-"S5V<]
M1+('!7U`(%T`4<0A0A\-F&*&!Z95U](&#4SPB`2F77/("_/4H,<?66PAGW]]
M*$!".8G5<$4C;(A&FCU]K``)%#[4TX<(</R!1?\1YV1!"A@IV..?C3L]H@,]
MC`A2177/.)`'%9WU(@(>7.!`$!$&1(%($P@0.)IBSI0!B0;R^$(&%X(@(%`+
MHRR!@A!2^M&"#291,@4N4QP"0VL1/=0+!#L(0H=TI%6!R!4*V=,2/4(8$8<C
M7(1CS@]J:FF!>7)@H@0"'0!7S1H;54+`5P;]\15$`Q$8@@1%_0$'@8J==8@9
M%DCWC`(*F1;",HU(80%$(:B`"!@X^>'/)0O4`%$?@-:*"0!]P'!(#A"9XX<1
MSAVRA':``GB(%L[XX8P#&OC29"-I2$`=$2.D<T@K!,%EB1/Z@L6#%@>4$H4!
M0GPFR`DR=``!%2QP`)O_(%<P,`\^@G31`E@6E)"$=GN1T8@*OM'&`P(J"N+$
M$(\R5`D)U58&Q!BS:,!#&/M%TL`Y+MTAR!86E)8*!6"\$<%@$4!QB!<^_$@$
M`U(XHH4O0D1*R1PCF),*$B;6XC0F-D"T`2-2B/`*1!'$@<4/`UEPER!VL$O$
M!B@LX4@8]K@+W@NXM-2'`0BL=$@;`J7BPP,1"#:>"5;\L8*\D_'\!P$>$-@2
M!<PV<D`(J2A0I2,+4`'H3PW(;/@?73MCFCE<RL"L&'OA<H$@4VP`)P\X1$+%
M*QNT\9>H$1E1ZNJ"!-"HUP(Y$/D@1OA'@Q-)1-?'!D*(`$(DD^.BRR,8?"7O
M_WA:Q(K\'V(`2]<Y*(2=2>(6@+&"[J3U`<`;D4A16WYX>@ZBHT90W?D.H88?
MF(T%:FB$'$)0'C_\@`$-Y):W'$&`9^GN!HZ8@L;$80`A#1`27<``''#F"#"=
M!E=^4,`:*L$/@0"A$6/8@OHRXZ0/FB)09_*#!,86"3RX8S[$.`0=Q-<+`\S`
MAK-H`$$"4J,26.(,M9D,&PZ1AB%(20@C&!T22;&$"`P$`C/P%R7>H!U<G.`0
M>2A'1`QPNRW6X@PV4,&.3D$!>1G@!U4Y@/((XHP(B,2-J]L"ISJ0!C?0+''G
M@,$<`;F2$ZSO`B50`$1P00%+,=)P;7`3$430N-9<SS\%>KOD2I00O1F9YA6`
MZD#51&DX.QQ('(J9RAQ8N3H]".26J2""`H1%R]5AQ5P10(#Y>FDX-3R`#!JX
'P3!M&`@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>f59106def5910622.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910622.gif
M1TE&.#EA"0!_`.8``&YK:M32T:NGI'IV=6%=7)22D6QH9IR:F82!@7)N;$5#
M0Y*/C]74T\;%Q&EE9+:SLF5A8,3#PM'/SNCFY?/R\7!L:NGIZ$U+2YF6E;V[
MNLC'Q[&OKH*`@,S*R75Q<-?5U-_=W.'@WZRHIY>4DZ&>G7Y\?)J8EL3`OXJ(
MB+:UM=S;VJ6CHO7T](R*B5E654(^/(:$A.+@X,O)R,_-S$9!/N/BX<"^O>#?
MWMC6UCDU,_#O[KFWMLK(QUU:6>7CXMK9V%924$Q&1-73T2,?']+1SSPY.??V
M]JZLJZ.@G^_N[NSLZ^SKZNCHYXB&A;JYN6-?7Z.AH).1D(%_?L+"PK*QL*^M
MK7MX=ZVKJI*0CS<R,>?EX_O[^_CX]_W]_<'`P.[M[/;V]?KZ^>_N[:NIJ>;E
MY/GX^-;3TE)/3X6#@S0P+]W<VSLX-W=T<XZ,C,+`P')P<'AU=)^=F^/BXI&-
MB8N(AXZ,BUM85_'P[U104,W,RS0O+KZ\NZBDHX2!?Y^<F____R'Y!```````
M+``````)`'\```?_@'^"@X0'-$-9<!:"1UA_9$]D!D9_42F"+W]-#7]?$&@`
M*W]U>8(Q57N"3&6"52Y#-"TZ@CLP76H5*@9A?PM.F'\PG!-/"W`FFCR"'P=7
M77\A+'\!.']"04%>@@O:+UM_!A]_)R-<%X(P4X)]`S1237"S?V41!0M4283Z
M@E]"_OX?P/R9\6*$P1$FF`CBPV"?PX>#6&B9.'$"KPA%4&A$T8:,H#CB((K\
M4T/@OA(A'VY!D*!E!1+/-D3Y]H<+`"%_#HPA9$6#(`(*##@HTH*0#B%F*#TT
M`<)A!"6"ECP8@2&#R2]!'@@)0**'-"P9"*7[D^>-#"T^O#B0(TB#@PL7_][4
M&+D/P@RZ#HD<-)CPCP4@'?X%%#2CZ4@*)J'`8'#G`("F$@;4`)(#V;:P*.8.
M6K#F@AX%%\Y4DTA1BT6\J%.K7LVZ=>H,3PS(-I#@AM\>6@&:!#$![P\)#KT(
M"#Y\GW#B?RBXF;.@PY8R7+38V:!!PPH(LZ+L((0@PA\>N?YTD4`@AJ``#A0H
ML++HCP09#A=`J%#`XV8O2_P8X%"MES9!#;@`W`,-[4/!$C6U@,(7@HSP"P%C
M4&&`0B1L8(X@:'CW!P$:0`!"#!"H((@2"+Q0!`%J#"*&%M!D)H@*/0S0!!XB
M.*#0""ETX4(U&?Y!10$A9`'%'QX$((@4/7SAP*T0(Q`2@@`BB#'(%_L9!(<4
MTC3#DT\;U$$3%P84B$$6:>BQA@VNP38;;;:!TZ8^8E"0&A=6>(``!P`4P(L(
M!Q"2`'!(##D(&QT(DL`:>)R11I^#;&$:(2NUE,!+,<TDB$TXZ;3E3T$-5=0@
M1R75*$LNP?0'":(,X@%\?J0J"!OP_=&."RZ\@(234$HY"!T>R%;!3G_PP:@@
8`-R%P1&;;F'`!4(I@,4SIE0'E2"!```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>f59106def5910620.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910620.gif
M1TE&.#EA"`!.`.8``,3!P%!,3N;EY+FVMO;U]7]Z>SHT-EY75=W;VBDD)HV)
MBN[L['%L;<S*RF)<79>2D^;CXN+AX$I%1[*OKIR8F,K(R?O[^^CFYC<Q,D<^
M/M?5U)Z;FT]+32$;'3XY.^SKZS$L+IJ6EXJ'B=/1T>CGYL7#Q-_=W5924Z"<
MG)B4E$(]/QL5&+6QL9",COCW]ZZKJO/R\LK'QJ>CHJ2AH!X8&M;3TB<A(ZRI
MJ71P<:JGI^KIZ=K8URXH*C0O,:^IJ!D3%B4?(=72TJNFI?KY^6!;7/W]_/3S
M\ZRHI[>TLYZ9FM?4TV1?8)F5EL*_OW1O;Y&-CO7T\_+Q\*^LK%M66,[+RX2`
M@65@88^,BT5`0L_-S)..C9.0CZFFIM'/S^_N[KRYNL*^O6->7A80$X)]?;Z\
MO,"]O9F6E<"^O>SJZ+2PKRLE)YN8F%1.4)^;F\/!P=S9V40_0)R7EX-_@)F3
MD%]:6JVJJI.,BJ^LJZ>DH[JWN.GHY[RWMDU'2::BH140$____R'Y!```````
M+``````(`$X```?_@']_:$(^"X(N;"M`0#]A.B\8>4%!93PW+"`Y%14W'1-_
M!31^?C1718)_)"2I5"@?@A,[?T)B)X=L'B9"-!AP!'\&*$)`,1X)82M(>QD(
M1E<8?1:IU-76U]C9VMO<W=ZI$Q)`-A(`?U0T#"$A!1T`22H"@@(@,Q<]!B<G
M&+I_"Q1.G#"!(L@(%3MS&@SYXP*$GPX=_'B(`(_5'QWU8J@IL*Y`@C-_4$BP
M02Z'-@485JPP$.</&!XBCAQY8F,`"@\C!-4`(>./!U*D^+"RL*-$"0VI`,@A
MXJ!*EC\1>&`A0D1"#PT/`J`29"`)!!H&IDS!`*3+GQ%;#AQX\J8@E2,OY!3^
ML>"`ADH:3A;,Z)'S3PTU.=(DN$')QZ<_8U:0^J%EX1\H2I0`$W1C"8<`8?(4
MJ=&!B`@186@T82)AL@4#;:+TZ)72`RL2+YX\D0+KCX`Z+6;#B@*"-0T/%TA/
M#M:&,YW/=9O\N6,E`.8OU"!8%*0%""D@>"SL`<*$4QP:2%`8B"`(`@\9+DXL
M:K0$EA<R%"B0@2$(P8;/2>0MZ*"&`P<;"2B1`@>.^93$&_TQP``;/.3T!0[Z
MX.!&*@)PHD<J;`#EAQ50R&!`"1!`T``/7.0!@AE&K9$`"W_@D``I-E1A!#:!
#```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>f59106def5910616.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910616.gif
M1TE&.#EA-@$Z`,0``%E65<'`P+V]NV5C8<?%Q.?EXU-.2T%`0)"+B(V&@[JW
MM,_-RW-L;*ZII>3DX-C8UKFVL\K(Q-32TN_N[=W=VHV)A[BTL?GX^*BDHNGJ
MY]'0S1X<'#0S,_____'R\````"'Y!```````+``````V`3H```7_8">.9&F>
M:*JN;.N^<"S/=&W?^'H%?.__P*!P2"P:C\BD<LEL.I_0J/0G&14V@ZQVR^UZ
MO^"P>$PNF\_HM'K-;KO?6X/UX*G;[_B\?L_O^_^`@8*#A(6&AXB)BHMW<B(%
M=(R2DY25EI>8F9I[CAV0FZ"AHJ.DI:*=GZ:JJZRMKJ"HD:^SM+6VMK&WNKN\
MO96YOL'"P\1VP,7(R<JKQ\O.S]"3S='4U=9]T]?:V]'9W-_@P][AY.6UX^;I
MZJ7HZ^[OE^W""`2;"O6K"*P-^'L+"7P<,/@F+Q@]>_U,Z5O%K\^_@`.Y%?1U
M4-,]5@M5->3S<(]`@G.@5<QT,=^^A'DZ_^KY*#'DLY&82JK*:&JC/X`>(VZ;
MV`OF)9D*3SK$N5*G-IZ\?%H"6HIF*9MZ5.9AN=.E,Z65F))R2@IJ2J)3C5Y#
MN@LK):VCN([RBD<J'JI'K2XS.PFM*+6BV-YQ>P?N6+G*Z$JR&PIO*+UV^-KQ
M:XVL+L&,"(,R#`IQ'<5U&%=S?`OR(LF;*&^R[`&S!\W4.-ORK`BT)M&:2)M&
MW0UP,M:)7&>"G4DVV+=B&]M&AAN1;DR\,?F&"/*1K+DHET9/*Y3C[[[!-P\O
M5OS0\4O)+RW/V=S3\\#3SZ8O7/TF\Y;.1:X?/#]T^ZC7%V=/O9U8=T/?61*>
M)>,555XJ5]7WF<>"N]WWU7M5Q?<2@[E1")Z#;>67V7ZU2>@,!`]LHD&(JT#`
M2@0D[D&!!7QD@,&!Y\$CXXR2J$;CC3@:TU^.//;8R(X^!HFCC4(6&0Z11B89
MEX=*-@D/DDY&N0R44E9)#)569MD+EEIVB0N07H9Y)9ABEKFE%1P(H.::;+;I
MYIMPQBGGG'36:>>=>.:IYYY\]NGGGX"RV<D$`!1JZ*&()JKHHHPVZNBCD$8J
@Z:245FKII9AFJNFFB%:0PZ>@ABKJJ*26:NJI,80``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>f59106def5910617.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910617.gif
M1TE&.#EA.P`2`;,``"TI*.?EXT%`0"LG)YV9F'-L;,?%Q-S;VM'0S^;FY1`-
M#LW,S/____'R\````````"'Y!```````+``````[`!(!``3_D,E)J[TXZ\V[
M]X$RC&1IGFBJIL`4"$TLSW1MW_C=2F_N_T#;CM$+&H]"%PS)1`Z+S>CON91:
M=<JKMD;=>F/=[S8LOI++TC.ZJ5X[L^YH.QZ<TZ?P^]&NQ_'[23Q5@'B"A'5Y
M-0<$C(V.CY",!VR)AWZ5EH%$@YF:4)V>G*`S?YVEF:>6J8>KA*V`KWVQ>K-W
MM72W<;ENNVN]:+]EP6+#7\5>QV.8HV#+S,E:T&;.H])6UFG4H-ARVJ;>J."J
MU`@%YN?HZ>KF")2&S%SBK/*N]+#VLOBT^K;\N/ZZ`/(2Z(L@,(/"$!)3:(PA
M,H?*WL$C!3%:Q6D2)S;+J)&;NTT:_RERG.B12<DW(^&=W'/Q6LML*9^][!:S
MVLR/GSK>-+D3)<B0&W\"76F$***:VWJR1/JM9@(#4*-*G4H5:@*<HF0LBL0U
MTB2>3,.%'3=V7MEZ9^^ES;=V7]M^;__%#3AW8-V"=P_F3;AW8=^&?Q\&CB@T
MI%$@APL5UCG88F.,BTDJ+3KY:&25E1%G5IQ3\F.7GV%>EAF:YFB;I;$"#=H9
M<VJPIY.^]MF:=.RFM\6>+K>N][IVL&NCSDV6N%GC:)&K5<Z6N5OG<*'+E4Z7
MNMW36[MJEZ1Z=6(?WW.$OS1[J76\Y_6FY[O>;WO`V+?+_TH[JVWALM\+UD\8
M/V[_N@%8G-V`QQ&8G('+(=B<@L\Q&)V#TT%8G83748B>A>IAR)Z&[G$(GX?[
M@=B??<.)Z!A_)YH(F8J@H;@BB?FQ*)J,IM'8W5";@9>C>#N2YV*+-@8'XW]#
M!ECD@$<6F.2!2R;8Y()/-ACE@U-&6.6$5U:8Y85;9MCEAE]V&.:'8X98YHBK
M-3`>%N51UJ9E0=:7YIJAS-DCFS_.>&:*>[YHYYN:`<I9GT`2JN>?>=9HJ**(
MQFF>HVXF>J-A=];I7:7Q"*JCICQRZB.D<"XZ*6.2"HGH`B*LH.JJK)XPQ`>P
&QJI!!``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>f59106def5910615.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910615.gif
M1TE&.#EA4`'Y`.8``-74TJZKJ7Q[>_[^_E).3)V:F!@5%65C8:"=FXF$@K.P
MK=K9UEQ34I",BHV+B>3DX4E%17)M;()\>:6CH<'`P(2"@4Y*2960CLG(QN'A
MWL+!OD1"0:RIIL_+R`@&!_K[^F%=7&EE9)63D2TI*,W,R=W<VG5S<OS\_&=@
M7E124;"NJ]+1SNCHYGIU<\?%Q,K&P[FXMFUK:NOKZ+V\NJ.@GK:VM5U:6>[N
M[%E03N;FX]C7U.WLZL;$P9B5DX)_?C4R,N7BX?;V]#TZ.:BFI+FWM,&^N[>T
ML<_.S"DF)3@U-.SKZ"4B(C$M+(J'AIJ8EN+BW[JYM]O:V,O*R$$^/=[>V^CF
MY,3#P/+Q\,[.S+R[N+2SL&MH9N_P[A\;&[^^O'IX=G-P;TY(1MS:U[*QK_'P
M[N#?W/#N[?7T\_CX]T-`0%I75CLX-PX,#/3S\OCW]BLG)S,O+R,?'W1J:!00
M$??W]G%G8_[^_?W^_?S\^]_?W?;U]/W]_?7U]/O[^_____'R\"'Y!```````
M+`````!0`?D```?_@'Z"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F,7!2=GI^@
MH0":I*6FIZB:+*&LK:ZOL*ZCJ944(P>XN;J[NR*TO\#!PI88O,;'R,G*R`3#
MD!0'?]+3U-750<[9VMO`'];?X.'BX^'-W(K0Y.#8Y^WN[X[>ZO/T]7_F\(3I
M]M+L^?\`V\GC1[#@O8""]O'SA["APU0##4J<AP^@0GL,'VK<:"GBQ(_E&EZL
MEY&CR9.,/()<2:WBOY'T2J*<25.02I8L7>:#.4]FS9\<;^($J1,>3W4^@2IM
M*'3HQ*+OCI)+NK1JOJ9.#4)U)W4<5:M@SV'-2G!KNZ[BOH9=ZVPL67MF_\^A
M#:>6K=U?;M_2B\MM[KJ[@+?EU:N.[S:_W^H&7IQI,.%QAK4AMJ:8L65*CA^'
M1#CYVN7/IS)K_A8Y6V=JE4&K7B1Z=+72SDY/2WUY@&T_)X+LV.%FCQ_;`PK=
M'G#BS&XT>X#_!C[@0Q`Z?90';.UZ&NQALONM7C1@CXPA8))T8<,FCA`P''8D
M'W1GSX,)$>",GQ,GC00%9O;<N0+E0@@&-LC11``KR(!'</]05]U!G$5#$&V!
MV;8"`QY4:.&%%:90@AW)'9$&AB"RL<46773QQ@\;X%"'!!<$\$(9:`"D8'77
M"9/='Q#>-4`?![!Q(1,H""!!"#_X6"$;!["0`O^&280@@``H,&$A&W,8T,42
M.#0Q@0)&**``#V6X(>."98GDX$+;&;+'$5)ZP$88"%2!8'`#[*`""',<6>$<
M*4P@`X*"#/#`$&K,,0<$"`!QQVV"]''%#C$F2"8_-09S8XZ&,+=<-HPB`F@A
M:XY0X0@]7*$IG7;8\<$8/U@(!P=M+*KI<D$,T<.?G0XB'26=?CK)C*Y5"LRE
MF1#71A4W(.?K+P/8L>QRN09:QAH5"I'!G'N<`4099)R`X!XLV.!!&&;,R>$'
MR-WAS(YFL'`%'I@`.YJPOQ!;27=](/!#GFQT`8$5=OAQ!0(-%&SPP08#X%MW
M1T@PXL-;A-"#<$6DH6'_KN"JL<$0F:I181)\V&9''T.LD:>;(U1P0W(#N-'#
M!]UU!T`,3!A@P!(6!-"&KBN$$`(-SPZ"@<\<*[+''F:`L82/;"P1@ZF5R*L9
MO;382\D=9U`+(A@G^%%%FR!B.,'")A@)8@J%G&!`A2#X1L@=!(QJB!05QL$%
MRSPL$;8'<S3P[<(`?!@B#>S54&$(00LR084Q++('"6N#:(:ZF$T*EYD%82K(
M'BA4:``*/K1`0!<K!"P#`2.D/D(<>ZJ>N@+!Z6#VV80,D(&%71SQZ0U&LL'"
MG!\DX:8*S:)10.\C$*#&%"=[$,+.@IQ``^L5O@&!!4FP$4.DOQGN_"*+>]"X
M_R)*=#$J&#YL(<0/B3<B]6-4IV+U)%<PW0/+'Y#@K1][*%'%_U4H0(4@`,#_
M!2$X3:@0$B;`@08ZD`>UT\"%+O`I&%R(`W/2084V`*\[!"!R(RC`$VQ#!QB`
M@'%F6(X&0"A"/-S!#`HH`Z`&X+T0@(]QB["@!YBP`N"8P067>!]AXH>*^4GB
M"*-Z0/L"Q8$*60`1G?-`$Y8X`!I<R"51K%`"`-6#"O4@.&YH4Q)6!J@]?*``
M`=A#P.YP`E%Y(`E?H>'A;BB^15R@0F!88B2$J!<BGL*(D2C!D1"@'^XTT0-/
M/$04+_`;10P@`1>:@Q+HI`0]><`&;AM`&#Q@``#8IO\!GM-#M)A#IQE4:`E0
M<V0-Z3B^1%AQAR787V,L5P\_F@*0D-B#WMP4@AL8THE0K!`C'><Q#\3-`PX(
MV`#")P`?P2%@_,M3&`ZX!R%4R`<'8L0`CNDW;:Y2$>%K)2(68*$X.*!KLZ0E
M13#W($L,8`7F.U(*%'`&3QTRD8:(XAI`P$]^HL!M@U""\#RP@+4E05UH.*$'
M`""J.2!(#Q4Z@&WVD*<Y[,`1`V`=&]1@@HYZ5`N9^F8BPNFX!)C-`"TX`CJC
MILYU-BAS[AR`%Z80R1CH`9JUNV<P]P9000#`?$LX`03<Q`4_`(!U2\##)CU`
M!D%4T@,1$(0;ZJ;'1D4N;";_".D<P8E#HZ'A`KM48`"B!0D^OL66I<!E)`9`
M!Q58P&PA6*FN=*K(O;%!KG[0@H\@@(<$>@`!?KBC!Q+`N0H!46","PX:*M2%
MJOH!#U<%45:%(U)$D)0[>ZA"$P;JIM*QM*7D0"LIU`H)YCR!LTT5#EWS6:$*
M%/!_PG%`A20P@`ZL;00GL$"%?N=7)P@"#Q6R@;?N8#XVS((1>WB#FT0@A>8Z
M]PE:_1Y7ZZC-W^QA!I&;@F,/85:RB%83I)6$;:Y`O2)D:K6%6"1W#E`A$N!&
MH23(DQ!\<T@UT,F:29CD-BNDAO5D:H8FJ-`6NC,(9T77AM,5IS;W(`+/<4\2
MW<W*_W<S$=Y)[`$.%3*O:H%95P\T@#NZ]0`+?H.`:K4V8!A8&Q(6Y@,W42`X
M4&":!IZEAS[H2@R>RX*-51G1]H5O"VL-@(,_"UIQ3!@3%79<`:J0'&<IP$@7
MW3`B$;$%_B+G:%C&Z0"0P+>NV<YL;/B`('8@/#;0P38\J-`7@K.'8\YA!GAP
M5G?V``0"V"`_RW%S$0Z$(%GIRI0>$`(0L$QH!`G9`U.H`AX(?;1!/,`(9P`.
M&L3UQNT:(L)..?(EDJP(%KB)"79NE1-[RD0.&P+0G"R1JKN`@D'LP4=KH-,>
M8F`A?`Z@F"7X#1K6%H<K\*\$&!Z@%I1P!1U$(')(B+(?VO_`V0T0`0@L($$(
MO#!#`%AH#JLN4:]]>NULE\B7?A#R'(2@AA10SP,\H-ROB@P9=J*I$EK8VP;J
M>5Y3%R((G*6=(.CF@10`"@H6^G"@OE`A:O-/L"#PU@"B8,V]N<D*/<W`DL(F
MA!$76*%A8T-J]U#,O>DWQ!ABP\0ZPFXCNQLCEB##!6R0A#AT(0DVF$`JA:.%
M.,0!!,_:0Q1,(`0X^/SG<`##()S@\RD.0@])@,,&%C!7GQ.O.VX0%1N&T&0N
M^""L%OI<"=2X!S(L[`PTV,#L//`&D!*"#DW8`-!__@-?\R\("5#[VN'P`U\.
M```"L``3NA"'*8`!8$$L^68"PFG_QUU!##K(3^(&\(<2B"$'0>N.'I1`^<K+
MP.T"H_P!"WP#)9AAI6S5_+<04%$OL&P/"[C`%E)``!`T`>*!6D$8W+LY/1BA
M"29`'PVH`"_AT*'RP%="3_?@AN!77LO@TD$)W+"H>`D>')JV1.&YLU:R!NI9
MN:*3IW2%()S^IL45*@`:M%\[X.PA`!K50A]8]M\=C7].OMK56J^?SN>_YN0D
M25,AT-`""ZWA"(DP`"4P5!>2`IZ$"'80!1NP!C-`:H30:))B?_?W4NVD?X30
M!Q-@-C\`!@%`!LZR!U#P!5-@)'-094>R!B:@`..W!R=@!"T@!.11)4+@`UH0
M!"QC!HCW_P0/]@Z8-A315PMG@G(6J"MV<`0@$%E\TSR>LP5'L`<ND`)C9R@7
MTB]Q8"4GD@8V``8L$@!@LH/NT(,X\8.4,'V6<0)Z8`4ML`9(R$E"\`4\(&:"
M0`<U$`%)H(2,E08^<`12T`0$L`9),`4X$`(LH@!'L#)C(H$M@7\Q,83"H2MD
M(`4!(`(B$``=D%J>L@-6,`222(CT-B=T(`8O4`0\H`-*`#,(`88YH8@]P8@!
MJ!S6)QS`(6?8QRBO^(6(F(@4^&ZLN(N7=HO6H8I(P8O"2`BHN!)B.`ED.(R7
M48Q$`8Q3H8S#R(P?<8R2D(S0N!C2^!3.Z!77R(O9*!'4&`G6V/^-=_&-6K&-
M:4&.K&B.!1&.SQ"$^:>.0\B.99*+0BB/^D>/E(*.=(&/%JB/EV./\>B/VP&0
MM<2/?T&0!>F+TN".CS"."KD4!KD7")D8$;D:$^E2A`>/BWB1H)&1A5&1E.&1
M'\F0#+*1,$62RVB2#ND($*F2,P&2H262G@&3C"&3[2:0'6F3@8&3)J>3\]`&
M=#"41%F41GF42)F42KF43-F43OF44!F54CF55(F4?,"2-&F26KF57!F0*-F5
M8!F68GF00#F69GF68-F2C7`CU"`#+&`/.7`#]<`%3R`1.?"6:)F7H*66C,"6
MTH``&R`$6D`#$)`&UP.8$``!-0`"-9#_!6F`=U,``5@0=HGI`BTP`=.0`D<@
M#0"@!D)P`%P@#B"0!FKP!S'@!#<``3)0`5.P`5J@E[!I.7RY"'X)`$@@!D10
M`7_P!!Z0`W^P!28@#5G`!J-C`!60!G\0`0X`G-/`!"H@#5*P!G@)`B:@)'49
M#D.0!-)@`"D@!5U`!$B0`2)@`[%9GC22E=6P`P1@``D0FE`0!](P!4Q@`5]P
M`1#`!A$`!FG@!-,@G_0I`T@``-(@`2`P#4[`!A"@`^/@`^19`EVP!CX``1O`
MG^99H?."GM4@`V,P!P'P!PU@`=(0!R)0`R2P!0(@!1;@!$N0!7]0!G\@HB1:
M`"#:D$U`#4:H_YWBD`*ZJ041D`(C8`)=P*+7::%$*F$8.@T@$`,:L`0S\`<A
MT`)_4`1,4`,SH(!#\`<&P`,CT``T8`!&,*55>@`V,`,SD`-(T`0SX`4DL`1>
M(``0\`=Y@`'?P`-OX`!_@`(%D$!&,`(.0`,C4`)_4*9%.JC-6);S,`80X'<[
M\`=@0`1_0)D0D`4@@`4RD`95(`)"``$!`*E9``8;D)A'\*D00``[``)"0`!>
M\`<<P)%_D`)I$`T'@`$:``$WP`%"L`$](`UAH*"$VJOM>*2TY`3/Z:O$>IZ&
M2@\R\`#?P`540`[,ZJQ#.AI4$)KC4`9R^0=T6:QC.9OHP*KU(`$&,/\'$<"9
M4_`'8[`$7?`#U4`!AC('/G"NZ?H'%M``),`&7!`"?`,`[]D%2'`#;U4E-S`'
M5$*8!?`'(G`]5&(`URH-*5!1%J`&Y$&>;(`!]OE3<8`$&#`>5**;TQ`%JQ,'
M-;"A!G``Y.0"/N"<?-,%,/`'BT,%,B`$`B`#;-`$;UH`:8"7?_"R,<L&,E`-
M+:NMTPBL?Q``<)`!.K`%<FD"5O`':R`",N`!FVF@R"D-3?NT1_`&,,`!ZJH#
M;^";_%0&#<`"2U`#G,FS!\!/3:`#7:`#8PL.63`%/3NV"+`$`,`&.Q`#IPD'
M#T`#F^D#P5D-("``?^``3F``5I`#2W`!AQ+_!RE0`.4*`0*0!R-@N%9@`/]B
M`0#`!#.P!+PJ#95[N=60!QN`!$L+M.`HM"80A#H@!'`Z`@MP`PM%#4!Z/9+[
MNNC&!"7@`S'P!UHP`M(P!D@P!2I0!8$&`4/``0;`<A3@`#Y0`6I`O)EZI=4@
M`-'PM"D`LV/`!'\``1=P!".0!-([!0A0#2S`!E'PNV^0LV\0`000!V$@`"WP
M`TW0!4/PH7!0`P4@!%V0`#5Z`''0H=20O_M;H]3PH8QINJ=[K.2@!KH)`QGP
M!Q4POD/PIAHP!]5@`7;Z!Q/L`D/`!B*0`G^0!$W*ASDK!3?P!7"@`4@P#6H`
M`G#PG%!``#_P`"H<_PX64*,53`#!V031,+9RV@!P4)=SP`/54*_"V0!OV@,6
M<`!-D`%30`,6$`8Q,`,Z,`(Q\`8%T`(",`5+\)HD7`U:S,6O.0TW,`(V8`$2
M@,#GJ,#CL`5J$&,:L`"E^0<N\+]3X`/5$`<-,`,N4,<1X`%?$*$3,`<WL`*M
M]P`8P`99P+XF``)D*K8UX`,@Z@(>$)R-_,C6T+9.H)I=8`4"P,!A0,E9X`,$
M\`?6MK#2D`<>8`0'8`$%$`=YXP13X*(<B@0]RZ@;D`!"D``60`.@M`!_``)I
M?,&^3%!_(`7GVP*YK#Q_L`!RJL9D^94%$05?``)&\`<%(`+34``@D*O3^_\D
M_,G-&]`$.9"ZJ8H`3^*;3F`#%9`!!?`D`G`#`I`!`*";.5`!P/S.3X+*TC#/
M?P`#K^D$6:`#!P`&`AH`:O`%"@H`!%P-4)`"/E`",M``*3`$5-``.2L`*Y#!
M@[N94%`#(J`#.H#'V+P"UA#2(RT-!2"@3;"9+E"P4,`!T!S-%N&MU?$$RCK3
M.ATL0GO,5'K+U$`"$W"^X;``-5`#P"P#1)`>&:`!-_`$-<`%"P`%#VS*4*"L
M-S`#6#`-#Y"J._W5I-'3$"`$2##'V[P$$&``BPH./M!W;/`$+@P'!1H'#VT"
M"\`$\OD'7L`$2?"F4S`%7>`"?\`"(%"N8'W8O\C_QN)``O"99M7P!E<ZL>&@
MHP_`!AP`!WF`7<'L+W_@`V!0QW\P`@B`!5*@`=H;)+^))(B]VMR:"'[)`6R0
M`DOP!=2P`DF0`T\+J.#0)C80`V!@KKZ;`'/PE@?*!A=@;2$P`ARPN4[0!0AP
M`:U,H:L-UJV-"'[I`VE``UY`K=(P`6\Z!O`)#BP0H"K`)W@<`B8P`VL`!S20
M`7.@`PE``%"0!%Q@`PF0`140`DN09FK0!;0]W=0MM&I`TM)``W*Z`DL@`$DP
MOEY``]8P`4L@R0,.LW&`!6]``PZP`5'@P6G0`QA@3FL``"#0`BE@`@#0`%NP
M!#(-X%]=W8?@ET[PS"KM_Z)_H`(Q`,`P,*S4H`5/,KZ#:]`3,+XZ(+@<$`'#
M6@!@(`5_$`5;(+U_8`4^SN([[>*&X)=2?N7J1.6%8.43`,\+T`0"H`$Y*P("
MH)L+T`(FX)L8$`/:#`7C:^#A,`/CFP4L:LH-/0TF2P+=G<$RT`0K;JYU/@0.
M4-74L``^(-A_<`0"(*<WX.<%G--87F1:K@\VK0XO^P45T`1:$.$&,`-/0"(7
M\``;(``CK@4_D`!=,`8'X+LC(.;@D-Q10`"N[@13.PTK,`5;L,(DWL)_\`,F
MD`0J\`058`!7Z@`IH`;D20TZ$`=-P`1'``5P(`$04`93\`4_D*N5"@'<'>DM
M-?_I@^"7+M`%9/H`#@"BW.NA(+H`(]#2.F`#P6D!%[`!!K`";`#IUC`%Q#X'
M.6T"6P"X#>`"%FP!%;`%M&W9$*`!*-X%2JZC6S"NU$`!2#`&&BX$+5``7C`#
M7?`'-N`#7$`BN\OMDBZT"&``:9`&)'``4/H#,KT%4&JN,+@"3#`&(3P$/P`"
M#!#>X&``(-"^TV`!4;Z=&M"[IR.?8D`":_`#I1RE;RH#!R"?2YL%-7#03+`$
M34`"XL,$38`!<]`#<R`"S@OO(!_RBAT.7W`F4[#2'E`"-S`%CMH`"A#"$Q"D
MJCP$%J`"L5W476#W&$RB2\#/!$7J#A"<!-`#(Z`%/!#_WE\PKC2`G`10HQN0
M!@$0!1X@`TY@`36P!'_`P%6@`42`Q1Z`!+&][6$_*=Z>$)5.#A:`!(G)`G.0
M!`8PO@3`!@5J`CAC`!E@`7#`!#X@`%]P.S+=Y=80`&"0`7"0^$S`!!R)UC^0
M!Q.`!-@C`Y_:)-)@`=H\!@:@!DD@H%R=O%U``[(#`EV`=]\K`HA<!!Y@TJ.?
MY4+K`D=-MD>-_C!0`X(M`UDP!'D`IQS`HEB@H%D`"#E_%PY_AH<`.G\843L<
M-2R'AU$<BG]$*GE_+$,S,H96&899`9J2?U$34H8`$U1_.1PSARQ9I[>XN;J[
MO+V^O\#!PL($?L;'R,G*R\S-_\T4!\/2OT:BT]?8V=K;W-W>NL7.XN/DR]#?
MZ.GJZ^SM[M+AY?+SYM'O]_CY^OOZ\?3_\\[Q&TBPH,&#I_P!7"A.(,*'$"-*
MQ*:0H45E#B=JW,AQ8L6+(/UD[$BRI,EW'T-:''FRI<N7TU*J7,@2ILV;.`_)
MG/F/PH@#0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JU:M`E(;)JW<JUJ]>O8+FF
M6&"L9LZS:$E:>"B@0UE[:>/*U;@68=NW<_/J/5CWX%V1</<*'NRNK\&_9@DK
M7HS-<$'$@1E+GBS,,4'(E#-K[F5Y(.;-H$,;ZLSOL^C3E$GO,XVZM6+5^EB[
MGJT7=O\^V;1SI[6-#[?NWS=YW_,-O'A+X>^(&U_>$;D[Y<RC2W3>#KKTZWSQ
M:;"$RSKV[_RH8Y,Q9((N[[QD8%A?<@>&2*<`-#A5HL*[&QAP(7"R;0>-^:V)
M)TP`&Q188`CGN058-BL@8<`(ZG@Q!#<:&,#!+36\<0H&<[Q3@@&XF!##-B;$
MH6&`[!Q1P(HL?M*=@HD!@P$;DGBQ@@H4&)(#%(;D8047AI#``1:28#&!"X<<
MH48*"!QQ"!8<Y&<("S!@,`9\N3A@`8*'8,`!`B?^0<(06G1H2`T89#+)$%Y(
M`L`0%.R`B"R[+.#!*3)X40.2AN@```PJN/A'!@'4<,,N4Q3_$.9I`JJ#'B\S
M2O+&'&H@48@,4_3P1PP@G-F%&G%<^$</<50PAQ:&$"%$$@<084@/;[0PP@6&
M8."!!4)$L`L3+K`AYQ]#&*!&%R?V8``(!ICYAP=I6)""(5[$84,<(ABR`AL2
M,/&%(65T`08<8.ABYREEV#!"&H<DP$880FS0)QPI_+#%+BQDZ%JCZ3RZ2Z2'
MO&&>`Q`84L%:2$SXQQH;'+`&`89<8*D@Z0H@R0\35EBK!SM(84LNUVJP!(]_
MP''A!"=:T,0ERGIP!`"H_@'&3P3$$20;%:QP2`E="+"*N'?>@@"ZAB2@QA^]
M&M)`'`>`X,$#N]B+HETP1B8-OX:\_U'#'PT$+.8<),S!]!],A-!``Z)R$L,2
M`40L"1-C$$WC(F_O@D`7$"!AWQ]+&/%'`"="4*T5*2\@R180C%VM(0J`\4,+
MAVAA@A`CYC*NST#_D8#$_"8`Q]@-8(F+TZCABXZ^N0!0@0<(F&(UUEK_(408
MNAK20@I0.`&R"$U@0$`"ATQ@@1$[AW"`"U\\"W<O$9CPAQ/&QT"[&B>"$<8,
M*00NB1-)U$##U7]D$0$&8-2EPA<N-`&AY*@CD/HA/ZO-KQ9,!*""IDTO*IKH
MWY#^.03\DV`("DCB`.,,H0(([,P0(4A#"LI0JQ0HT!I_N$$*(-`V!*;!!O`!
M`&],8`5#'/^`@3>P0<)08(@,Q"`-SCL$!"!HM#1`0$HL4(,"-7`($#3+2;G(
M`/_Z=X@:A,L00RC`'S38NP)Q3Q<N(.'3_!(U\#CQ(?CSAOZ>2,5O1+$;4]3+
M`_A$"QH2!`L'Q`86`M"F)1ZFB=A80%#4004B;4,'!Y"2)&#`A%-(H0OO>(#4
M_H"#UEVC"".8P@CNQBBVH/$:&0"#!TZ6CLMQ@P9=(&0/[<>A=TSN%"OP7S9X
MH`@7]*R04,-+-J@&-B&P(0XVT\$(\G,!"P`I!R-@PP^^A@$F&&`)46B8!SS`
M!EK]H00_N*7@_B"%.=@2`;NP`0)D5L(EL.$-)R+!#V2I+#;8\F[_.5`#&[JP
M,QFLP0!Q4,$A-F```VP,%Y<T1!28P(;6.6`*R0+0#5K`ACD<41<-P&/H#"E*
M;)#R#2:X@0\8MJEHI(&1:F@"%UK0J3\,[`\J`(#:#F$!^]#@?+9:P`5BAXL<
ML$$&!M!D&"1P@R^<"`3S2D#*B,`!&QBB"4,;@KO^,(,.:<"+&I@E"4"&SD\:
M@@M4:$#E$H"$)T`!1'^8@!!DT+5=:!"59GS,(:_QSZMEC8!+>``;;/:'$22!
M?P,\`@C@0``<6DYB_;H:OTB9"RVP(0USX,\?XL`C+9QH`YIR@?4.<0`D\,]X
M+`C!#R"0-D/$8`UI$"?Z]#/4;?&K`G3C_Q\+)7$#5GUMGZ%<T"CC]H?57146
M!DC`3/\`@9-%(9<TQ<`14D!($8"!"R["ZQ_&L(1:<387%2!`#4(PKS],X61-
M.)$:PG6!O1I"`$-[P#!74`,=A*]6,XB"^7C&6/>]S0EKN($,S'J+(:3ALIAE
M!Q6RH`'PWB*+DD#`+CTPB\Y:M75-\(!Y6-&%)73!8")80AA.=8@5S(%:AIC!
M&S;0!9"Q%1<$0.8*DL`T*8"36&>*`Q+B8-PAKJ$+<Q`BT0P0ACCX`%I+V$`<
MT-K3];;W#^T+&N;>]H`4&*`+7,+%Z79Y6]!<D1=$@$"!<,#3\TYU'R40U!]D
M,$Q)R.`)E"U!-_\F>X-7]"(/GN/"`H2\@R@(^1LY0/)U;JR+(^#@`B20PD`]
M)PGT5O',C6$'#42%.`W[N)]HCG,[N)R+`A1!$A@`T)LU>XUZU>">&ZF7>?_@
MA3!@<@WOD`&@#;$%EV:C`2.(-!RB^@T52,!%,G!`8?<<(U\LF%GJ$`&)LZ$%
M#QQ.$J"KE;+8D<Y#7("1V"@!!C0P`H*"4ATLB$`8>$N`AKX(SM,@90R:0(#>
MZ@`$3(/!%X#T!P%8X,,Z<C88#O4'#KS!KVP>V`__H`,U?$$-<L3%%UHPVC]$
M@``'.!$+?&`!$R@K!<4[(@TL<``L-<$"6Y!HPRR`;.I*X@G.(S$'+@#_@A3P
MX!!&L(`-4)M#"Q"`V;=6QP-Z0(`P)(#AG-ZC,/X)`0ZD8%Y<4(/$U*`\RZ6`
M`Q4UA`/6,`,4=)#;(0!!<PT1`37`(`2.MM4%@**+'71A`7-0\A]:8`&4G^@+
M:1B#!5+F@R_4A09K4,$6>MLK*`A`PRL8P1@J<.I;M)H%"+!AN@R``!^<:`8_
MF$`%$*T+(Z0A"=".^$^!0>UMF+E+G'U#VC[;`R%PH0LM^\%@1U"7`(2M!X)R
MY"'@D#;`74S*W-T0S0Q06"2TS=J&@`"M'&\(#P`@#SL[&P2$H$\=Q`$$%T#M
M$WY@@R9HN:?5#5HT^-6$R'I@LK>P`AN$?K]3_W!AT[P0`PUXH2(6K2CRA[B[
M;27UWCZQP0CZ_,,/@*^C"VQNHH:8_A\X?^!;..P`2=A65\5),D.$H1!9J'`,
MMIU>"!AOR$-(`=MA3SGKOM36O9"!RO:Y`B+X7P$2P%6WL`/^YW\J$&.YH`)A
ML(`0L(!L=@K*!P5I<"MNY%FM<P`&H&=#T`428`&'$P,0`#^^1%-Q8`(&LW(<
M(`30UGVG``*\HP`0`"1.T`5?@`0GDD\)@&&'X`%%]@=:X"TI`"!#$`=:0`#&
MXP1,P`$@,`4\8P%.Z$8H-E0K%B18L04,H`OL=@"!A"(-8"`%,D"W\`!>6"!A
MI`LZ,'PLE0O*!P#JL_\^>Z-D1W!$;,A",W`!;,8"'-``8P!QU>8$198%%]`R
M?_``P\<+6L!`U08Q6B`"4%!87`"(&C!?*'9E1W`!"(`E8]``0W!96M``-'!E
M1M:&;CA$@D@"^4&(D]`#(F`*N)`'$]``*L"'H;$6)7`$MFB+`G@*-W"+M^AD
MO'"&E_"`9?9C<E:,5O0..R`*#X"(&6>,SH@.=)8-RI<63U!&M-!C^X`!7)0-
M.K"-O9=9G=8+)%!.2(4.4;!HP68`@CA)&[)JZ_`AN&`!E8,-7)`"A4!IGD&,
MPD`>;!!NOT1FN,`=AZ!)/1(!!Z`!K/@'/7@SO'`!25!RA[``H',#*U!)DB#_
M!IAT"RMP90))?[V0`[QG"$'&"QPP:??"3WQ&57G'!!8`!Q.2!S\@3L@%)%8`
M!Q;P`^VE`C^``DMP<!`%!R.0`HJE`D)@`VM@,+82+[RC"QM`!`;P*S#P!BUY
M(BI`5G"0,NS26R2P`02@=^J$!"#P`X?S!&N@!F+I;X=0+N>2+F\``6O06R60
M`C<):[C`6EXP:)L1C=@PC?]D'P_U!R;@4DE`/Q:@!@A0F"^U!EXP`[RG>(:0
M!M6B`K6U"!Z0!RK0=:=`!6P``%W@DU,P'PX@7,HC`BFC`5[`2!*0!`BP!4E@
M"#S`!C!``6ZT`F\P!E;@CY+0:H:08I:S!BS@!692_P!+@`#J`HK6`@=9=V+?
MR$3`-C5YUWS=8P!/X`&6\`93D`(I`&V)=)5RY)CN=3S@N0L!P$L>`"!=8`MV
M90@;P!]ZM8,]J(78Z6NI:0!R]0=-L`89AI;I)87@60%Q@)TI\'H0&`=+)P0=
MF9<H&8[I801LL`"_8H&'L`0H`!<V8`)<L`+ZY@3B%`%QYP1;(`-?0P`6]0/+
MQPM?,"\.X&CMQ@4F<%+1$`$5U@0;<`-1H&]9,!\7,%,JP!]:P$P]M0!`^BM1
M:'])Q00YD`,^&9`S,`-+(`(`J1EZ>0W*-P%S4*5>E`0\(@+OYP1SX"HZL@'6
MI$DS8$M,H&^#.`)S,%\E`/\!!K`&J$4"T0<.J)(#:Z!D9,D&4]":0P0!;)`"
M/AITDI`#,<`&!E!&P/0@BE4"\-0%Z"B256JEO=,7#6`?<&H(.]`$;,`&R,0+
M:^!%<G<9^OB,HBH-43H-TSBJHEJJTG"JJ.J,JCH,RI<!"3"KZV"<TO``%W<+
M=&1'<;H.++"4I]!'V]`%F>I'LYB@&@<,>1`#'B!)WM``HX8-0S`']XAJE.2.
MZJ";?P`#ZW@-(\`#"\",RWE&S3D,I(0"$5"8$I4'(&`S`O1*!P`!(?`U*Q`"
M*0`"IF!MV":26]!K0J=!!Y`"C8I`3:"G?_`$-@`!7<D*(0`!(*`L$'``!%"(
M.>#_`^ZG;S(0`2E@`SEB""9@A+@9D3XU*"@``=LV!!I;=(9P`ST``1;@C:=P
M+`U@JYGQJL+`EWFG6R#04!7Z!_!F"%\``C#PL_8I!"X`!GQ2`EMP`(SI02!@
M!1][,1,0`;V%"R"5!W,P3#&@!C4`/88@/5F@!BG3!!5PA%,`!2;04+K'`TTP
M7R0P`E`@`F[F=2,K`P&P!4-E(0XPF43P`UI@?;H@`PG0!%/`?L<*CLDJ(WF'
M*I^%`#]P`W/P<K&4J75!!$O`!$T`,6?%?.#)@C7"!@(0!P9#5SYX5WE582'`
M2]M40B.P!`(@@#]0@@N9FR.[FT.E/(^ENFR`<;A``>4X_ZY25:X;]YRL8PA:
M-0'G<S`&<PA/4`5'8`'`ZIU'26A(Y;F'(*,U``(_1#'+4S+V,085)B*GP`)/
MH`/IJB,/$`4)D+QT&WN;RR\.8&B_(`(F^:GY*+S`H`5)P"P[`Z%?FY^&4"$$
MP`2;*@!,<`!Q((GC:`&%J`)@.0*;:KV&H`:T\@)3\`EE0@`0EE1=X&(5A@%2
MN08`XI0'``>]102G)P1*U%-IT,('Q)N.Q"\EL`8ZYFL:"0$_L`1F"KR@BK^_
M4`)_5@-?XP5(UHTW(\22(`4TP%,R``4(8(VCP`&^B`$TP$54T@LN`#$S`!\N
M,`128(U2,`$KP%,U<&4+,`&!<O\(%(``,(`E5D`#6E!WMZ!H07Q9)<!%?K()
M,'`(&<`!0Z"YM_`$-)`%-%NSR-JJB#P,-AL,K)K(<;;(P-#(<B.,P4`%LC@-
M'*`WCKP1D/P+IVJ1N7``T?K#2#`'2]"MJPJLFSP=AZP-H`PL35!!?Y`T3;!I
M"$`$#E"(=89H(B!7-T"<\P5V$^`$(M`R?IS+$"<`JDQH3:#+JSP0G>P+GZPL
M#3`%`C`%<G4`70`"75!&;\`$$9`$F"D),V``(O!Z3@`!/C`"';0`;[`%'I`"
MYP,!2W!8U:K,DI!U$2`$U?K,^Q#-O3#-AV``.3(!>GH`\U(X56,>GY4+,)`$
M3+`S-S#_!`T`O0JI(1Z@`/H$`;S#`\J"SWQ542!@L/ZL#P#-"\IW`30`ROWX
M!S5P/J),6@#BOP&92YPRP6J0!0?`.^Z\+!J=>85P+8?@`ZI,`#'P9U!<TK?@
M`@P`!G5@`6`0U4\=U4X-U5)MU4Z-`U2-`EH=U1+0RM?@`U,0`Z.U!2"@`@2`
M5C&MT-_9T+=0`"/@`"HX&C$P`:%UT3Z]T8-I`X[V!W#=`);PTB)0`?6IU$M]
M`7X`!'5P#(K-V(MM#(T-V0EP#"\PV<;PU8C+C3%@`W*4`\7C`_"!`!?B`-SS
M!412`_T\OCZ0`@E@#58`%#Z`*@^P+0=``B7GLC80`9>5`P)P_P!0*`)J$$>&
MG0LN@-B1G=B/C=R.S=B6[0>5?0R8S9PI*1=L/=S8X`()``0=@`)`T-W;W=W:
MS=W>+=[:+0'@;03FW=W13:[3'1<D$)+6+0TN$`8,T$<,<-_VC=\0<-_UO=_X
M3=__S=_K';SM_49$4,CQ31+%K=R0G=S'_>#-_=R7#=;3D`.*M*E_$`)?-0)E
M=$)3L$@1R00AZR8I\')_X`.%<`21<P&:P@&8#0).\@3&,P'5$@",M%K8B58J
MD./6@.,I,,J2(`+XIDE-`*#&(P78:0+Z)N/Q:0A*DN.O8N2,L>`/[N!6SMR4
MW=P#WL,%'@P7L`9P@.$<\``WL+2'P/\%7Y`$`A@#D;,+36``A`0!G2E@AA``
M2"`#:0`@<6`+0MULT5#D`=8%8V,PD!:_F%U3@]YE<T!Q#:4"#?`&8``@-2#H
M6V((=C(V]%/.B7X)CPX">D885'[E#;[<DIWET$WATF`+:8#AZI0&<8>IG@I2
M,'L+/T!L*A0',4#GZKD%&P`Q(U`#3\`OO6V?QC,#[%N\*L!VY=P+P#F[:>"I
M]J(",]5J,]"KC\GJH)[=WSW>X+WMX=WMZ0T$Z`W>6WZ_72X,JRX)`7`LDD!P
M:?I2-I!JMU`%OA+1F6=2H&,KRYL&7]`%/]ULY%GLJGN/#6``4\`&!C,#JKO,
MIZ!(6P!>S][_0V\U!XQD)YG:6S.0J6R@RND^Y?2=W_W-WR`_\@!>WR5?[DL&
M0660D!`8JNB.X0K`!NCH`T/S!UT0!A9@`'1Y"D;@`6_`!G(%`0CP+8O2TH:0
M`G#@`4(`-`)@`PL@`,6.!$`*'PV0!`)@L.4,I%7PBP30UW\0\1%V`2-`;78"
MI%]3[5HO"1V_&*%.Z@S^]D`0X5K.#@&@!ESE!2C?;"X?#&LO!`U@]H8@!3*0
M`RD0.0Y0`1B([64&!C,@/)F'`"3@\Y)@]``/`1[P0\,.Z#0E]0O@9%G#`G%0
M05G?^;J`<C)0`7X$]BZM(6>ID#RX`*B%]IT/<6NO&&T_ZK@/]W)__^KK$``X
MT`!$<"@!`-_)M_?```&ZC`1(P`1,@-D'L"I30)#;6D>ZL$K5)@2C,7P@0/V&
M,`<'%`!S0`-LT#(^@*(U#YS,7Q>MA&*^26C6Q)+BD@1"$.:2``%)NJM$*3A1
M\/YZ"@A>!DQ,%F5_B!`TB(R-CH^0D9*3E)62+A=^0'5^G9N=FIR>HIH)H"^F
MG1*6K)`!#$\H+4TH+)$"'9T4!ZV]OK_`P<+#Q,7&QRX)0!TH0,[,SLO-S]/+
M$M%&U\ZKQY!:*'\[+3:+M[E^N]WJZ^SM[N_PB"YA##@0#/CV^/7W^?WU]/(%
M9,`MGB5<NG@97,BPH<.'K#"%`O5I%$520/]2^4$%JB!$1PC1*1Q&!4$.1@%(
M_`%0X\\-!0O^8(`RJ42/,8T0(!CR`)$6G3L10<'P9X4"7RMZ:&"D@<@?&1-^
MT5C1Z,B!%HZF4BH1`ERC(409<?7Z$9[$BA,MJBUU2J/'LHA"IB/6@TU+1&_6
MR$``X0^7$%O^0*@@B8H%"%VT,(+@@0``1&"$L(&0`E&"O@="]'I0Z,<,1`?B
MY%@P!RD;`8QT"%G2E]$*#R8F+;#PXTVC,FQ`,)I=&Z[93&B#8\2HD:,JWXWD
MCA0&84O!-VPX\$6$94X6`QDD]1#R1XI*1AYB,L+0I5$&`UF68.DE`<P?)VE`
MLS%!VI>/+1!N(*+_X:!!:T0%6&"`?I%``48-MC&2P!1),&(@@LBYDXPTT4!#
M3875=*`-$-E$\Q9<RA&3!QL`E(=7"`04\)\`'B`PB0"!/1)>(^0Y@H`'A/7R
M`TXNE/;'`2D8H(./K3`QPP]6-.)?(VID@422DT#(B`5\4<6(E!&N,P\_^^CC
M3Y?_X#"0F/M\6%:(PW#0A0!LA/7&#$FD\!\`'NSP8@R0S#B>B8S<P(8+OL"A
M6(^@56!#"T1:\@!L;S2@Y'^+FM`H)5C^8<`!:\1V98)9JG/6<!>%ZDEQ;G6*
MIC`F;"``$SW@-4,#<_RW@`>4++G"8^")ATB-CK3IB`H-9!?)%C[\,<0/_X5B
M,$>BE:B`A``6V/`H(RHL(8`:TD;)Z1%Q"`#"%(U4VJDQGXJ:UKD9M=61J>?,
M%<P.$#@E@$)O1@&'K+1.<L0/+8Q0`"(ZL`A&6#+QR8BOC'C1A0%12+*"M6NT
M^B-A:S!+B0"H:<'$M(CXH%L93#0L"98)8+7"'`3^(>ZXQ)2[EG`4D;INEJ<"
MDT<3B`#@!"(-Z/"'%O\BD@-JE&`1`\X`8RP`P24@W8@/)31"@`%&4.+%%E$A
MP@%-6.3(R@4^/^!`(UX$_<<$G_WA`*Z1`.`H@&'YD`<C;K/<S8064GCAWM9@
MLZ&9']5L]S`3&*#8X(@/OJ677'[I.$!=#@0X1/^")_Z+#B);KGF$+J,+ZJCJ
M'D=SN\MM;OKIJ'<.\\LRBQYAY:C'+ONXJG^.;NM^3/X0[+/W[OM#>&<H/(85
M;MCA-NPF]/ORS#>T>)C0@QGY]/CH[A#OS6>O_3"UFQL<[M8WA/WVY)=?2?<O
M$Q=Z[LF+9/[[\%>R0@4(]-`"4/;C?[].^?,O`5`7^)].W#,ZY<7O@`B,AP7:
MYZX$.O"!Q5A@`=T'P0I:T!<2?!WI+LC!#DHB@\@9GP='Z$`0^D:$)$PA_$P(
MH@VJ\(4/9.&97`C#&L9/AH&CX1^.T(LC"`L`PIK$`WSFB!VD;1(L^`XKEH((
MIU""AY!8`1$G00);($+_"D&L1!(1P0(>5,*(D'B!%2=1A%YX\8J5P"(D=@#%
M20"1$4[,618ID8$V1@*'E-.AV2Q1`$#]@0-^U%<`'O&`"%1"!Q?H!580H1M*
M[+$1-!@D)<#&B`8$\I")_(,.BD6)0D*B"5.4A!S84\E*6!(2#W@D)`#)"++\
M\9*4<($J'8''W>FQ%WW4&BPA<01)-L*3E$"D(AG1R$G,\@^1K`0E>;9+20A3
MDYP4HB$?`<I*C+(5!7G;)$Y)R&,V@I6(<"4X+2%+2M3R>K=L12Y?68E>$G*:
MDW@F*Q;YAV)*XIC)G.04N6F)9VZR$L!T1#4I<4U69-.4S4QE)<8ISF9&HIR3
M_SBG^-+)BG6.4Q+N=$1`G9G)/U!!6`\0E@R"2$][1@*?OI3$,O_`3TP"+)J2
MV"@C!CJ)@EKBH+5*J#<9P=!O.A02$/T@`Y=C-A:X"!%50X0*A&710!I!6#P(
M8D:CBHB``H`F?\A`4C79T7P609(Z\&5)&:%51ASU#T4]RGY\^52AL&VE_,0J
M,H755JZ^E!$\L!()Y`I,'ISQ#S3=J@@:4=`H_/6H1F4$3O_``K7^8:G,-"LC
M%(H('N#*LCP-9$,9,5A$#($1C@WJ'8?:"+,%M*,#;2HCEAF`*6:TM56%)T3E
M*4^O@E6LQ$Q-1^%I6FWF\P_+7"=P]QE(L[6`B,OT9_\T`U#&/Q#!M-,,@"]I
MVE%7%C2C?YAF0!?[`&T.E)_PI"P[QTO>S893L:64QT[_(%&&U`RZJYTI$56+
M"-:Z5I*P_4-`9]O1VDKRJP##+2-URPC>3M:WO@QN(.%:7$8<M[Y$5"Y*FOO<
MR49WNE.L+F$9@5WMPI.[WB4B>"=K-G".LZ>9;25Z><8(T4*BO0MYKX7CBXC4
M^G&<]N4P?HFXWZ#1MJO_O:V#<PNPW3*BMXSXK8)72]PC.QBY$<[D/Q'!W";"
M]P_2E2^-_V!='1<XMBMFZ8&US-)`AK?$-PXDBG6I8D0LUL6/@+%!:I:U/^2@
M(&:[@!@0,0$I($(!?@;0GG__-NBB'$X+@[XS(Z20-3&8S=&+AJ(.H/B`-B:`
M$06%M)L94><<2.R/AT/KH/M\Y$+W(-!G8T0%!EV`06M:#-K4PAF+T&EN:"'4
M>G8R(N#YAX*L(-3<4#0BQH:(3WMZM8,^=9AS4&=`_QG5SMYU(Z*=7480^P^?
M9K0Y23M91G"!"MU&Q!,(]``9<-'<5240"U*V`RNN&Q'?9H0,>N(2>M>[%T&,
M&B)N8&]P5]7;3V!$#L;X`'*C6[\I>\+![5T&<A.(W_L.(@O0S0)[QYNQ8QQW
MN/^@;T0<`A'M9H2_+YY51@0<WB?_@\95?G!_^\7>$S\W(V*.B(XS]N`=#V+*
MYTV)=!\`Y>=`#[K0AT[TH:?@'%(8@=*7SO2F._WI4(^ZU*=.]:I;_>I8S[K6
MM\[UKGO]ZTP?3`7&3O:RF_WL:$^[VLV>`U"X_>UPC[O<YT[WNMO][GC/N][W
@SO>^^_WO@`^\X`=/^,(;_O"(3[SB%\_XQCN>[H$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>f59106def5910621.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f59106def5910621.gif
M1TE&.#EA"0!_`.8``.+@X'EV=6YK:922D:NGI(2"@G)N;)V:F=32T6%=7$5#
M0_/R\9*/C\;%Q&EE9&QH9F5A8,3#PM'/S<C'Q]74T^CFY;:SLDU+2YF6E7!L
M:K"NKNGIZ*RHIX*`@,S+RG5Q<-?5U.'@W[R[NM_=W)>4D[JYN:&>G8J(B'Y\
M?)J8EL3`O[:UM=S;VJ6CHO7T](R*B<_-S%514"DE)5E654(^/(:$A,O)R-'/
MSNSKZH%_?D9!/L"^O=C6UCDU,_#O[KFWMLK(Q^/BX=K9V$Q&1-73T=+1T+*O
MKCPY.??V]JZLJZ.@G^_N[NSLZ^CHYXB&A>'?WV-?7Z.AH%U:69^<FY.1D,+"
MPL+!P+*QL*^MK7MX=ZVKJI*0CS<R,>?EX_O[^_W]_?CX]\'`P.[M[/;V]>_N
M[?KZ^:NIJ?GX^.;EY-;3TC0P+]W<VX:#@U)/3ZBDHW)P<'=T<SLX-[Z\NWAU
M=(N(AY&-B5-04)^=G!41$2$='/'P[S0O+H2!@(Z,C(Z,B____R'Y!```````
M+``````)`'\```?_@'^"@X0'.G@]<QN"25M_35!H#TA_5"N"-'].#7]B$&P"
M+7]^'H(`6'*"36>"6#-Y.B\^@C\U7VL9+`]E?PPEF'\UG!50#',IFD""(`=:
M7W\A+G\(/']$0T-A@@S:-%Y_#R!_*B1@%X(U58)\`3HY3G.S?V<1`PQ72X3Z
M@F)$_OX@QOR!08.$01(IF@AR0V&?PX>#7'29.+$"KPA'3F@\T0>-H#OB((K\
M$T3@/A0A'WKA8Z!E!A//C%#Y]@>,`")_#I@AE&6"H`0*'C@X\H*0#R)I*#U,
M,<)A!":"<%@@@4&$23%#+!!!8$**M"TB"*7[X^&-C2Y!PC@((FB"@PL7_]ZP
M':D/`@RZ#HL<-)CPSX88-OX%%`2CZ<@%)J/4H*#G@("F$@($B=$#V;:P)^9N
MBW-!AH(+;:I)I-C%(M[3J%.K7LW:80X[1@0=N/''2`X8;#(L..&3Q*\_'#($
M\(GCSB`K,GPZ%"+!81@"SJ'O>Q[]SX(P=1AX\'(&3)<9&B9,:`%A%I4?A/A$
M^`,DUY\O-Q(`$(3`@0(%61;]N6'#(0,(&0S@T2#<X##%`QU4TXLV@C0P`VT6
M-+3/`CC4],()8@CBVQ\)F''%`PJ9H($Y@K"Q'H<30#`"`!"P(`@3?-!P1`)K
M#$)&%]!D)@@+4@3@A!T<.*`0"2M\,4,U)OYQQ<$`(7`1Q1\?("!(#E*(X8`,
M)!`2`@$<D#&(&`@:-$<.TC3#DT]&^$$3&`](B`$7:NP1QPZMB0#%`W@^8,`3
M@CS`YSYD+(`:&%E\4$`'`@S`"P<'$&(`;4H\.0@<I?QA0!QVM*%&HX-X41HA
M*[5DP$LQS22(33CI=.9/00U5U"!')=4I2R[!](<)H@SR07]3Y"H('/W]T<X,
L,]"@A)9<>CD('1_@F<%.?[C!J2`"W(5!$JMZ\<`%0BFPQ3.FB`>5(($``#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
